Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16369821,systemic clearance,"The mean irinotecan systemic clearance and steady-state volume of distribution values were 14.3 l/h/m(2) and 211 l/m(2), respectively.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),[h·l] / [m(2],14.3,1034,DB00650,Leucovorin
,16369821,steady-state volume of distribution,"The mean irinotecan systemic clearance and steady-state volume of distribution values were 14.3 l/h/m(2) and 211 l/m(2), respectively.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),[l] / [m(2],211,1035,DB00650,Leucovorin
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,1,1036,DB00650,Leucovorin
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,0.3,1037,DB00650,Leucovorin
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,0.17,1038,DB00650,Leucovorin
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,0.27,1039,DB00650,Leucovorin
,11474245,response rate,"Antitumor activity was similar in the two arms and was very promising both in pretreated patients (response rate 29%; 95% confidence interval 15-46%) and in chemotherapy-naive patients (response rate 56%, complete response 9%, 95% confidence interval 40-71%).",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),%,29,2284,DB00650,Leucovorin
,11474245,response rate,"Antitumor activity was similar in the two arms and was very promising both in pretreated patients (response rate 29%; 95% confidence interval 15-46%) and in chemotherapy-naive patients (response rate 56%, complete response 9%, 95% confidence interval 40-71%).",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),%,56,2285,DB00650,Leucovorin
,11474245,complete response,"Antitumor activity was similar in the two arms and was very promising both in pretreated patients (response rate 29%; 95% confidence interval 15-46%) and in chemotherapy-naive patients (response rate 56%, complete response 9%, 95% confidence interval 40-71%).",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),%,9,2286,DB00650,Leucovorin
,11474245,survival,"Median survival of the patients with and without pretreatment was 12 and 16 months, respectively.",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),month,12,2287,DB00650,Leucovorin
,11474245,survival,"Median survival of the patients with and without pretreatment was 12 and 16 months, respectively.",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),month,16,2288,DB00650,Leucovorin
,11933030,limit of detection,The limit of detection was 10 ng/mL for LV in plasma and the linear range was 50-1500 ng/mL in plasma.,High-performance liquid chromatographic method for determination of leucovorin in plasma: validation and application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11933030/),[ng] / [ml],10,5804,DB00650,Leucovorin
over,11933030,extraction recoveries,The extraction recoveries of LV in plasma were over 90%.,High-performance liquid chromatographic method for determination of leucovorin in plasma: validation and application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11933030/),%,90,5805,DB00650,Leucovorin
,32474564,OS,"The median PFS was 10.2 months (95%CI 8.8-14.3) and 10.0 months (95%CI 7.4-11.0), and the median OS was 29.7 months (95%CI 22.9-43.9) and 28.8 months (95%CI 18.4-ND), respectively (p = 0.3758, p = 0.8234).",Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32474564/),month,29.,6333,DB00650,Leucovorin
,32474564,OS,"The median PFS was 10.2 months (95%CI 8.8-14.3) and 10.0 months (95%CI 7.4-11.0), and the median OS was 29.7 months (95%CI 22.9-43.9) and 28.8 months (95%CI 18.4-ND), respectively (p = 0.3758, p = 0.8234).",Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32474564/),month,28.8,6334,DB00650,Leucovorin
,16968871,area under the curve (AUC),"The 5-FU area under the curve (AUC) measured at the first cycle ranged between 146 and 1236 mg x min/l and was significantly correlated with drug dose, patients' body weight (BW) and gender, females having higher AUCs.",Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16968871/),[mg·min] / [l],146 and 1236,6345,DB00650,Leucovorin
,16968871,AUC,"AUC and age were the only covariates which discriminated between toxic (grade > or =2) and nontoxic cycles (grade <2), with an optimal AUC cut-off value of 596 mg x min/l.",Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16968871/),[mg·min] / [l],596,6346,DB00650,Leucovorin
,16968871,AUC,"A method for calculating the initial 5-FU dose is proposed which takes into account patient BW, gender and a target AUC of 596 mg x min/l.",Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16968871/),[mg·min] / [l],596,6347,DB00650,Leucovorin
,32572849,plasma ultrafiltrate Cmax,The plasma ultrafiltrate Cmax of oxaliplatin reached 1.36-1.90 µg/mL after 30 min with an AUC0-24 h of 9.6-11.7 µg/mL * h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),[μg] / [ml],1.36-1.90,12797,DB00650,Leucovorin
,32572849,AUC0-24 h,The plasma ultrafiltrate Cmax of oxaliplatin reached 1.36-1.90 µg/mL after 30 min with an AUC0-24 h of 9.6-11.7 µg/mL * h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),[μg] / [h·ml],9.6-11.7,12798,DB00650,Leucovorin
,32572849,plasma Cmax,The plasma Cmax reached 2.67-3.28 µg/mL after 90 min with an AUC0-24 h of 49.0-59.5 µg/mL * h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),[μg] / [ml],2.67-3.28,12799,DB00650,Leucovorin
,32572849,AUC0-24 h,The plasma Cmax reached 2.67-3.28 µg/mL after 90 min with an AUC0-24 h of 49.0-59.5 µg/mL * h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),[μg] / [h·ml],49.0-59.5,12800,DB00650,Leucovorin
,32572849,absorption rate constant (Ka),The absorption rate constant (Ka) was 1.13/h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),1/[h],1.13,12801,DB00650,Leucovorin
less,10561167,UH(2)-U ratios,Toxic side effects were observed only in patients with initial UH(2)-U ratios of less than 1.8.,"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561167/),,1.8,13105,DB00650,Leucovorin
greater,10561167,UH(2)-U ratios,No adverse effects were noted in patients with UH(2)-U ratios of greater than 2.25.,"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561167/),,2.25,13106,DB00650,Leucovorin
,15060739,Normalized clearance,Normalized clearance of MDAM was approximately 1.5 times that reported for MTX (125 vs 80 ml/min per m2) in adults.,Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060739/),[ml] / [m2·min],125,13873,DB00650,Leucovorin
,15060739,Normalized clearance,Normalized clearance of MDAM was approximately 1.5 times that reported for MTX (125 vs 80 ml/min per m2) in adults.,Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060739/),[ml] / [m2·min],80,13874,DB00650,Leucovorin
,21750645,plasma concentrations,"The plasma concentrations of 5-FU at 24 hr after the start of treatment were 27.4 ng/mL and 9.4 ng/mL in the patients with and without the bolus injection, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[ng] / [ml],27.4,15050,DB00650,Leucovorin
,21750645,plasma concentrations,"The plasma concentrations of 5-FU at 24 hr after the start of treatment were 27.4 ng/mL and 9.4 ng/mL in the patients with and without the bolus injection, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[ng] / [ml],9.4,15051,DB00650,Leucovorin
,21750645,AUC(0-48),"At 48 hr, they were 31.3 ng/mL and 10.4 ng/mL with the AUC(0-48) values of 22.16 mg h/L and 0.65 mg h/L, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[h·mg] / [l],22.16,15052,DB00650,Leucovorin
,21750645,AUC(0-48),"At 48 hr, they were 31.3 ng/mL and 10.4 ng/mL with the AUC(0-48) values of 22.16 mg h/L and 0.65 mg h/L, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[h·mg] / [l],0.65,15053,DB00650,Leucovorin
,6539365,half-life,These values were compared to a mean half-life of 2.83 (+/- 0.34) hours following 489 courses administered to 71 patients who had not received cisplatin.,The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539365/),h,2.83,16994,DB00650,Leucovorin
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],320,17617,DB00650,Leucovorin
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],290,17618,DB00650,Leucovorin
,10873073,terminal phase half-life,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),h,12.4,17619,DB00650,Leucovorin
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17620,DB00650,Leucovorin
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],234,17621,DB00650,Leucovorin
,10873073,terminal phase volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17622,DB00650,Leucovorin
,10873073,steady-state volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],123,17623,DB00650,Leucovorin
,22978343,inter-compartmental clearance,A bimodal distribution of the inter-compartmental clearance was observed allowing two subpopulation with high (17 L/h) and low values (3.35 L/h).,Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978343/),[l] / [h],17,18340,DB00650,Leucovorin
,22978343,inter-compartmental clearance,A bimodal distribution of the inter-compartmental clearance was observed allowing two subpopulation with high (17 L/h) and low values (3.35 L/h).,Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978343/),[l] / [h],3.35,18341,DB00650,Leucovorin
,8458180,absolute bioavailability,The absolute bioavailability of levoleucovorin (74%) was not significantly different from that of leucovorin (65%).,Bioequivalence of oral and injectable levoleucovorin and leucovorin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458180/),%,74,18785,DB00650,Leucovorin
,8458180,absolute bioavailability,The absolute bioavailability of levoleucovorin (74%) was not significantly different from that of leucovorin (65%).,Bioequivalence of oral and injectable levoleucovorin and leucovorin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458180/),%,65,18786,DB00650,Leucovorin
,31152507,maximum observed concentrations (Cmax),"The results showed that the maximum observed concentrations (Cmax) of 6S-leucovorin and L-5-methyltetrahydrofolate were (3137.917±408.837) and (1679.633±244.132) μg/L, respectively, and the areas under the curve from the time of dosing to the last measurable concentration (AUC0-t) were (7504.883±1185.101) and (14001.214±2868.949) μg/L in the 125 mg/m2 6R,S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],3137.917,19100,DB00650,Leucovorin
,31152507,maximum observed concentrations (Cmax),"The results showed that the maximum observed concentrations (Cmax) of 6S-leucovorin and L-5-methyltetrahydrofolate were (3137.917±408.837) and (1679.633±244.132) μg/L, respectively, and the areas under the curve from the time of dosing to the last measurable concentration (AUC0-t) were (7504.883±1185.101) and (14001.214±2868.949) μg/L in the 125 mg/m2 6R,S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],1679.633,19101,DB00650,Leucovorin
,31152507,areas under the curve from the time of dosing to the last measurable concentration (AUC0-t),"The results showed that the maximum observed concentrations (Cmax) of 6S-leucovorin and L-5-methyltetrahydrofolate were (3137.917±408.837) and (1679.633±244.132) μg/L, respectively, and the areas under the curve from the time of dosing to the last measurable concentration (AUC0-t) were (7504.883±1185.101) and (14001.214±2868.949) μg/L in the 125 mg/m2 6R,S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],7504.883,19102,DB00650,Leucovorin
,31152507,areas under the curve from the time of dosing to the last measurable concentration (AUC0-t),"The results showed that the maximum observed concentrations (Cmax) of 6S-leucovorin and L-5-methyltetrahydrofolate were (3137.917±408.837) and (1679.633±244.132) μg/L, respectively, and the areas under the curve from the time of dosing to the last measurable concentration (AUC0-t) were (7504.883±1185.101) and (14001.214±2868.949) μg/L in the 125 mg/m2 6R,S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],14001.214,19103,DB00650,Leucovorin
,31152507,Cmax,"The Cmax values of 6S-leucovorin and L-5-methyltetrahydrofolate were (3187.917±387.298) and (1739.204±224.755) μg/L, respectively, and AUC0-t values were (7426.664±854.825) and (14884.331±1843.353) μg/L in the 62.5 mg/m2 6S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],3187.917,19104,DB00650,Leucovorin
,31152507,Cmax,"The Cmax values of 6S-leucovorin and L-5-methyltetrahydrofolate were (3187.917±387.298) and (1739.204±224.755) μg/L, respectively, and AUC0-t values were (7426.664±854.825) and (14884.331±1843.353) μg/L in the 62.5 mg/m2 6S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],1739.204,19105,DB00650,Leucovorin
,31152507,AUC0-t,"The Cmax values of 6S-leucovorin and L-5-methyltetrahydrofolate were (3187.917±387.298) and (1739.204±224.755) μg/L, respectively, and AUC0-t values were (7426.664±854.825) and (14884.331±1843.353) μg/L in the 62.5 mg/m2 6S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],7426.664,19106,DB00650,Leucovorin
,31152507,AUC0-t,"The Cmax values of 6S-leucovorin and L-5-methyltetrahydrofolate were (3187.917±387.298) and (1739.204±224.755) μg/L, respectively, and AUC0-t values were (7426.664±854.825) and (14884.331±1843.353) μg/L in the 62.5 mg/m2 6S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],14884.331,19107,DB00650,Leucovorin
,1530284,molar ratio,The zinc/folate molar ratio was 1:1.,[Effect of folic acid and folinic acid on zinc absorption]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),,1,20010,DB00650,Leucovorin
,1530284,areas under the curves,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),[μM] / [6·h],48.2,20011,DB00650,Leucovorin
,1530284,areas under the curves,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),[μM] / [6·h],57.0,20012,DB00650,Leucovorin
,1530284,peak zinc concentration,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),[μM] / [l],28.8,20013,DB00650,Leucovorin
,1530284,peak zinc concentration,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),[μM] / [l],32.1,20014,DB00650,Leucovorin
,1530284,half-life,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),h,3.12,20015,DB00650,Leucovorin
,1530284,half-life,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),h,3.42,20016,DB00650,Leucovorin
,1530284,elimination rate constant,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),,0.22,20017,DB00650,Leucovorin
,1530284,elimination rate constant,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),,0.24,20018,DB00650,Leucovorin
,1530284,urinary,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),[μM] / [6·h],58.1,20019,DB00650,Leucovorin
,1530284,clearance,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),[l] / [h],1.15,20020,DB00650,Leucovorin
,1530284,clearance,"The areas under the curves varied from 48.2 +/- 20.0 mumol/6 h (1) to 57.0 +/- 10.3 mumol/6 h (3), peak zinc concentration from 28.8 +/- 7.3 mumol/l (1) to 32.1 +/- 4.1 mumol/l (3), half-life from 3.12 +/- 1.12 h (3) to 3.42 +/- 1.48 h (1), elimination rate constant from 0.22 +/- 0.08 (1) to 0.24 +/- 0.07 (3), mean urinary zinc excretion from 58.1 mumol/6 h (2) to 98.7 mumol/6 h (1) and mean zinc clearance from 1.15 l/h (3) to 3.26 l/h (1).",[Effect of folic acid and folinic acid on zinc absorption]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530284/),[l] / [h],3.26,20021,DB00650,Leucovorin
,18451241,area under the time/concentration curve (AUC),The area under the time/concentration curve (AUC) of 5-FU was significantly lower in 58 subjects who recurred (7.5 +/- 2.9 h x mg/L) with respect to other patients (9.3 +/- 4.1 h x mg/L).,5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451241/),[h·mg] / [l],7.5,20231,DB00650,Leucovorin
,18451241,area under the time/concentration curve (AUC),The area under the time/concentration curve (AUC) of 5-FU was significantly lower in 58 subjects who recurred (7.5 +/- 2.9 h x mg/L) with respect to other patients (9.3 +/- 4.1 h x mg/L).,5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451241/),[h·mg] / [l],9.3,20232,DB00650,Leucovorin
lower,18451241,AUC,"Furthermore, AUC values lower than 8.4 h x mg/L together with lymph node involvement and the interruption of treatment or reduction of doses were identified as risk factors at univariate analysis.",5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451241/),[h·mg] / [l],8.4,20233,DB00650,Leucovorin
,18451241,AUC,"The completion of 6 cycles of adjuvant treatment without dosage modifications was the only independent risk factor at multivariate analysis, despite a trend toward significance for 5-FU AUC values (cutoff value, 8.4 hxmg/L) was observed (P = 0.06).",5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451241/),[h·mg] / [l],8.4,20234,DB00650,Leucovorin
,8398300,response rate,"In the phase II study 28 patients were evaluable for response: three complete responses and 12 partial responses were observed (response rate 54%, 95% confidence interval, 34 to 72%).",Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398300/),%,54,21843,DB00650,Leucovorin
,18343925,overall response rate,"The overall response rate of PMC-cisplatin as ICT was 76%, including a complete remission rate of 23%.",Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343925/),%,76,23231,DB00650,Leucovorin
,18343925,complete remission rate,"The overall response rate of PMC-cisplatin as ICT was 76%, including a complete remission rate of 23%.",Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343925/),%,23,23232,DB00650,Leucovorin
,18343925,overall,"The overall organ preservation rate of the multimodality treatment was 75%, with 97% in ICT responders.",Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343925/),,75,23233,DB00650,Leucovorin
,18343925,overall survival rate,The 3-year overall survival rate was 67%.,Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343925/),%,67,23234,DB00650,Leucovorin
,1738182,response rate,"The response rate was 52% (complete response, 12%; partial response, 40%).",Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738182/),%,52,25676,DB00650,Leucovorin
,1738182,time to disease progression,"The median time to disease progression for responding patients was 9.2 months (range, 5.9-15+ months).",Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738182/),month,9.2,25677,DB00650,Leucovorin
,1738182,half-lives: alpha,"After IV injection, (6S)-folinic acid was rapidly cleared from plasma (mean half-lives: alpha = 7.2 minutes and beta = 126 minutes).",Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738182/),min,7.2,25678,DB00650,Leucovorin
,1738182,beta,"After IV injection, (6S)-folinic acid was rapidly cleared from plasma (mean half-lives: alpha = 7.2 minutes and beta = 126 minutes).",Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738182/),min,126,25679,DB00650,Leucovorin
,2783877,peak plasma folate concentrations,"In patients with lung carcinoma, oral administration of dl-LV at 125 mg/m2 hourly for 4 hours (total dose of 500 mg/m2) gave the following peak plasma folate concentrations: dl-LV, 4.6 + 1.9 microM; 5-methyltetrahydrofolate, 4.3 + 2.1 microM; and no detectable l-LV in most cases.",Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783877/),μM,4.6,26488,DB00650,Leucovorin
,2783877,peak plasma folate concentrations,"In patients with lung carcinoma, oral administration of dl-LV at 125 mg/m2 hourly for 4 hours (total dose of 500 mg/m2) gave the following peak plasma folate concentrations: dl-LV, 4.6 + 1.9 microM; 5-methyltetrahydrofolate, 4.3 + 2.1 microM; and no detectable l-LV in most cases.",Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783877/),μM,4.3,26489,DB00650,Leucovorin
,7595715,overall response rate,"Among 62 previously untreated patients, two complete responses (CRs) and 18 partial responses (PRs) were observed (overall response rate, 32%; 95% confidence interval, 21% to 45%).",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),%,32,27040,DB00650,Leucovorin
,7595715,response duration,"The median response duration was 4 months (range, 2 to 13) and the median survival time, 14 months.",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),month,4,27041,DB00650,Leucovorin
,7595715,survival time,"The median response duration was 4 months (range, 2 to 13) and the median survival time, 14 months.",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),month,14,27042,DB00650,Leucovorin
,7595715,response rate,"Among 46 pretreated patients, there were three CRs and three PRs (response rate, 13%; 95% confidence interval, 5% to 26%).",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),%,13,27043,DB00650,Leucovorin
,7595715,response duration,"In this group of patients, the median response duration was 4 months (range, 1 to 12) and the median survival time, 12 months.",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),month,4,27044,DB00650,Leucovorin
,7595715,survival time,"In this group of patients, the median response duration was 4 months (range, 1 to 12) and the median survival time, 12 months.",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),month,12,27045,DB00650,Leucovorin
,3500051,peak plasma concentration,"The patients received, first, two methotrexate intravenous bolus test doses (50 mg/m2) one with and one without concomitant administration of folinic acid (15 mg every 6 h) in a random sequence, and, second, an 8 h infusion, individualized to achieve a peak plasma concentration of 5 X 10(-4) M methotrexate (infusion rates greater than 1000 mg/h).",Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500051/),M,5 X 10(-4),28388,DB00650,Leucovorin
,16203781,activation ratio,"Patients with CES2 mRNA expression above the median cutoff value presented an activation ratio higher (median, 0.25; range, 0.15-0.42) than those with CES2 mRNA below the median (median, 0.20; range, 0.10-0.40; P = 0.013).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),,0.25,30569,DB00650,Leucovorin
,16203781,activation ratio,"Patients with CES2 mRNA expression above the median cutoff value presented an activation ratio higher (median, 0.25; range, 0.15-0.42) than those with CES2 mRNA below the median (median, 0.20; range, 0.10-0.40; P = 0.013).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),,0,30570,DB00650,Leucovorin
,16203781,AUC,"This was associated with a nonsignificant trend of 1.34-fold increase of SN38 AUC in the group of patients with high CES2 mRNA expression (mean, 1.03 +/- 0.62 versus 0.77 +/- 0.32 micromol/L hour).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),[μM] / [h·l],1.03,30571,DB00650,Leucovorin
,16203781,AUC,"This was associated with a nonsignificant trend of 1.34-fold increase of SN38 AUC in the group of patients with high CES2 mRNA expression (mean, 1.03 +/- 0.62 versus 0.77 +/- 0.32 micromol/L hour).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),[μM] / [h·l],0.77,30572,DB00650,Leucovorin
,29691300,progression-free survival (PFS),"In first-line patients (n = 36), median progression-free survival (PFS) was 9.9 months [95% confidence interval (CI), 5-13.9 months], and the overall response rate (ORR) was 50%.",Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691300/),month,9.9,31475,DB00650,Leucovorin
,29691300,overall response rate (ORR),"In first-line patients (n = 36), median progression-free survival (PFS) was 9.9 months [95% confidence interval (CI), 5-13.9 months], and the overall response rate (ORR) was 50%.",Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691300/),%,50,31476,DB00650,Leucovorin
,29691300,PFS,"Among all patients (n = 40), median PFS was 7.8 (90% CI, 5.5-13.9) months, and ORR was 48%, with a median duration of response of 8.4 months.",Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691300/),month,7,31477,DB00650,Leucovorin
,2057988,terminal half-life,"However, a prolonged mean terminal half-life of 51.5 h was observed.",Methotrexate disposition following disruption of the blood-brain barrier. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057988/),h,51.5,32408,DB00650,Leucovorin
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,25.8,32507,DB00650,Leucovorin
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,57.3,32508,DB00650,Leucovorin
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,25,32509,DB00650,Leucovorin
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,181,32510,DB00650,Leucovorin
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,200,32511,DB00650,Leucovorin
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,132,32512,DB00650,Leucovorin
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,121,32513,DB00650,Leucovorin
,11899652,overall response rate,Two (4%) patients had a complete response and 21 (45%) patients had a partial response for an overall response rate of 49% (95% confidence interval: 35%-63%).,"Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),%,49,32571,DB00650,Leucovorin
,11899652,duration of response,"The median survival was 17.7 months, median duration of response was 8.6 months, and median time to disease progression was 6.3 months.","Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),month,8.6,32572,DB00650,Leucovorin
,11899652,time to disease progression,"The median survival was 17.7 months, median duration of response was 8.6 months, and median time to disease progression was 6.3 months.","Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),month,6.3,32573,DB00650,Leucovorin
,11899652,peak plasma concentrations,Responders had higher peak plasma concentrations of paclitaxel than nonresponders (4.46 vs. 2.9 micrograms/mL; P = 0.02).,"Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),[μg] / [ml],4.46,32574,DB00650,Leucovorin
,11899652,peak plasma concentrations,Responders had higher peak plasma concentrations of paclitaxel than nonresponders (4.46 vs. 2.9 micrograms/mL; P = 0.02).,"Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),[μg] / [ml],2.9,32575,DB00650,Leucovorin
,15634630,time to progression,"Median time to progression was 6 months, and median survival was 8.4 months.","A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634630/),month,6,32870,DB00650,Leucovorin
,15634630,survival,"Median time to progression was 6 months, and median survival was 8.4 months.","A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634630/),month,8.4,32871,DB00650,Leucovorin
,8045919,peak plasma levels,"BVdUrd was rapidly absorbed, peak plasma levels of 0.6-7.1 micrograms/ml being achieved after 1-2 h.",Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8045919/),[μg] / [ml],0.6-7.1,33244,DB00650,Leucovorin
,8045919,total body clearance,The total body clearance of FUra was approximately 61/h and t1/2 markedly increased to 4-7 h.,Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8045919/),1/[h],61,33245,DB00650,Leucovorin
,8045919,t1/2,The total body clearance of FUra was approximately 61/h and t1/2 markedly increased to 4-7 h.,Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8045919/),h,4-7,33246,DB00650,Leucovorin
,8045919,urinary excretion,The mean urinary excretion of FUra was 50%.,Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8045919/),%,50,33247,DB00650,Leucovorin
,24382596,Response rate,Response rate was 65%; median progression-free survival 16.4 months.,"Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24382596/),%,65,33960,DB00650,Leucovorin
,24382596,progression-free survival,Response rate was 65%; median progression-free survival 16.4 months.,"Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24382596/),month,16.4,33961,DB00650,Leucovorin
,28763145,response rate,"Of 71 eligible patients, the response rate was 53.5%, and the disease control rate was 83.1%.","Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28763145/),%,53.5,34211,DB00650,Leucovorin
,28763145,progression-free survival,"Median progression-free survival and median overall survival were 6.5 and 24.3 months, respectively.","Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28763145/),month,6.5,34212,DB00650,Leucovorin
,28763145,overall survival,"Median progression-free survival and median overall survival were 6.5 and 24.3 months, respectively.","Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28763145/),month,24.3,34213,DB00650,Leucovorin
,8173189,residual concentrations,"After administration of dl FA, the accumulation of d FA in plasma was confirmed: mean residual concentrations were 420 and 652 nM after 2 and 6 intakes respectively.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,420,36597,DB00650,Leucovorin
,8173189,residual concentrations,"After administration of dl FA, the accumulation of d FA in plasma was confirmed: mean residual concentrations were 420 and 652 nM after 2 and 6 intakes respectively.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,652,36598,DB00650,Leucovorin
,8173189,Total active folate concentrations,"Total active folate concentrations (1 FA + 5-MTHF) were similar between the two types of rescue: 92 and 100 nM respectively for dl FA rescue and 1 FA rescue after two intakes, 186 and 184 nM respectively for dl FA rescue and 1 FA rescue after six intakes.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,92,36599,DB00650,Leucovorin
,8173189,Total active folate concentrations,"Total active folate concentrations (1 FA + 5-MTHF) were similar between the two types of rescue: 92 and 100 nM respectively for dl FA rescue and 1 FA rescue after two intakes, 186 and 184 nM respectively for dl FA rescue and 1 FA rescue after six intakes.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,100,36600,DB00650,Leucovorin
,8173189,Total active folate concentrations,"Total active folate concentrations (1 FA + 5-MTHF) were similar between the two types of rescue: 92 and 100 nM respectively for dl FA rescue and 1 FA rescue after two intakes, 186 and 184 nM respectively for dl FA rescue and 1 FA rescue after six intakes.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,186,36601,DB00650,Leucovorin
,8173189,Total active folate concentrations,"Total active folate concentrations (1 FA + 5-MTHF) were similar between the two types of rescue: 92 and 100 nM respectively for dl FA rescue and 1 FA rescue after two intakes, 186 and 184 nM respectively for dl FA rescue and 1 FA rescue after six intakes.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,184,36602,DB00650,Leucovorin
,8173189,terminal half-lives,"For both types of rescue, MTX terminal half-lives were identical (average value 13.9 h).",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),h,13.9,36603,DB00650,Leucovorin
,16257855,t1/2,"Irinotecan and 5-FU were observed to be rapidly eliminated (t1/2 = 1 h and 0.5 h, respectively).","Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16257855/),h,1,36707,DB00650,Leucovorin
,16257855,t1/2,"Irinotecan and 5-FU were observed to be rapidly eliminated (t1/2 = 1 h and 0.5 h, respectively).","Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16257855/),h,0.5,36708,DB00650,Leucovorin
,15177306,Cmax,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[μg] / [ml],55.44,37970,DB00650,Leucovorin
,15177306,Cmax,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[μg] / [ml],6.23,37971,DB00650,Leucovorin
,15177306,AUC(0-2 h),"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[h·μg] / [ml],11.59,37972,DB00650,Leucovorin
,15177306,AUC(0-2 h),"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[h·μg] / [ml],5.94,37973,DB00650,Leucovorin
,15177306,CLTB,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),1/[(m)^2·lh],30.64,37974,DB00650,Leucovorin
,15177306,CLTB,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),1/[(m)^2·lh],51.81,37975,DB00650,Leucovorin
,15177306,AUC ratio,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),,0.47,37976,DB00650,Leucovorin
,15177306,AUC(0-2 h),"In eight subjects, we compared the PK data of the first and the fifth day of dose administration, and we found stable 5-FU values, but the 5-FUH2 disposition decreased with lower AUC(0-2 h) (7.90 hx microg ml(-1) versus 5.99 hx microg ml(-1)) and, particularly, Cmax (8.38 microg ml(-1) versus 5.50 microg ml(-1)) at day 5.",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[h·μg] / [ml],7.90,37977,DB00650,Leucovorin
,15177306,AUC(0-2 h),"In eight subjects, we compared the PK data of the first and the fifth day of dose administration, and we found stable 5-FU values, but the 5-FUH2 disposition decreased with lower AUC(0-2 h) (7.90 hx microg ml(-1) versus 5.99 hx microg ml(-1)) and, particularly, Cmax (8.38 microg ml(-1) versus 5.50 microg ml(-1)) at day 5.",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[h·μg] / [ml],5.99,37978,DB00650,Leucovorin
,15177306,Cmax,"In eight subjects, we compared the PK data of the first and the fifth day of dose administration, and we found stable 5-FU values, but the 5-FUH2 disposition decreased with lower AUC(0-2 h) (7.90 hx microg ml(-1) versus 5.99 hx microg ml(-1)) and, particularly, Cmax (8.38 microg ml(-1) versus 5.50 microg ml(-1)) at day 5.",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[μg] / [ml],8.38,37979,DB00650,Leucovorin
,15177306,Cmax,"In eight subjects, we compared the PK data of the first and the fifth day of dose administration, and we found stable 5-FU values, but the 5-FUH2 disposition decreased with lower AUC(0-2 h) (7.90 hx microg ml(-1) versus 5.99 hx microg ml(-1)) and, particularly, Cmax (8.38 microg ml(-1) versus 5.50 microg ml(-1)) at day 5.",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[μg] / [ml],5.50,37980,DB00650,Leucovorin
,10912573,half-life,The mean half-life of CSF MTX was 8.7 +/- 3.4 h.,Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912573/),h,8.7,40639,DB00650,Leucovorin
,10912573,plasma clearance,The mean plasma clearance of MTX was not significantly different in patients with CNS disease (84 +/- 41 ml/min per m2) versus without CNS disease (59 +/- 38 ml/min per m2).,Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912573/),[ml] / [m2·min],84,40640,DB00650,Leucovorin
,10912573,plasma clearance,The mean plasma clearance of MTX was not significantly different in patients with CNS disease (84 +/- 41 ml/min per m2) versus without CNS disease (59 +/- 38 ml/min per m2).,Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912573/),[ml] / [m2·min],59,40641,DB00650,Leucovorin
,12827293,relative dose intensity,The median relative dose intensity was 1.28 (range 0.5-1.54) compared with the non-adapted theoretical total 5-FU dose.,Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),,1.28,41626,DB00650,Leucovorin
,12827293,objective response rate,The objective response rate was 37% (95% CI 23-50%) in the intention-to-treat population and 47% (95% CI 29-65%) in the first-line per-protocol population.,Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),%,37,41627,DB00650,Leucovorin
,12827293,objective response rate,The objective response rate was 37% (95% CI 23-50%) in the intention-to-treat population and 47% (95% CI 29-65%) in the first-line per-protocol population.,Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),%,47,41628,DB00650,Leucovorin
,12827293,response duration,The median response duration was 10.4 months.,Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,10.4,41629,DB00650,Leucovorin
,12827293,progression-free survival (PFS),"The median progression-free survival (PFS) and overall survival (OS) were, respectively, 7 and 18.6 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,7,41630,DB00650,Leucovorin
,12827293,overall survival (OS),"The median progression-free survival (PFS) and overall survival (OS) were, respectively, 7 and 18.6 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,18,41631,DB00650,Leucovorin
,12827293,PFS,"PFS and OS in first-line per-protocol patients were, respectively, 9.2 and 20 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,9.2,41632,DB00650,Leucovorin
,12827293,PFS,"PFS and OS in first-line per-protocol patients were, respectively, 9.2 and 20 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,20,41633,DB00650,Leucovorin
,12827293,OS,"PFS and OS in first-line per-protocol patients were, respectively, 9.2 and 20 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,20,41634,DB00650,Leucovorin
,6974592,half-life (beta),The natural (l) isomer had a half-life (beta) of 47 +/- 4 (S.E.) min compared to 143 +/- 15 min for the unnatural (d) isomer.,Differences in the pharmacokinetics of the diastereoisomers of citrovorum factor in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6974592/),min,47,42467,DB00650,Leucovorin
,6974592,half-life (beta),The natural (l) isomer had a half-life (beta) of 47 +/- 4 (S.E.) min compared to 143 +/- 15 min for the unnatural (d) isomer.,Differences in the pharmacokinetics of the diastereoisomers of citrovorum factor in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6974592/),min,143,42468,DB00650,Leucovorin
,11953843,area under the curve(0-->3h),The 5-fluorouracil area under the curve(0-->3h) in the index patient was 24.1 mg h l(-1) compared to 9.8+/-3.6 (range 5.4-15.3) mg h l(-1) in control patients.,Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[h·mg] / [l],24.1,43593,DB00650,Leucovorin
,11953843,area under the curve(0-->3h),The 5-fluorouracil area under the curve(0-->3h) in the index patient was 24.1 mg h l(-1) compared to 9.8+/-3.6 (range 5.4-15.3) mg h l(-1) in control patients.,Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[h·mg] / [l],9.8,43594,DB00650,Leucovorin
,11953843,clearance,The 5-fluorouracil clearance was 520 ml min(-1) vs 1293+/-302 (range 980-1780) ml min(-1) in controls.,Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[ml] / [min],520,43595,DB00650,Leucovorin
,11953843,clearance,The 5-fluorouracil clearance was 520 ml min(-1) vs 1293+/-302 (range 980-1780) ml min(-1) in controls.,Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[ml] / [min],1293,43596,DB00650,Leucovorin
,11953843,activity,"The activity of dihydropyrimidine dehydrogenase in mononuclear cells was lower in the index patient (5.5 nmol mg h(-1)) compared to the six controls (10.3+/-1.6, range 8.0-11.7 nmol mg h(-1)).",Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[mg·nM] / [h],5.5,43597,DB00650,Leucovorin
,11953843,activity,"The activity of dihydropyrimidine dehydrogenase in mononuclear cells was lower in the index patient (5.5 nmol mg h(-1)) compared to the six controls (10.3+/-1.6, range 8.0-11.7 nmol mg h(-1)).",Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[mg·nM] / [h],10.3,43598,DB00650,Leucovorin
,8198932,distribution half-life,"2. After intravenous infusion of 600 mg m-2 rac-LV (group 1, n = 7) or 300 mg m-2 [S]-LV (group 3, n = 7), the decay of [S]-LV in plasma was biexponential with a distribution half-life of 0.8 to 1 h and an elimination half-life of 11 to 23 h.",Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198932/),h,0.8 to 1,44978,DB00650,Leucovorin
,8198932,elimination half-life,"2. After intravenous infusion of 600 mg m-2 rac-LV (group 1, n = 7) or 300 mg m-2 [S]-LV (group 3, n = 7), the decay of [S]-LV in plasma was biexponential with a distribution half-life of 0.8 to 1 h and an elimination half-life of 11 to 23 h.",Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198932/),h,11 to 23,44979,DB00650,Leucovorin
,8198932,half-lives,"When rac-LV was administered as a 2 h i.v. infusion (400 mg m-2) following a loading dose of 200 mg m-2 (group 2, n = 7), the plasma concentrations of [R]-LV and [S]-5-MTHF decayed monoexponentially with mean (+/- s.d.) half-lives of 10 +/- 3 h and 7 +/- 2 h, respectively.",Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198932/),h,10,44980,DB00650,Leucovorin
,8198932,half-lives,"When rac-LV was administered as a 2 h i.v. infusion (400 mg m-2) following a loading dose of 200 mg m-2 (group 2, n = 7), the plasma concentrations of [R]-LV and [S]-5-MTHF decayed monoexponentially with mean (+/- s.d.) half-lives of 10 +/- 3 h and 7 +/- 2 h, respectively.",Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198932/),h,7,44981,DB00650,Leucovorin
,8198932,AUC,3. The AUC of [S]-5-MTHF was significantly higher after infusion of 300 mg m-2 [S]-LV than after infusion of 600 mg m-2 rac-LV (83 +/- 22 micrograms ml-1 h vs 53 +/- 22 micrograms ml-1 h; P = 0.01).,Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198932/),[h·μg] / [ml],83,44982,DB00650,Leucovorin
,8198932,AUC,3. The AUC of [S]-5-MTHF was significantly higher after infusion of 300 mg m-2 [S]-LV than after infusion of 600 mg m-2 rac-LV (83 +/- 22 micrograms ml-1 h vs 53 +/- 22 micrograms ml-1 h; P = 0.01).,Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198932/),[h·μg] / [ml],53,44983,DB00650,Leucovorin
,12537514,steady-state AUC(MTX),The results of this study suggest that a steady-state AUC(MTX) value of 700 nmol x h/L and higher are associated with a significantly better success rate of antipsoriatic therapy than lower values.,Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12537514/),[h·nM] / [l],700,45213,DB00650,Leucovorin
,27507617,MTD,Conclusions: The MTD of irinotecan in FOLFIRI plus bevacizumab is 310 mg/m2 for UGT1A1 *1/*1 patients and 260 mg/m2 for *1/*28 patients.,Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27507617/),[mg] / [m2],310,47547,DB00650,Leucovorin
,27507617,MTD,Conclusions: The MTD of irinotecan in FOLFIRI plus bevacizumab is 310 mg/m2 for UGT1A1 *1/*1 patients and 260 mg/m2 for *1/*28 patients.,Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27507617/),[mg] / [m2],260,47548,DB00650,Leucovorin
,10999043,MTD,"The MTD of 5-FU in this schedule was 700 mg/m2/week, with diarrhea dose-limiting.",Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999043/),[mg] / [m],700,48373,DB00650,Leucovorin
,2966610,clearance,"The mean clearance following bolus injection was 38 ml/min per m2, with a range of 15 to 55 ml/min per m2.",Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966610/),[ml] / [m2·min],38,49314,DB00650,Leucovorin
,2966610,half-life,The postdistributive half-life ranged from 6 to 16 h.,Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966610/),h,6 to 16,49315,DB00650,Leucovorin
,2966610,bioavailability,"With oral administration, the mean bioavailability was 44% (range, 19 to 67%).",Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966610/),%,44,49316,DB00650,Leucovorin
more,15025795,AUC,"Although there was no relationship between the area under the plasma concentration time curve (AUC) for the first dose of 5-FU and worst-grade toxicity during the first cycle of therapy, 3 of the 4 patients in whom the AUC on week 4 was more than equal to 5 microgram/h/mL greater than the value for the first dose experienced grade 3/4 toxicity during subsequent treatment.",Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025795/),[μg] / [h·ml],5,51828,DB00650,Leucovorin
,25591799,MTD,MTD for tivozanib with mFOLFOX-6 was confirmed as 1.5 mg.,A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25591799/),mg,1.5,51885,DB00650,Leucovorin
,10663632,terminal half-life,"The pharmacokinetic parameters obtained for (-)-fTHF following the administration of (-)-fTHF only were: terminal half-life, 1.2 h; area under the curve, 10 microg.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),h,1.2,52545,DB00650,Leucovorin
,10663632,area under the curve,"The pharmacokinetic parameters obtained for (-)-fTHF following the administration of (-)-fTHF only were: terminal half-life, 1.2 h; area under the curve, 10 microg.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),μg,10,52546,DB00650,Leucovorin
,10663632,maximum concentration,"h/ml; maximum concentration, 12 microg/ml; clearance, 305 ml/min; volume of distribution, 19 l.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),[μg] / [ml],12,52547,DB00650,Leucovorin
,10663632,clearance,"h/ml; maximum concentration, 12 microg/ml; clearance, 305 ml/min; volume of distribution, 19 l.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),[ml] / [min],305,52548,DB00650,Leucovorin
,10663632,volume of distribution,"h/ml; maximum concentration, 12 microg/ml; clearance, 305 ml/min; volume of distribution, 19 l.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),l,19,52549,DB00650,Leucovorin
,30843362,maximum tolerated dose,"Dose-limiting toxicities of grade 3 diarrhea and myelosuppression were reported for the bolus schedule at 575 mg/m2 (maximum tolerated dose 525 mg/m²), whereas none were reported for the infusional schedule.","First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843362/),[mg] / [m²],525,53379,DB00650,Leucovorin
,30843362,Disease control rate,Disease control rate was 64% despite most patients having failed previous 5-FU regimens.,"First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843362/),%,64,53380,DB00650,Leucovorin
,3209285,half-lives,The concentration-time decay of MTX in serum observed in 29/34 patients receiving 4 x 15 mg/m2/d p.o. leucovorin up to 5 days was biphasic with mean half-lives (+/- SD) of 2.42 +/- 0.45 h for t1/2 alpha and 19.9 +/- 7.6 h for t1/2 beta.,High-dose methotrexate: pharmacokinetics in children and young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),h,2.42,54422,DB00650,Leucovorin
,3209285,t1/2 beta,The concentration-time decay of MTX in serum observed in 29/34 patients receiving 4 x 15 mg/m2/d p.o. leucovorin up to 5 days was biphasic with mean half-lives (+/- SD) of 2.42 +/- 0.45 h for t1/2 alpha and 19.9 +/- 7.6 h for t1/2 beta.,High-dose methotrexate: pharmacokinetics in children and young adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),h,19.9,54423,DB00650,Leucovorin
,3209285,steady-state volume of distribution (Vss),The steady-state volume of distribution (Vss) was 0.56 +/- 0.18 l/kg and the total body clearance (CL) 71 +/- 20 ml/min/m2 (mean +/- SD).,High-dose methotrexate: pharmacokinetics in children and young adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),[l] / [kg],0.56,54424,DB00650,Leucovorin
,3209285,total body clearance (CL),The steady-state volume of distribution (Vss) was 0.56 +/- 0.18 l/kg and the total body clearance (CL) 71 +/- 20 ml/min/m2 (mean +/- SD).,High-dose methotrexate: pharmacokinetics in children and young adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),[ml] / [m2·min],71,54425,DB00650,Leucovorin
,3209285,Peak serum concentrations,"Peak serum concentrations ranged from 674-1778 mumol/l (mean +/- SD, 1201 +/- 293 mumol/l).",High-dose methotrexate: pharmacokinetics in children and young adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),[μM] / [l],674-1778,54426,DB00650,Leucovorin
,3209285,Peak serum concentrations,"Peak serum concentrations ranged from 674-1778 mumol/l (mean +/- SD, 1201 +/- 293 mumol/l).",High-dose methotrexate: pharmacokinetics in children and young adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),[μM] / [l],1201,54427,DB00650,Leucovorin
greater,3209285,elimination t1/2 alpha,In 5/34 patients who received a prolonged leucovorin rescue due to a delayed MTX elimination t1/2 alpha was greater than 3.1 h.,High-dose methotrexate: pharmacokinetics in children and young adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),h,3.1,54428,DB00650,Leucovorin
less,3209285,t1/2 alpha,"The data of this study suggest that patients with MTX serum concentrations of less than or equal to 6.3 mumol/l at 24 h, less than or equal to 0.77 mumol/l at 48 h, and less than or equal to 0.33 mumol/l at 72 h after the end of infusion, and a t1/2 alpha of less than or equal to 3.1 h (97.5th percentiles) are at low risk of toxicity.",High-dose methotrexate: pharmacokinetics in children and young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),h,3.1,54429,DB00650,Leucovorin
,18172273,time to tumor progression,The median time to tumor progression was 7.7 months.,"Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18172273/),month,7.7,55179,DB00650,Leucovorin
,18172273,RD,The RD of EKB-569 is 25 mg/day when combined with FOLFIRI and results in complete EGFR inhibition.,"Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18172273/),[mg] / [d],25,55180,DB00650,Leucovorin
,9515187,peak drug plasma concentrations (Cmax),"Significant inhibition of tumour growth was obtained in mice bearing human colon cancer xenografts and given intraperitoneal zidovudine 300 to 600 mg/kg weekly in combination with methotrexate 87.5 mg/kg or intraperitoneal fluorouracil 85 mg/kg, and in pharmacokinetic studies high peak drug plasma concentrations (Cmax) of zidovudine were obtained, ranging from 610.3 to 1698.8 mumol/L.",Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9515187/),[μM] / [l],610.3 to 1698.8,57087,DB00650,Leucovorin
,30657223,progression-free survival,The median progression-free survival was 5.42 months (4.14-6.70 months) and the median overall survival was 15.59 months (11.20-19.81 months).,Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),month,5.42,57848,DB00650,Leucovorin
,30657223,overall survival,The median progression-free survival was 5.42 months (4.14-6.70 months) and the median overall survival was 15.59 months (11.20-19.81 months).,Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),month,15.59,57849,DB00650,Leucovorin
,30657223,maximum concentration,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[μg] / [ml],73.2,57850,DB00650,Leucovorin
,30657223,clearance,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [d],0.805,57851,DB00650,Leucovorin
,30657223,volume of distribution,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),l,6.2,57852,DB00650,Leucovorin
,30657223,clearance,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [d],0.162,57853,DB00650,Leucovorin
,30657223,clearance,"Aflibercept did not significantly affect the pharmacokinetics of irinotecan or 5-fluorouracil: The clearance was 11.1 L/h/m2 (28%) for irinotecan and, at steady state, 72.6 L/h/m2 (56%) for 5-fluorouracil (N = 10).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [h·m2],11.1,57854,DB00650,Leucovorin
,30657223,clearance,"Aflibercept did not significantly affect the pharmacokinetics of irinotecan or 5-fluorouracil: The clearance was 11.1 L/h/m2 (28%) for irinotecan and, at steady state, 72.6 L/h/m2 (56%) for 5-fluorouracil (N = 10).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [h·m2],72.6,57855,DB00650,Leucovorin
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],23.18,57930,DB00650,Leucovorin
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],5.66,57931,DB00650,Leucovorin
>,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57932,DB00650,Leucovorin
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57933,DB00650,Leucovorin
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57934,DB00650,Leucovorin
>,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57935,DB00650,Leucovorin
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57936,DB00650,Leucovorin
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57937,DB00650,Leucovorin
>,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57938,DB00650,Leucovorin
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57939,DB00650,Leucovorin
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57940,DB00650,Leucovorin
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.95,57941,DB00650,Leucovorin
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.05,57942,DB00650,Leucovorin
,16628132,elimination clearance (CL),"The elimination clearance (CL) and the elimination clearance of the peripheral compartment (CL2) (median +/- SE) were 25.2 +/- 6.3 L/hr and 68 +/- 24.8 L/hr, respectively.",Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628132/),[l] / [h],25.2,61625,DB00650,Leucovorin
,16628132,elimination clearance of the peripheral compartment (CL2),"The elimination clearance (CL) and the elimination clearance of the peripheral compartment (CL2) (median +/- SE) were 25.2 +/- 6.3 L/hr and 68 +/- 24.8 L/hr, respectively.",Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628132/),[l] / [h],68,61626,DB00650,Leucovorin
,16628132,volume of distribution (V1),The median volume of distribution (V1) was determined to be 41.6 +/- 9.4 L and the median volume of distribution of the peripheral compartment (V2) was 452.5 +/- 96.4 L.,Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628132/),l,41.6,61627,DB00650,Leucovorin
,16628132,volume of distribution of the peripheral compartment (V2),The median volume of distribution (V1) was determined to be 41.6 +/- 9.4 L and the median volume of distribution of the peripheral compartment (V2) was 452.5 +/- 96.4 L.,Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628132/),l,452.5,61628,DB00650,Leucovorin
> or =,12448653,T1/2,"Partial responses to 5-FU plus leucovorin therapy were seen only in patients with a long intratumoral half-life (trapping) of 5-FU (3 PR in 11 patients with T1/2 > or = 20 minutes, compared to 0 PR in 11 patients with T1/2 < 20 minutes).",Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12448653/),min,20,61844,DB00650,Leucovorin
<,12448653,T1/2,"Partial responses to 5-FU plus leucovorin therapy were seen only in patients with a long intratumoral half-life (trapping) of 5-FU (3 PR in 11 patients with T1/2 > or = 20 minutes, compared to 0 PR in 11 patients with T1/2 < 20 minutes).",Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12448653/),min,20,61845,DB00650,Leucovorin
,7602355,Response rates,"Response rates on lymph nodes (n = 27) were 40.7% CRs, 37.1% PRs, and 22.2% treatment failures.","Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602355/),%,40.7,63679,DB00650,Leucovorin
,7602355,Response rates,"Response rates on lymph nodes (n = 27) were 40.7% CRs, 37.1% PRs, and 22.2% treatment failures.","Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602355/),,37,63680,DB00650,Leucovorin
,7602355,plasma concentrations,"Pharmacokinetic analysis showed a wide interpatient variability for both FU (mean, 1.01 mumol/L; range, 0.16 to 2.09), l FA (mean, 1.89, mumol/L; range, 0.52 to 7.88) and 5MTHF plasma concentrations (mean, 3.85 mumol/L; range, 1.30 to 8.11).","Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602355/),[μM] / [l],3.85,63681,DB00650,Leucovorin
,16825251,overall response rate,"The overall response rate was 35% [95% confidence interval (CI), 23-48%], and 52% of patients had stable disease.",A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16825251/),%,35,65409,DB00650,Leucovorin
,16825251,time to progression,"The median time to progression was 5.5 months (95% CI, 4.2-6.7 months).",A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16825251/),month,5.5,65410,DB00650,Leucovorin
,16825251,overall survival,"The median overall survival was 20.2 months (95% CI, 16.6-27.8 months).",A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16825251/),month,20.2,65411,DB00650,Leucovorin
,8426214,maximally tolerated dose (MTD),"After decreasing the 5-FU dose to 640 mg/m2/d, the maximally tolerated dose (MTD) of IFN was 2.0 x 10(6) U/m2/d.","Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8426214/),,2,65829,DB00650,Leucovorin
,9552052,areas under the curve (AUC),The mean areas under the curve (AUC) for the i.v. (n = 14) and oral (n = 13) doses were 1.20 +/- 0.09 (SE) and 1.05 +/- 0.14 micromol x h/L respectively.,Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552052/),[h·μM] / [l],1.20,66052,DB00650,Leucovorin
,9552052,areas under the curve (AUC),The mean areas under the curve (AUC) for the i.v. (n = 14) and oral (n = 13) doses were 1.20 +/- 0.09 (SE) and 1.05 +/- 0.14 micromol x h/L respectively.,Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552052/),[h·μM] / [l],1.05,66053,DB00650,Leucovorin
,9552052,half-life,The half-life was 3.64 +/- 0.28 hours and the oral bioavailability in 12 matched subjects was 83.5% +/- 8.3%.,Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552052/),h,3.64,66054,DB00650,Leucovorin
,9552052,oral bioavailability,The half-life was 3.64 +/- 0.28 hours and the oral bioavailability in 12 matched subjects was 83.5% +/- 8.3%.,Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552052/),%,83.5,66055,DB00650,Leucovorin
,19337632,time of progression,The median time of progression was 9.3 months.,Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19337632/),month,9.3,68766,DB00650,Leucovorin
,20658719,overall response rate,"The overall response rate and the median time to progression (TTP) were 53.49% and 7.1 months, respectively.",Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),%,53.49,68798,DB00650,Leucovorin
,20658719,time to progression (TTP),"The overall response rate and the median time to progression (TTP) were 53.49% and 7.1 months, respectively.",Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),month,7.1,68799,DB00650,Leucovorin
,20658719,area under the time-concentration curve (AUC),The area under the time-concentration curve (AUC) in UFT was 4.8 + or - 0.72 standard deviation (SD) microg h/ml and the total clearance 30.17 + or - 7.75 l/min.,Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),[h·μg] / [ml],4.8,68800,DB00650,Leucovorin
,20658719,total clearance,The area under the time-concentration curve (AUC) in UFT was 4.8 + or - 0.72 standard deviation (SD) microg h/ml and the total clearance 30.17 + or - 7.75 l/min.,Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),[l] / [min],30.17,68801,DB00650,Leucovorin
,20658719,volume of distribution,"The values for volume of distribution and the maximum concentration were 567 + or - 20 liters and 0.38 + or - 0.17 ug/ml, respectively.",Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),l,567,68802,DB00650,Leucovorin
,20658719,maximum concentration,"The values for volume of distribution and the maximum concentration were 567 + or - 20 liters and 0.38 + or - 0.17 ug/ml, respectively.",Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),[ug] / [ml],0.38,68803,DB00650,Leucovorin
,11127938,terminal half-life (t 1/2beta),"At the various study doses, the terminal half-life (t 1/2beta) of FT ranged from 3.9 to 5.9 h, the area under the concentration-versus-time curve (AUC0-6h) ranged from 16,220 to 52,446 (ng/ml)h, the total clearance (ClT) ranged from 100 to 175 ml/min, and the steady-state volume of distribution (Vd(ss)) ranged from 18.3 to 28.7 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),h,3.9 to 5.9,71829,DB00650,Leucovorin
,11127938,area under the concentration-versus-time curve (AUC0-6h),"At the various study doses, the terminal half-life (t 1/2beta) of FT ranged from 3.9 to 5.9 h, the area under the concentration-versus-time curve (AUC0-6h) ranged from 16,220 to 52,446 (ng/ml)h, the total clearance (ClT) ranged from 100 to 175 ml/min, and the steady-state volume of distribution (Vd(ss)) ranged from 18.3 to 28.7 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),[ng] / [ml)h],"16,220 to 52,446",71830,DB00650,Leucovorin
,11127938,total clearance (ClT),"At the various study doses, the terminal half-life (t 1/2beta) of FT ranged from 3.9 to 5.9 h, the area under the concentration-versus-time curve (AUC0-6h) ranged from 16,220 to 52,446 (ng/ml)h, the total clearance (ClT) ranged from 100 to 175 ml/min, and the steady-state volume of distribution (Vd(ss)) ranged from 18.3 to 28.7 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),[ml] / [min],100 to 175,71831,DB00650,Leucovorin
,11127938,steady-state volume of distribution (Vd(ss)),"At the various study doses, the terminal half-life (t 1/2beta) of FT ranged from 3.9 to 5.9 h, the area under the concentration-versus-time curve (AUC0-6h) ranged from 16,220 to 52,446 (ng/ml)h, the total clearance (ClT) ranged from 100 to 175 ml/min, and the steady-state volume of distribution (Vd(ss)) ranged from 18.3 to 28.7 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),l,18.3 to 28.7,71832,DB00650,Leucovorin
,11127938,apparent distribution half-life (t 1/2alpha),"The 5-FU generated from FT had an apparent distribution half-life (t 1/2alpha) and an apparent elimination half-life (t 1/2beta) of 0.3-1.3 h and 4.9-7.0 h, respectively.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),h,0.3-1.3,71833,DB00650,Leucovorin
,11127938,apparent elimination half-life (t 1/2beta),"The 5-FU generated from FT had an apparent distribution half-life (t 1/2alpha) and an apparent elimination half-life (t 1/2beta) of 0.3-1.3 h and 4.9-7.0 h, respectively.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),h,4.9-7.0,71834,DB00650,Leucovorin
,11127938,AUC0-6h,The AUC0-6h of 5-FU ranged from 120 to 325 (ng/ml)h.,Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),[ng] / [ml)h],120 to 325,71835,DB00650,Leucovorin
,11127938,t 1/2alpha,Uracil had a t 1/2alpha of 0.2-0.5 h and the level quickly returned to the endogenous level.,Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),h,0.2-0.5,71836,DB00650,Leucovorin
,11127938,AUC0-6h,"The AUC0-6h for uracil ranged from 605 to 3764 (ng/ml)h, the ClT ranged from 3225 to 7748 ml/min, and the Vd(ss) ranged from 341 to 1354 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),,605 to 3764,71837,DB00650,Leucovorin
,11127938,ClT,"The AUC0-6h for uracil ranged from 605 to 3764 (ng/ml)h, the ClT ranged from 3225 to 7748 ml/min, and the Vd(ss) ranged from 341 to 1354 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),[ml] / [min],3225 to 7748,71838,DB00650,Leucovorin
,11127938,Vd(ss),"The AUC0-6h for uracil ranged from 605 to 3764 (ng/ml)h, the ClT ranged from 3225 to 7748 ml/min, and the Vd(ss) ranged from 341 to 1354 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),l,341 to 1354,71839,DB00650,Leucovorin
,21447616,objective response rate,"At the MTD, non-haematologic grade 3/4 adverse events with a frequency of >10% were diarrhoea, vomiting and lethargy, and the objective response rate was 57.9% (95% confidence interval 33.5-79.7).",A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447616/),%,57.,73220,DB00650,Leucovorin
,21447616,MTD,The MTD of sunitinib combined with FOLFIRI in chemotherapy-naive mCRC was 37.5 mg/day on Schedule 4/2.,A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447616/),[mg] / [d],37.5,73221,DB00650,Leucovorin
,2789922,steady state volume of distribution (Vss),"The mean steady state volume of distribution (Vss) was 161; systemic and renal clearances averaged 335 and 53 ml min-1, respectively.",Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2789922/),,161,73751,DB00650,Leucovorin
,2789922,systemic,"The mean steady state volume of distribution (Vss) was 161; systemic and renal clearances averaged 335 and 53 ml min-1, respectively.",Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2789922/),[ml] / [min],335,73752,DB00650,Leucovorin
,2789922,renal clearances,"The mean steady state volume of distribution (Vss) was 161; systemic and renal clearances averaged 335 and 53 ml min-1, respectively.",Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2789922/),[ml] / [min],53,73753,DB00650,Leucovorin
,2789922,Absolute bioavailability,Absolute bioavailability was only 4% as a consequence of a significant intestinal first pass effect.,Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2789922/),%,4,73754,DB00650,Leucovorin
,8325125,clearance,The clearance was fast at 158 +/- 81 ml/min/m2 and the elimination half-life (t1/2 beta) 3.0 +/- 0.7 h (mean +/- SD).,Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325125/),[ml] / [m2·min],158,74024,DB00650,Leucovorin
,8325125,elimination half-life (t1/2 beta),The clearance was fast at 158 +/- 81 ml/min/m2 and the elimination half-life (t1/2 beta) 3.0 +/- 0.7 h (mean +/- SD).,Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325125/),h,3.0,74025,DB00650,Leucovorin
,8325125,half-lives,The patients were at low risk for toxicity with a predicted MTX concentration at 39 h (5 half-lives) postinfusion of 0.28 +/- 0.10 mumol/l (mean +/- SD).,Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325125/),[μM] / [l],0.28,74026,DB00650,Leucovorin
,11459996,plasma:peritoneal fluid concentration ratio,The steady-state HU plasma:peritoneal fluid concentration ratio ranged from 1.06 x 10(3) to 1.25 x 10(3) and the plasma HU clearance ranged from 4.63 to 5.81 l/h/m(2).,Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),,1.06 x 10(3),74233,DB00650,Leucovorin
,11459996,plasma:peritoneal fluid concentration ratio,The steady-state HU plasma:peritoneal fluid concentration ratio ranged from 1.06 x 10(3) to 1.25 x 10(3) and the plasma HU clearance ranged from 4.63 to 5.81 l/h/m(2).,Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),,1.25 x 10(3),74234,DB00650,Leucovorin
,11459996,clearance,The steady-state HU plasma:peritoneal fluid concentration ratio ranged from 1.06 x 10(3) to 1.25 x 10(3) and the plasma HU clearance ranged from 4.63 to 5.81 l/h/m(2).,Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),[h·l] / [m(2],4.63,74235,DB00650,Leucovorin
,11459996,Peritoneal fluid,"Peritoneal fluid AUC = 137,639 +/- 43,914 microg/ml x min, t(1/2) = 100.9 +/- 56.4 min and Cl = 25.29 +/- 10.88 ml/min.",Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),[μg] / [min·ml],"137,639",74236,DB00650,Leucovorin
,11459996,AUC,"Peritoneal fluid AUC = 137,639 +/- 43,914 microg/ml x min, t(1/2) = 100.9 +/- 56.4 min and Cl = 25.29 +/- 10.88 ml/min.",Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),[μg] / [min·ml],"137,639",74237,DB00650,Leucovorin
,11459996,t(1/2),"Peritoneal fluid AUC = 137,639 +/- 43,914 microg/ml x min, t(1/2) = 100.9 +/- 56.4 min and Cl = 25.29 +/- 10.88 ml/min.",Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),min,100.9,74238,DB00650,Leucovorin
,11459996,Cl,"Peritoneal fluid AUC = 137,639 +/- 43,914 microg/ml x min, t(1/2) = 100.9 +/- 56.4 min and Cl = 25.29 +/- 10.88 ml/min.",Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),[ml] / [min],25.29,74239,DB00650,Leucovorin
,23228985,clearance (CL),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),[ml] / [d],214,74560,DB00650,Leucovorin
,23228985,central volume of distribution (V(1)),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),ml,"2,830",74561,DB00650,Leucovorin
,23228985,central volume of distribution (V(1)),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),[ml] / [d],636,74562,DB00650,Leucovorin
,23228985,intercompartmental clearance (Q),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),ml,"2,830",74563,DB00650,Leucovorin
,23228985,intercompartmental clearance (Q),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),[ml] / [d],636,74564,DB00650,Leucovorin
,23228985,peripheral volume of distribution (V(2)),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),ml,"2,490",74565,DB00650,Leucovorin
,23228985,disposition,"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),d,1.33,74566,DB00650,Leucovorin
,23228985,elimination half-life,"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),d,19.1,74567,DB00650,Leucovorin
,6609105,duration of survival,The median duration of survival in the squamous group was 9 months and in the nonsquamous groups 6.5 months.,Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6609105/),month,9,75275,DB00650,Leucovorin
,6609105,duration of survival,The median duration of survival in the squamous group was 9 months and in the nonsquamous groups 6.5 months.,Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6609105/),month,6.5,75276,DB00650,Leucovorin
,3502454,terminal half-lives,The average terminal half-lives of methotrexate and 7-hydroxy-methotrexate in plasma were 15.02 and 15.19 hours respectively.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),h,15.02,75278,DB00650,Leucovorin
,3502454,terminal half-lives,The average terminal half-lives of methotrexate and 7-hydroxy-methotrexate in plasma were 15.02 and 15.19 hours respectively.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),h,15.19,75279,DB00650,Leucovorin
,3502454,area under concentration-time curve,The area under concentration-time curve was 723.8 +/- 196.4 microM x h for methotrexate and 598.1 +/- 212.5 microM x h for 7-hydroxy-methotrexate.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),h·μM,723.8,75280,DB00650,Leucovorin
,3502454,area under concentration-time curve,The area under concentration-time curve was 723.8 +/- 196.4 microM x h for methotrexate and 598.1 +/- 212.5 microM x h for 7-hydroxy-methotrexate.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),h·μM,598.1,75281,DB00650,Leucovorin
,3502454,urinary excretions,The total average urinary excretions of methotrexate and 7-hydroxy-methotrexate over a 96 hour period were 52% and 5.4% respectively.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),%,52,75282,DB00650,Leucovorin
,3502454,urinary excretions,The total average urinary excretions of methotrexate and 7-hydroxy-methotrexate over a 96 hour period were 52% and 5.4% respectively.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),%,5.4,75283,DB00650,Leucovorin
,3502454,Urinary clearance,Urinary clearance of methotrexate was 3.46 +/- 1.4 1/h.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),[1] / [h],3.46,75284,DB00650,Leucovorin
,7581908,Time of analysis,Time of analysis is 70 min.,Highly sensitive coupled-column high-performance liquid chromatographic method for the separation and quantitation of the diastereomers of leucovorin and 5-methyltetrahydrofolate in serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7581908/),min,70,76541,DB00650,Leucovorin
,7581908,Detection limit,Detection limit is 5 ng/ml for each diastereometer.,Highly sensitive coupled-column high-performance liquid chromatographic method for the separation and quantitation of the diastereomers of leucovorin and 5-methyltetrahydrofolate in serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7581908/),[ng] / [ml],5,76542,DB00650,Leucovorin
,8612313,Cmax,"Plasma levels of 5-FU (Cmax 1.4 +/- 1.9 microM) were comparable to those achieved with protracted venous infusions, and folate levels (Cmax 6.1 +/- 3.6 microM) were sufficient for biochemical modulation.","A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612313/),μM,1.4,77168,DB00650,Leucovorin
,8612313,Cmax,"Plasma levels of 5-FU (Cmax 1.4 +/- 1.9 microM) were comparable to those achieved with protracted venous infusions, and folate levels (Cmax 6.1 +/- 3.6 microM) were sufficient for biochemical modulation.","A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612313/),μM,6.1,77169,DB00650,Leucovorin
,7332733,peak level,"3 At an oral dose of 65 mg/m2 without leucovorin, a peak level of 0.6 microgram/ml and an AUC of 52 micrograms ml-1 h produced significant leukopenia and thrombocytopenia.","Kinetics of metoprine, a lipid-soluble antifolate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[μg] / [ml],0.6,79316,DB00650,Leucovorin
,7332733,AUC,"3 At an oral dose of 65 mg/m2 without leucovorin, a peak level of 0.6 microgram/ml and an AUC of 52 micrograms ml-1 h produced significant leukopenia and thrombocytopenia.","Kinetics of metoprine, a lipid-soluble antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[h·μg] / [ml],52,79317,DB00650,Leucovorin
,7332733,peak serum level,This patient also had the highest peak serum level (2.8 micrograms/ml) and AUC (228 micrograms ml-1 h).,"Kinetics of metoprine, a lipid-soluble antifolate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[μg] / [ml],2.8,79318,DB00650,Leucovorin
,7332733,AUC,This patient also had the highest peak serum level (2.8 micrograms/ml) and AUC (228 micrograms ml-1 h).,"Kinetics of metoprine, a lipid-soluble antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[h·μg] / [ml],228,79319,DB00650,Leucovorin
,7332733,peak levels,"5 One partial response and one minor regression were observed in the studied patients; these two patients had the 175 mg/m2 dose, highest peak levels (2.4 and 2.8 micrograms/ml) and highest AUCs (197 and 228 micrograms ml-1 h).","Kinetics of metoprine, a lipid-soluble antifolate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[μg] / [ml],2.4,79320,DB00650,Leucovorin
,7332733,peak levels,"5 One partial response and one minor regression were observed in the studied patients; these two patients had the 175 mg/m2 dose, highest peak levels (2.4 and 2.8 micrograms/ml) and highest AUCs (197 and 228 micrograms ml-1 h).","Kinetics of metoprine, a lipid-soluble antifolate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[μg] / [ml],2.8,79321,DB00650,Leucovorin
,7332733,AUCs,"5 One partial response and one minor regression were observed in the studied patients; these two patients had the 175 mg/m2 dose, highest peak levels (2.4 and 2.8 micrograms/ml) and highest AUCs (197 and 228 micrograms ml-1 h).","Kinetics of metoprine, a lipid-soluble antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[h·μg] / [ml],197,79322,DB00650,Leucovorin
,7332733,AUCs,"5 One partial response and one minor regression were observed in the studied patients; these two patients had the 175 mg/m2 dose, highest peak levels (2.4 and 2.8 micrograms/ml) and highest AUCs (197 and 228 micrograms ml-1 h).","Kinetics of metoprine, a lipid-soluble antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[h·μg] / [ml],228,79323,DB00650,Leucovorin
,7332733,Total urinary excretion,7 Total urinary excretion of dihydrofolate reductase inhibitors (as metoprine equivalents) in the first 120 h ranged from 5 to 17% of the administered dose.,"Kinetics of metoprine, a lipid-soluble antifolate. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),%,5 to 17,79324,DB00650,Leucovorin
,10228497,AUC,"The distribution of doxifluridine parameters remained the same between days 1 and 5, with an AUC that ranged between 72.2 and 74.5 mmol h/l and a C max that remained in a narrow band of 67.1 to 68.3 mmol/l.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[h·mM] / [l],72.2 and 74.5,80790,DB00650,Leucovorin
,10228497,C max,"The distribution of doxifluridine parameters remained the same between days 1 and 5, with an AUC that ranged between 72.2 and 74.5 mmol h/l and a C max that remained in a narrow band of 67.1 to 68.3 mmol/l.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[mM] / [l],67.1 to 68.3,80791,DB00650,Leucovorin
,10228497,AUC,"In contrast, the variability of fluorouracil parameters increased from day 1 to day 5, with an AUC of respectively 5.46 and 7.52 mmol h/l and a C max that increased from 5.81 on day 1 to 7.34 mmol/l on day 5.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[h·mM] / [l],5.46,80792,DB00650,Leucovorin
,10228497,AUC,"In contrast, the variability of fluorouracil parameters increased from day 1 to day 5, with an AUC of respectively 5.46 and 7.52 mmol h/l and a C max that increased from 5.81 on day 1 to 7.34 mmol/l on day 5.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[h·mM] / [l],7.52,80793,DB00650,Leucovorin
,10228497,C max,"In contrast, the variability of fluorouracil parameters increased from day 1 to day 5, with an AUC of respectively 5.46 and 7.52 mmol h/l and a C max that increased from 5.81 on day 1 to 7.34 mmol/l on day 5.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[mM] / [l],5.81,80794,DB00650,Leucovorin
,10228497,C max,"In contrast, the variability of fluorouracil parameters increased from day 1 to day 5, with an AUC of respectively 5.46 and 7.52 mmol h/l and a C max that increased from 5.81 on day 1 to 7.34 mmol/l on day 5.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[mM] / [l],7.34,80795,DB00650,Leucovorin
,15150625,time to progression,"The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months.","A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150625/),month,7.26,85493,DB00650,Leucovorin
,15150625,overall survival,"The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months.","A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150625/),month,22,85494,DB00650,Leucovorin
,19940012,maximum tolerated dose,Two of the four patients receiving axitinib with FOLFOX plus 5 mg/kg bevacizumab experienced dose-limiting toxicity (DLT) of inability to resume treatment for 14 days following treatment interruption (associated AE: hypertension); the maximum tolerated dose of bevacizumab in this combination was 2 mg/kg.,A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940012/),,2,86414,DB00650,Leucovorin
,19940012,objective response rate,Ten patients had RECIST-confirmed partial tumor responses (objective response rate: 33.3%).,A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940012/),%,33.3,86415,DB00650,Leucovorin
,10993519,limit of detection,The limit of detection was 0.17 pmol which corresponds to a plasma concentration of 1.7 nmol/l.,High-performance liquid chromatographic assay for the determination of 5-methyltetrahydrofolate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993519/),pM,0.17,86781,DB00650,Leucovorin
,15596912,Objective response rate,Objective response rate in 23 evaluable patients was 39.2%.,"Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15596912/),%,39.2,86860,DB00650,Leucovorin
,3501545,plasma half-life (t1/2),"In both studies the plasma half-life (t1/2) of the active isomer, L-formyltetrahydrofolate (CHO-THF), was only 32 to 35 minutes, whereas the inactive isomer, D-CHO-THF had a plasma t 1/2 of 352 to 485 minutes.","Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501545/),min,32 to 35,87922,DB00650,Leucovorin
,3501545,plasma t 1/2,"In both studies the plasma half-life (t1/2) of the active isomer, L-formyltetrahydrofolate (CHO-THF), was only 32 to 35 minutes, whereas the inactive isomer, D-CHO-THF had a plasma t 1/2 of 352 to 485 minutes.","Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501545/),min,352 to 485,87923,DB00650,Leucovorin
,17112298,V(1),For children aged < or =10 years: CL (L/h) = 0.287 . TBW(0.876); V(1) (L) = 0.465 .,Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112298/),l,0.465,88231,DB00650,Leucovorin
,9241112,concentrations,"AMT can be detected in the CSF after oral administration of ZDV; concentrations of AMT in CSF ranged from 0.75 to 4.8 ng/ml (median, 1.7 ng/ml).","Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241112/),,0.75 to 4.8,88251,DB00650,Leucovorin
,9241112,concentrations,"AMT can be detected in the CSF after oral administration of ZDV; concentrations of AMT in CSF ranged from 0.75 to 4.8 ng/ml (median, 1.7 ng/ml).","Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241112/),ng,1.7,88252,DB00650,Leucovorin
,9241112,CSF-plasma concentration ratio,"The median CSF-plasma concentration ratio was 1, and equaled that for ZDV.","Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241112/),,1,88253,DB00650,Leucovorin
,23082002,overall response rates,"The overall response rates for placebo-treated and vismodegib-treated patients were 51% (90% CI: 43-60) and 46% (90% CI: 37-55), respectively.",A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23082002/),%,51,88444,DB00650,Leucovorin
,23082002,overall response rates,"The overall response rates for placebo-treated and vismodegib-treated patients were 51% (90% CI: 43-60) and 46% (90% CI: 37-55), respectively.",A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23082002/),%,46,88445,DB00650,Leucovorin
,309355,half-life,CPDG1 rescue resulted in a prolonged CSF-MTX half-life of 16.5-23 hours in comparison with CF rescue where the CSF-MTX half-life was 6.5-7.2 hours.,Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/309355/),h,16.5-23,89411,DB00650,Leucovorin
,309355,half-life,CPDG1 rescue resulted in a prolonged CSF-MTX half-life of 16.5-23 hours in comparison with CF rescue where the CSF-MTX half-life was 6.5-7.2 hours.,Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/309355/),h,6.5-7.2,89412,DB00650,Leucovorin
,18282,half-life,The half-life of MTX in the CSF (11.95 hours) is twice as long as the serum half-life.,Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282/),h,11.95,90825,DB00650,Leucovorin
,7479197,total clearance,"The mean (SD) ZDV pharmacokinetic values were total clearance 1.44 (1.09) L/hr/kg, volume of distribution 2.72 (2.97) L/kg, and half-life 1.2 (0.6) hours.",Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479197/),[l] / [h·kg],1.44,91924,DB00650,Leucovorin
,7479197,volume of distribution,"The mean (SD) ZDV pharmacokinetic values were total clearance 1.44 (1.09) L/hr/kg, volume of distribution 2.72 (2.97) L/kg, and half-life 1.2 (0.6) hours.",Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479197/),[l] / [kg],2.72,91925,DB00650,Leucovorin
,7479197,half-life,"The mean (SD) ZDV pharmacokinetic values were total clearance 1.44 (1.09) L/hr/kg, volume of distribution 2.72 (2.97) L/kg, and half-life 1.2 (0.6) hours.",Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479197/),h,1.2,91926,DB00650,Leucovorin
,18441330,confirmed response rate,"The confirmed response rate for patients receiving 5-FU at standard 2000 mg/m(2) (N = 41) was 56%, with a median duration of 9.3 months.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),%,56,95589,DB00650,Leucovorin
,18441330,progression-free,"Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0-9.7) and 28.2 months, respectively.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),month,8.1,95590,DB00650,Leucovorin
,18441330,overall survival times,"Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0-9.7) and 28.2 months, respectively.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),month,28.2,95591,DB00650,Leucovorin
,1557660,serum half-life times,5-FU kinetics are characterized by short serum half-life times of 4.5 to 13 minutes.,Clinical pharmacokinetics of fluorouracil and folinic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),min,4.5 to 13,96571,DB00650,Leucovorin
,1557660,half-life,"After administration of the commercially available d,l-folinic acid (d,l-CHO-THF), the biologically inactive d-form is cleared very slowly with a median half-life of 438 +/- 63 minutes.",Clinical pharmacokinetics of fluorouracil and folinic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),min,438,96572,DB00650,Leucovorin
,1557660,elimination half-lives,l-CHO has short elimination half-lives of 56.5 +/- 10.5 minutes.,Clinical pharmacokinetics of fluorouracil and folinic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),min,56.5,96573,DB00650,Leucovorin
,1557660,body clearance,The high body clearance of 222 +/- 27 mL/min is partially caused by metabolism to l-methyltetrahydrofolic acid (l-CH3-THF).,Clinical pharmacokinetics of fluorouracil and folinic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),[ml] / [min],222,96574,DB00650,Leucovorin
,25563323,CL1,"The PPK parameters (RSD%) were CL1, V1, CL2 and V2 with values of 6.20 L/h (8.48%), 19.6 L (extremely small), 0.0172 L/h (50.9%) and 0.515 L (39.1%), respectively.",Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563323/),[l] / [h],6.20,97080,DB00650,Leucovorin
,25563323,V2,"The PPK parameters (RSD%) were CL1, V1, CL2 and V2 with values of 6.20 L/h (8.48%), 19.6 L (extremely small), 0.0172 L/h (50.9%) and 0.515 L (39.1%), respectively.",Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563323/),l,0.515,97081,DB00650,Leucovorin
,22020318,PFS,"The median PFS and overall survival on the low-dose arm were 2.4 and 6.5 months, respectively.",A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22020318/),month,2.4,99084,DB00650,Leucovorin
,22020318,overall survival,"The median PFS and overall survival on the low-dose arm were 2.4 and 6.5 months, respectively.",A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22020318/),month,6.5,99085,DB00650,Leucovorin
,32066346,Volume of distribution,"Volume of distribution and area under the curve of the 30% reduced L-OHP dose were 56.7 L and 30.0 μg·h/mL, respectively.",Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32066346/),l,56.7,99651,DB00650,Leucovorin
,32066346,area under the curve,"Volume of distribution and area under the curve of the 30% reduced L-OHP dose were 56.7 L and 30.0 μg·h/mL, respectively.",Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32066346/),[h·μg] / [ml],30.0,99652,DB00650,Leucovorin
,11886004,flow-rate,The flow-rate was 2 l/min for 30 min.,Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11886004/),[l] / [min],2,101973,DB00650,Leucovorin
,25687989,clearance,"The estimated clearance of bevacizumab was 0.18 L/day, the free VEGF165 levels at baseline were 212 ng/L, and the elimination rate constant of free VEGF165 was 0.401 day(-1).",A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687989/),[l] / [d],0.18,102885,DB00650,Leucovorin
,25687989,elimination rate constant,"The estimated clearance of bevacizumab was 0.18 L/day, the free VEGF165 levels at baseline were 212 ng/L, and the elimination rate constant of free VEGF165 was 0.401 day(-1).",A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687989/),1/[day],0.401,102886,DB00650,Leucovorin
,3876873,t1/2,"The levels declined rapidly with a two-phase elimination pattern (t1/2 = 1.2-2.5 hours, t1/2 = 18-32 hours).",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),h,1.2-2.5,104192,DB00650,Leucovorin
,3876873,t1/2,"The levels declined rapidly with a two-phase elimination pattern (t1/2 = 1.2-2.5 hours, t1/2 = 18-32 hours).",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),h,18-32,104193,DB00650,Leucovorin
,3876873,folate level,"The folate level in the plasma ranged from 5 X 10(-7) M to 1.4 X 10(-6) M when CF was administered every six hours or every three hours, respectively.",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),M,5 X 10(-7),104194,DB00650,Leucovorin
,3876873,folate level,"The folate level in the plasma ranged from 5 X 10(-7) M to 1.4 X 10(-6) M when CF was administered every six hours or every three hours, respectively.",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),,1.4 X 10(-6),104195,DB00650,Leucovorin
,12021636,MAE%,"MPE% ranged between -0.8% and -8.3% and MAE% between 6.1% and 9.5%, depending on the time combination used.",New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021636/),%,6.1,105318,DB00650,Leucovorin
,12021636,MAE%,"MPE% ranged between -0.8% and -8.3% and MAE% between 6.1% and 9.5%, depending on the time combination used.",New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021636/),%,9.5,105319,DB00650,Leucovorin
,3498014,survival time,Median survival time for all 28 patients enrolled in the study was 22 weeks.,A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3498014/),weeks,22,106107,DB00650,Leucovorin
,31370815,overall response rate,The overall response rate was 55.6%.,Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31370815/),%,55.6,107632,DB00650,Leucovorin
,31370815,progression free,"The median progression free and overall survival were 8.1 and 18.2 months, respectively.",Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31370815/),month,8.1,107633,DB00650,Leucovorin
,31370815,overall survival,"The median progression free and overall survival were 8.1 and 18.2 months, respectively.",Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31370815/),month,18.2,107634,DB00650,Leucovorin
,9815792,clearance,5-FU clearance was higher in 14 cycles with IFN-gamma compared to the patient's prior cycle with the same doses of 5-FU/LV/IFN-alpha: 798 +/- 309 versus 601 +/- 250 ml/min/m2 (mean +/- SD; P = 0.04).,"A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],798,108248,DB00650,Leucovorin
,9815792,clearance,5-FU clearance was higher in 14 cycles with IFN-gamma compared to the patient's prior cycle with the same doses of 5-FU/LV/IFN-alpha: 798 +/- 309 versus 601 +/- 250 ml/min/m2 (mean +/- SD; P = 0.04).,"A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],601,108249,DB00650,Leucovorin
,9815792,clearance,"In these 28 cycles, the median 5-FU clearance was significantly lower in 11 cycles that were complicated by more severe diarrhea: 524 versus 798 ml/min/m2 (grade 2 versus 0-1; P = 0. 0032).","A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],524,108250,DB00650,Leucovorin
,9815792,clearance,"In these 28 cycles, the median 5-FU clearance was significantly lower in 11 cycles that were complicated by more severe diarrhea: 524 versus 798 ml/min/m2 (grade 2 versus 0-1; P = 0. 0032).","A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],798,108251,DB00650,Leucovorin
,9815792,maximum tolerated dose,"Dose reductions of IFN-gamma for chronic fatigue, malaise, or anorexia were ultimately required more frequently with >/=2.4 MU/m2 (P = 0.018), and the maximum tolerated dose of IFN-gamma was considered to be 1.2 MU/m2/ day.","A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[Mu] / [·d·m2],1.2,108252,DB00650,Leucovorin
,22201120,Overall response rate,"Overall response rate and median progression-free survival in a total of 61 patients were 43% and 7.5 months, respectively.",Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201120/),%,43,108550,DB00650,Leucovorin
,22201120,progression-free survival,"Overall response rate and median progression-free survival in a total of 61 patients were 43% and 7.5 months, respectively.",Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201120/),month,7.5,108551,DB00650,Leucovorin
>,12707718,half-life,"EU on either schedule decreased 5-FU plasma clearance by 48 to 52-fold, prolonged the half-life to >5 h, and increased the percentage of 5-FU excreted in the urine from 2% to 64-66%.","Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12707718/),h,5,108587,DB00650,Leucovorin
,27067847,area under the curve (AUC),The sample group included 11 patients in whom 5-FU doses were adjusted individually based on pharmacokinetic monitoring according to an algorithm to maintain the area under the curve (AUC) in the range of 20-25 mg·h/L (Group A) and 9 patients in whom 5-FU doses were adjusted conventionally based on body surface area (Group B).,[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),[h·mg] / [l],20-25,109235,DB00650,Leucovorin
,27067847,objective response rate,"The objective response rate was 63% and 33% in Group A and Group B, respectively (p=0.174).",[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),%,63,109236,DB00650,Leucovorin
,27067847,objective response rate,"The objective response rate was 63% and 33% in Group A and Group B, respectively (p=0.174).",[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),%,33,109237,DB00650,Leucovorin
,27067847,overall survival,"The median overall survival was 34 months and 14 months in Group A and Group B, respectively (p=0.036).",[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),month,34,109238,DB00650,Leucovorin
,27067847,overall survival,"The median overall survival was 34 months and 14 months in Group A and Group B, respectively (p=0.036).",[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),month,14,109239,DB00650,Leucovorin
,30262136,progression-free survival,"Objective response (35 [49%] of 71 vs 40 [56%] of 71), clinical benefit (62 [87%] vs 65 [92%]), and progression-free survival (median 10·8 months [95% CI 7·4-11·5] vs 11·1 months [95% CI 8·0-12·8]) were similar in the BEVZ92 and reference bevacizumab groups.","Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30262136/),month,10·8,109658,DB00650,Leucovorin
,30262136,progression-free survival,"Objective response (35 [49%] of 71 vs 40 [56%] of 71), clinical benefit (62 [87%] vs 65 [92%]), and progression-free survival (median 10·8 months [95% CI 7·4-11·5] vs 11·1 months [95% CI 8·0-12·8]) were similar in the BEVZ92 and reference bevacizumab groups.","Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30262136/),month,11·1,109659,DB00650,Leucovorin
,12207632,-,"FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females.",Relationships between body composition parameters and fluorouracil pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207632/),[l] / [min],0.030,110790,DB00650,Leucovorin
,12207632,-,"FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females.",Relationships between body composition parameters and fluorouracil pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207632/),[l] / [min],0.022,110791,DB00650,Leucovorin
,12207632,normalized CL,"FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females.",Relationships between body composition parameters and fluorouracil pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207632/),[l] / [min],0.030,110792,DB00650,Leucovorin
,12207632,normalized CL,"FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females.",Relationships between body composition parameters and fluorouracil pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207632/),[l] / [min],0.022,110793,DB00650,Leucovorin
,2676149,steady-state plasma concentration,"Eleven patients treated with a 5.5-day continuous i.v. infusion of 500 mg/m2/day of (6R,S)-folinic acid in combination with daily bolus 5-fluorouracil had a median steady-state plasma concentration of 3.25 microM (6S)-folinic acid (the bioactive diastereoisomer).","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,3.25,111422,DB00650,Leucovorin
,2676149,steady-state plasma concentration,"The bioactive metabolite (6S)-5-methyltetrahydrofolic acid, analyzed in six patients, reached a median steady-state plasma concentration of 5.7 microM.","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,5.7,111423,DB00650,Leucovorin
,2676149,lowest plasma concentrations at steady-state,The lowest plasma concentrations at steady-state were 1.86 microM (6S)-folinic acid and 3.12 microM (6S)-5-methyltetrahydrofolic acid.,"Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,1.86,111424,DB00650,Leucovorin
,2676149,lowest plasma concentrations at steady-state,The lowest plasma concentrations at steady-state were 1.86 microM (6S)-folinic acid and 3.12 microM (6S)-5-methyltetrahydrofolic acid.,"Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,3.12,111425,DB00650,Leucovorin
,2676149,steady-state plasma concentration,"The median steady-state plasma concentration of (6R)-folinic acid was 38.2 microM, more than 10 times the concentration of (6S)-folinic acid.","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,38.2,111426,DB00650,Leucovorin
,2676149,terminal half-lives,"Along with other plasma pharmacokinetic parameters, terminal half-lives were estimated for (6S)-folinic acid (median, 45.4 min), (6R)-folinic acid (median, 388 min), and (6S)-5-methyltetrahydrofolic acid (median, 446 min).","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),min,45.4,111427,DB00650,Leucovorin
,2676149,terminal half-lives,"Along with other plasma pharmacokinetic parameters, terminal half-lives were estimated for (6S)-folinic acid (median, 45.4 min), (6R)-folinic acid (median, 388 min), and (6S)-5-methyltetrahydrofolic acid (median, 446 min).","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),min,388,111428,DB00650,Leucovorin
,2676149,terminal half-lives,"Along with other plasma pharmacokinetic parameters, terminal half-lives were estimated for (6S)-folinic acid (median, 45.4 min), (6R)-folinic acid (median, 388 min), and (6S)-5-methyltetrahydrofolic acid (median, 446 min).","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),min,446,111429,DB00650,Leucovorin
,2676149,renal clearance,"However, the low renal clearance of (6R)-folinic acid (median, 8.2 ml/min/m2) was attributable to the extensive binding of (6R)-folinic acid to plasma proteins (median, 8.7% free), not to reabsorption in the kidney.","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),[ml] / [m2·min],8.2,111430,DB00650,Leucovorin
,18555590,progression free survival,"Patients with > or =6.2 CD34+/vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+/vWF+/ml (6.0 months, p = 0.076).",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),month,3.7,112426,DB00650,Leucovorin
,18555590,progression free survival,"Patients with > or =6.2 CD34+/vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+/vWF+/ml (6.0 months, p = 0.076).",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),month,6.0,112427,DB00650,Leucovorin
,18555590,progression free survival,"Patients with > or =5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046).",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),month,4.,112428,DB00650,Leucovorin
,18555590,progression free survival,"Patients with > or =5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046).",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),month,6.1,112429,DB00650,Leucovorin
,18555590,maximum inhibition (I(max)),"In an ex vivo pharmacokinetic study, the maximum inhibition (I(max)) for HUVEC and YCC3 cells was 13.0 +/- 6.6% and 74.0 +/- 2.0%, respectively.",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),%,13.0,112430,DB00650,Leucovorin
,18555590,maximum inhibition (I(max)),"In an ex vivo pharmacokinetic study, the maximum inhibition (I(max)) for HUVEC and YCC3 cells was 13.0 +/- 6.6% and 74.0 +/- 2.0%, respectively.",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),%,74.0,112431,DB00650,Leucovorin
,18555590,time to reach I(max) (T(max)),The time to reach I(max) (T(max)) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells.,Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),h,72,112432,DB00650,Leucovorin
,18555590,time to reach I(max) (T(max)),The time to reach I(max) (T(max)) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells.,Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),h,0.5,112433,DB00650,Leucovorin
,2834981,resolution factors,"Baseline separation was achieved using 5 and 25 mM sodium phosphate buffers (pH 7.4) as the mobile phase with resolution factors of 1.65 for LV and 2.31 for MeTHF, respectively.",Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834981/),,1.65,113273,DB00650,Leucovorin
,2834981,resolution factors,"Baseline separation was achieved using 5 and 25 mM sodium phosphate buffers (pH 7.4) as the mobile phase with resolution factors of 1.65 for LV and 2.31 for MeTHF, respectively.",Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834981/),,2.31,113274,DB00650,Leucovorin
,28102464,PFS,"Six patients achieved a partial response, and in 15 patients with CRC median PFS was 5.95 months (95% CI: 5.29-8.77).",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),month,5.95,113620,DB00650,Leucovorin
,28102464,Cmax,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),[μg] / [ml],64.8,113621,DB00650,Leucovorin
,28102464,AUC,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),[d·μg] / [ml],291,113622,DB00650,Leucovorin
,28102464,CL,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),[l] / [d],0.92,113623,DB00650,Leucovorin
,28102464,Vss,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),l,5.9,113624,DB00650,Leucovorin
,10472335,AUC,"a) AUC in all patients, at the beginning of the treatment averaged 9.05 +/- 3.115 (range from 3.9 to 16.41).",Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10472335/),,9.05,114374,DB00650,Leucovorin
,2785400,AUC (area under the curve) ratios,"Considering FA plus 5-MTHF together, the AUC (area under the curve) ratios between CSF and plasma were close to 1%.",Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785400/),%,1,117185,DB00650,Leucovorin
,2785400,t 1/2,5-MTHF was cleared very slowly from CSF (t 1/2 = 85 h).,Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785400/),h,85,117186,DB00650,Leucovorin
,17216531,progression-free,"Median progression-free and overall survivals were 12.2 and 26.6 months, respectively.","Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216531/),month,12.2,119214,DB00650,Leucovorin
,17216531,overall survivals,"Median progression-free and overall survivals were 12.2 and 26.6 months, respectively.","Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216531/),month,26.6,119215,DB00650,Leucovorin
,8419064,total run time,"HPLC 1 allows quantification of 5MTHF by absorption at 313 nm; HPLC 2, the quantification of l-FA and d-FA by electrochemical detection in the oxidation mode (total run time 18 min).",HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),min,18,119499,DB00650,Leucovorin
>,8419064,Recoveries,Recoveries are > 80%.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),%,80,119500,DB00650,Leucovorin
,8419064,sensitivity,The sensitivity limit is 50 nmol/L for 5MTHF and 20 nmol/L for l-FA and d-FA.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),[nM] / [l],50,119501,DB00650,Leucovorin
,8419064,sensitivity,The sensitivity limit is 50 nmol/L for 5MTHF and 20 nmol/L for l-FA and d-FA.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),,20,119502,DB00650,Leucovorin
,21482491,AUC(0-t),"The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively.",Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21482491/),[h·mg] / [ml],31.15,119603,DB00650,Leucovorin
,21482491,AUC(0-t),"The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively.",Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21482491/),[h·mg] / [ml],7.96,119604,DB00650,Leucovorin
,21482491,AUC(0-t),"The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively.",Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21482491/),[h·mg] / [ml],4.93,119605,DB00650,Leucovorin
,21482491,AUC(0-t),"The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively.",Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21482491/),[h·mg] / [ml],2.93,119606,DB00650,Leucovorin
,19228749,progression-free survival,The median progression-free survival was 9.3 months.,Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19228749/),month,9.3,123484,DB00650,Leucovorin
,15229463,area under the plasma concentration-time curve from 0 to 1 hour,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[l·mg] / [h],11.6,124064,DB00650,Leucovorin
,15229463,area under the plasma concentration-time curve from time 0 to the last time point,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],14.9,124065,DB00650,Leucovorin
,15229463,area under the plasma concentration-time curve from time 0 to the last time point,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],13.4,124066,DB00650,Leucovorin
,15229463,area under the plasma concentration-time curve from time 0 to the last time point,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],35.4,124067,DB00650,Leucovorin
,15229463,area under the plasma concentration-time curve from time 0 to the last time point,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],13.9,124068,DB00650,Leucovorin
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [l],0.17,124069,DB00650,Leucovorin
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],13.4,124070,DB00650,Leucovorin
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],35.4,124071,DB00650,Leucovorin
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [l],0.46,124072,DB00650,Leucovorin
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],13.9,124073,DB00650,Leucovorin
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),,38.1,124074,DB00650,Leucovorin
,15229463,maximum velocity,"The inclusion of oxaliplatin coadministration as a covariate in a NONMEM analysis did not result in any change in the objective function or mean values for the following derived parameters: maximum velocity (1590 mg x h(-1)), day 1 Michaelis-Menten constant (7.8 mg x h(-1)), and day 2 Michaelis-Menten constant (11.9 mg x h(-1)).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [h],1590,124075,DB00650,Leucovorin
,15229463,Michaelis-Menten,"The inclusion of oxaliplatin coadministration as a covariate in a NONMEM analysis did not result in any change in the objective function or mean values for the following derived parameters: maximum velocity (1590 mg x h(-1)), day 1 Michaelis-Menten constant (7.8 mg x h(-1)), and day 2 Michaelis-Menten constant (11.9 mg x h(-1)).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [h],7.8,124076,DB00650,Leucovorin
,15229463,Michaelis-Menten constant,"The inclusion of oxaliplatin coadministration as a covariate in a NONMEM analysis did not result in any change in the objective function or mean values for the following derived parameters: maximum velocity (1590 mg x h(-1)), day 1 Michaelis-Menten constant (7.8 mg x h(-1)), and day 2 Michaelis-Menten constant (11.9 mg x h(-1)).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [h],11.9,124077,DB00650,Leucovorin
,21464401,OS,"With PTK/ZK and placebo, respectively, median OS was 13.1 and 11.9 months (hazard ratio [HR], 1.00; 95% CI, 0.87 to 1.16; P = .957).","Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21464401/),month,13.1,124150,DB00650,Leucovorin
,21464401,OS,"With PTK/ZK and placebo, respectively, median OS was 13.1 and 11.9 months (hazard ratio [HR], 1.00; 95% CI, 0.87 to 1.16; P = .957).","Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21464401/),month,11.9,124151,DB00650,Leucovorin
,30556906,execution time,"Compared to calling a NONMEM execution and reading its output, estimating individual parameters within R reduces the execution time from 8.7-12.8 seconds to 0.4-1.0 second.",Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30556906/),seconds,8.7-12.8,124335,DB00650,Leucovorin
,30556906,execution time,"Compared to calling a NONMEM execution and reading its output, estimating individual parameters within R reduces the execution time from 8.7-12.8 seconds to 0.4-1.0 second.",Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30556906/),second,0.4-1.0,124336,DB00650,Leucovorin
,3855472,half-life (t 1/2),[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),min,30,126941,DB00650,Leucovorin
,3855472,terminal phase (t 1/2,[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),h,17,126942,DB00650,Leucovorin
,20463088,MTD,"The MTD of vorinostat in combination with sLV5FU2 is 1,700 mg orally once daily x 3 or 600 mg orally twice daily x 3 days every 2 weeks.","A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20463088/),mg,1,127610,DB00650,Leucovorin
,23760811,steady-state plasma concentration (Cpss),"Doses were individualized to achieve a steady-state plasma concentration (Cpss) of 33 or 65 μM (approximately 2.5 or 5 g/m(2)/day) for low- and standard-/high-risk patients, respectively.",Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760811/),μM,33,128682,DB00650,Leucovorin
,23760811,steady-state plasma concentration (Cpss),"Doses were individualized to achieve a steady-state plasma concentration (Cpss) of 33 or 65 μM (approximately 2.5 or 5 g/m(2)/day) for low- and standard-/high-risk patients, respectively.",Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760811/),μM,65,128683,DB00650,Leucovorin
,33564926,run time,"The lower limit of quantification was 0.100 ng/ml, and the run time was only 3 min.",Studies on the intracellular accumulation process of methotrexate and its correlation with the key protein using an LC-MS/MS method: a novel way to realize prospective individualized medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33564926/),min,3,128743,DB00650,Leucovorin
> or =,8504623,half-life,"For pentamidine, a long half-life of > or = 4 days implies the need for a loading dose.",Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504623/),d,4,131379,DB00650,Leucovorin
,8504623,Plasma concentrations of,Plasma concentrations of the parent drug at steady-state varied between 30 and 100 micrograms/L.,Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504623/),[μg] / [l],30 and 100,131380,DB00650,Leucovorin
,383286,plasma AMT,Nephrotoxic drug courses were associated with 24-hr plasma AMT levels [3.6 +/- 2.0 (S.D.) X 10(-6) M] which were significantly higher than nonnephrotoxic courses (1.6 +/- 1.0 x 10(-6) M) (p less than 0.05).,A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/383286/),M,3.6,132364,DB00650,Leucovorin
,383286,plasma AMT,Nephrotoxic drug courses were associated with 24-hr plasma AMT levels [3.6 +/- 2.0 (S.D.) X 10(-6) M] which were significantly higher than nonnephrotoxic courses (1.6 +/- 1.0 x 10(-6) M) (p less than 0.05).,A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/383286/),M,1.6,132365,DB00650,Leucovorin
,383286,t1/2 alpha,"In nonnephrotoxic courses, serum elimination pharmacokinetics appeared to be biphasic with a t1/2 alpha of 1.08 +/- 0.01 hr and t1/2 beta of 12.31 +/- 0.06 hr.",A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/383286/),h,1.08,132366,DB00650,Leucovorin
,383286,t1/2 beta,"In nonnephrotoxic courses, serum elimination pharmacokinetics appeared to be biphasic with a t1/2 alpha of 1.08 +/- 0.01 hr and t1/2 beta of 12.31 +/- 0.06 hr.",A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/383286/),h,12.31,132367,DB00650,Leucovorin
,22490854,plasma concentrations,"The average plasma concentrations of fluorouracil of the three groups were (23.48 ± 1.95) ng/ml, (31.47 ± 2.33) ng/ml and (39.89 ± 3.87) ng/ml, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),[ng] / [ml],23.48,133672,DB00650,Leucovorin
,22490854,plasma concentrations,"The average plasma concentrations of fluorouracil of the three groups were (23.48 ± 1.95) ng/ml, (31.47 ± 2.33) ng/ml and (39.89 ± 3.87) ng/ml, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),[ng] / [ml],31.47,133673,DB00650,Leucovorin
,22490854,plasma concentrations,"The average plasma concentrations of fluorouracil of the three groups were (23.48 ± 1.95) ng/ml, (31.47 ± 2.33) ng/ml and (39.89 ± 3.87) ng/ml, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),[ng] / [ml],39.89,133674,DB00650,Leucovorin
,22490854,OS,"As for therapeutic efficacy, the median OS of the groups 2 and 3 were 18.0 and 17.5 months, significantly higher than that in the group 1 (13.0 months, P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,18.0,133675,DB00650,Leucovorin
,22490854,OS,"As for therapeutic efficacy, the median OS of the groups 2 and 3 were 18.0 and 17.5 months, significantly higher than that in the group 1 (13.0 months, P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,17.5,133676,DB00650,Leucovorin
,22490854,OS,"As for therapeutic efficacy, the median OS of the groups 2 and 3 were 18.0 and 17.5 months, significantly higher than that in the group 1 (13.0 months, P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,13.0,133677,DB00650,Leucovorin
,22490854,PFS,"The PFS were 4.5, 7.5 and 8.0 months, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,4.5,133678,DB00650,Leucovorin
,22490854,PFS,"The PFS were 4.5, 7.5 and 8.0 months, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,7.5,133679,DB00650,Leucovorin
,22490854,PFS,"The PFS were 4.5, 7.5 and 8.0 months, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,8.0,133680,DB00650,Leucovorin
,22966260,objective response rate,The objective response rate was 31.4% and the tumour stabilization rate was 85.7%.,Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22966260/),%,31.4,134669,DB00650,Leucovorin
,22966260,t,The objective response rate was 31.4% and the tumour stabilization rate was 85.7%.,Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22966260/),%,85.,134670,DB00650,Leucovorin
,1635087,residual concentrations,"Considering total active folate levels (l-FA + 5-MTHF), mean residual concentrations were similar for rescue by d,l-FA and l-FA, after two and six intakes, respectively: 92 and 186 nM for d,l-FA rescue versus 100 and 184 nM for l-FA rescue.","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),nM,92,136316,DB00650,Leucovorin
,1635087,residual concentrations,"Considering total active folate levels (l-FA + 5-MTHF), mean residual concentrations were similar for rescue by d,l-FA and l-FA, after two and six intakes, respectively: 92 and 186 nM for d,l-FA rescue versus 100 and 184 nM for l-FA rescue.","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),nM,186,136317,DB00650,Leucovorin
,1635087,residual concentrations,"Considering total active folate levels (l-FA + 5-MTHF), mean residual concentrations were similar for rescue by d,l-FA and l-FA, after two and six intakes, respectively: 92 and 186 nM for d,l-FA rescue versus 100 and 184 nM for l-FA rescue.","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),nM,100,136318,DB00650,Leucovorin
,1635087,residual concentrations,"Considering total active folate levels (l-FA + 5-MTHF), mean residual concentrations were similar for rescue by d,l-FA and l-FA, after two and six intakes, respectively: 92 and 186 nM for d,l-FA rescue versus 100 and 184 nM for l-FA rescue.","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),nM,184,136319,DB00650,Leucovorin
,1635087,terminal half-lives,"For both types of FA rescue, MTX terminal half-lives were identical (average value, 13.9 hours).","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),h,13.9,136320,DB00650,Leucovorin
,19940007,Response rates,"Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively.",Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940007/),%,15,137032,DB00650,Leucovorin
,19940007,Response rates,"Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively.",Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940007/),%,42,137033,DB00650,Leucovorin
,21499694,areas under the curves (AUC),"The areas under the curves (AUC) for free platinum were 17.6, 23.6, and 32.6 μg h/mL after doses of 60, 70, and 85 mg/m(2) oxaliplatin, respectively.",Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499694/),[h·μg] / [ml],17.6,137182,DB00650,Leucovorin
,21499694,areas under the curves (AUC),"The areas under the curves (AUC) for free platinum were 17.6, 23.6, and 32.6 μg h/mL after doses of 60, 70, and 85 mg/m(2) oxaliplatin, respectively.",Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499694/),[h·μg] / [ml],23.6,137183,DB00650,Leucovorin
,21499694,areas under the curves (AUC),"The areas under the curves (AUC) for free platinum were 17.6, 23.6, and 32.6 μg h/mL after doses of 60, 70, and 85 mg/m(2) oxaliplatin, respectively.",Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499694/),[h·μg] / [ml],32.6,137184,DB00650,Leucovorin
,9552054,area under the concentration-time curve at 0 to 8 hours [AUC0-8],"In a previous study with 5-FU stepwise dose escalation in a weekly regimen, and pharmacokinetic monitoring, we defined a therapeutic range for 5-FU plasma levels: 2,000 to 3,000 microg/L (area under the concentration-time curve at 0 to 8 hours [AUC0-8], 16 to 24 mg x h/L).",Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552054/),[h·mg] / [l],16 to 24,138082,DB00650,Leucovorin
,9552054,overall survival time,Median overall survival time was 19 months.,Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552054/),month,19,138083,DB00650,Leucovorin
,16395593,C (max),"The C (max) of oxaliplatin was observed at the end of infusion, with mean values of 4.66, 0.84, and 2.69 microg/ml for total plasma, plasma ultrafiltrate, and RBC samples, respectively.",Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16395593/),[μg] / [ml],4.66,138085,DB00650,Leucovorin
,16395593,C (max),"The C (max) of oxaliplatin was observed at the end of infusion, with mean values of 4.66, 0.84, and 2.69 microg/ml for total plasma, plasma ultrafiltrate, and RBC samples, respectively.",Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16395593/),[μg] / [ml],0.84,138086,DB00650,Leucovorin
,16395593,C (max),"The C (max) of oxaliplatin was observed at the end of infusion, with mean values of 4.66, 0.84, and 2.69 microg/ml for total plasma, plasma ultrafiltrate, and RBC samples, respectively.",Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16395593/),[μg] / [ml],2.69,138087,DB00650,Leucovorin
,16395593,C (max),"The C (max) of plasma 5-FU ranged from 23.9 to 533.8 ng/ml, indicating large inter-patient pharmacokinetic variations.",Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16395593/),[ng] / [ml],23.9 to 533.8,138088,DB00650,Leucovorin
,2076721,steady-state concentration,The median steady-state concentration of MTX was 66 mumol.l-1.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),[μM] / [l],66,138790,DB00650,Leucovorin
,2076721,elimination half-lifes,"Three elimination half-lifes were determined for MTX: 1.8 h, 6.4 h and a terminal 15 h.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,1.8,138791,DB00650,Leucovorin
,2076721,elimination half-lifes,"Three elimination half-lifes were determined for MTX: 1.8 h, 6.4 h and a terminal 15 h.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,6.4,138792,DB00650,Leucovorin
,2076721,elimination half-lifes,"Three elimination half-lifes were determined for MTX: 1.8 h, 6.4 h and a terminal 15 h.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,15,138793,DB00650,Leucovorin
,2076721,terminal,"Three elimination half-lifes were determined for MTX: 1.8 h, 6.4 h and a terminal 15 h.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,15,138794,DB00650,Leucovorin
,2076721,systemic MTX clearance,The median systemic MTX clearance was 110 mg.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),mg,110,138795,DB00650,Leucovorin
,2076721,Cmax,The 7-OHMTX level increased during each infusion and a Cmax of 19 mumol.l-1 was achieved at the end.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),[μM] / [l],19,138796,DB00650,Leucovorin
,2076721,initial half-life,Its initial half-life was 5 h and the terminal half-life was 12 h.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,5,138797,DB00650,Leucovorin
,2076721,terminal half-life,Its initial half-life was 5 h and the terminal half-life was 12 h.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,12,138798,DB00650,Leucovorin
,2076721,ratios of folinic acid to MTX,"The median folinic acid level during rescue, 48 h after starting the infusion, was 7.0 mumol.l-1 and 18 h following the last dose of LCV it was 0.44 mumol.l-1, leading to ratios of folinic acid to MTX of 31 and 6, respectively.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),,31,138799,DB00650,Leucovorin
,2076721,ratios of folinic acid to MTX,"The median folinic acid level during rescue, 48 h after starting the infusion, was 7.0 mumol.l-1 and 18 h following the last dose of LCV it was 0.44 mumol.l-1, leading to ratios of folinic acid to MTX of 31 and 6, respectively.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),,6,138800,DB00650,Leucovorin
,2076721,ratio of,The median 5-MTHF level during rescue was 0.44 mumol.l-1 with a median ratio of 5-MTHF to MTX of 2.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),,2,138801,DB00650,Leucovorin
,2076721,ratio of,Only one patient with a 48 h MTX concentration of 5.5 mumol.l-1 and a ratio of 5-MTHF to MTX of 0.08 suffered from ulcerating mucositis and septicaemia despite increased and prolonged LCV rescue.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),,0.08,138802,DB00650,Leucovorin
,8622018,peak AZT plasma concentration,The peak AZT plasma concentration increased from 21.9 to 995.6 micromol/L.,Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[μM] / [l],21.9,139452,DB00650,Leucovorin
,8622018,peak AZT plasma concentration,The peak AZT plasma concentration increased from 21.9 to 995.6 micromol/L.,Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[μM] / [l],995.6,139453,DB00650,Leucovorin
,8622018,area under the concentration/time curve (AUC),"The area under the concentration/time curve (AUC) also showed a progressive, but not linear increase from 40.34 to 3,108 h x micromol/L.",Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[h·μM] / [l],40.34,139454,DB00650,Leucovorin
,8622018,area under the concentration/time curve (AUC),"The area under the concentration/time curve (AUC) also showed a progressive, but not linear increase from 40.34 to 3,108 h x micromol/L.",Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[h·μM] / [l],"3,108",139455,DB00650,Leucovorin
,9210981,plasma half-life,"The mean plasma half-life was 3.2 +/- 0.62 and 4.2 +/- 0.68 h after intravenous and oral administration, respectively, to dogs.","The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210981/),h,3.2,139969,DB00650,Leucovorin
,9210981,plasma half-life,"The mean plasma half-life was 3.2 +/- 0.62 and 4.2 +/- 0.68 h after intravenous and oral administration, respectively, to dogs.","The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210981/),h,4.2,139970,DB00650,Leucovorin
,9210981,plasma half-life,The pooled plasma half-life after intravenous administration to rats averaged 1.2 h; a reliable plasma half-life value after oral administration could not be determined.,"The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210981/),h,1.2,139971,DB00650,Leucovorin
,9210981,total-body clearance,"Mean total-body clearance was 2.4 +/- 0.39 and 4.5 +/- 1.1 L h-1 kg-1 after intravenous and oral administration, respectively, to dogs, and averaged 12 and 77 L h-1 kg-1 after intravenous and oral administration, respectively, to rats.","The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210981/),[l] / [h·kg],2.4,139972,DB00650,Leucovorin
,9210981,total-body clearance,"Mean total-body clearance was 2.4 +/- 0.39 and 4.5 +/- 1.1 L h-1 kg-1 after intravenous and oral administration, respectively, to dogs, and averaged 12 and 77 L h-1 kg-1 after intravenous and oral administration, respectively, to rats.","The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210981/),[l] / [h·kg],4.5,139973,DB00650,Leucovorin
,9210981,total-body clearance,"Mean total-body clearance was 2.4 +/- 0.39 and 4.5 +/- 1.1 L h-1 kg-1 after intravenous and oral administration, respectively, to dogs, and averaged 12 and 77 L h-1 kg-1 after intravenous and oral administration, respectively, to rats.","The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210981/),[l] / [h·kg],12,139974,DB00650,Leucovorin
,9210981,total-body clearance,"Mean total-body clearance was 2.4 +/- 0.39 and 4.5 +/- 1.1 L h-1 kg-1 after intravenous and oral administration, respectively, to dogs, and averaged 12 and 77 L h-1 kg-1 after intravenous and oral administration, respectively, to rats.","The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210981/),[l] / [h·kg],77,139975,DB00650,Leucovorin
,9210981,Absolute bioavailability,Absolute bioavailability was 54 +/- 12% in dogs and 16% in rats.,"The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210981/),%,54,139976,DB00650,Leucovorin
,9210981,Absolute bioavailability,Absolute bioavailability was 54 +/- 12% in dogs and 16% in rats.,"The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210981/),%,16,139977,DB00650,Leucovorin
,21409383,t (½),The V (ss) and CL did not differ between the two regimens; t (½) during the PK cycle was also similar for both arms at approximately 16 days.,"A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21409383/),d,16,141601,DB00650,Leucovorin
,29527010,objective response rate,"Fifteen patients had a partial response (objective response rate, 17.6%).",A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29527010/),%,17.6,143147,DB00650,Leucovorin
,21931273,AUC,"Six-of-eleven patients with normalized tumor TS mRNA levels < 4.0 had a 5-FU AUC of 20 mg.h/L or greater, and 80% of patients (4 of 5) with TS levels > 4.0 had a plasma 5-FU AUC of less than or equal to 20 mg.h/L.",Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21931273/),[h·mg] / [l],20,144656,DB00650,Leucovorin
less,21931273,AUC,"Six-of-eleven patients with normalized tumor TS mRNA levels < 4.0 had a 5-FU AUC of 20 mg.h/L or greater, and 80% of patients (4 of 5) with TS levels > 4.0 had a plasma 5-FU AUC of less than or equal to 20 mg.h/L.",Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21931273/),[h·mg] / [l],20,144657,DB00650,Leucovorin
,10073326,t1/2,"The mean parameters obtained for the early, mid-, and late collection periods were the following: trimetrexate: t1/2 = 8.29, 9.15, 10.00 hr; AUC = 16.85, 22.38, 24.49 mg.hr/l; CI = 5.58, 4.14, 3.96 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),h,8.29,144810,DB00650,Leucovorin
,10073326,t1/2,"The mean parameters obtained for the early, mid-, and late collection periods were the following: trimetrexate: t1/2 = 8.29, 9.15, 10.00 hr; AUC = 16.85, 22.38, 24.49 mg.hr/l; CI = 5.58, 4.14, 3.96 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),h,9.15,144811,DB00650,Leucovorin
,10073326,t1/2,"The mean parameters obtained for the early, mid-, and late collection periods were the following: trimetrexate: t1/2 = 8.29, 9.15, 10.00 hr; AUC = 16.85, 22.38, 24.49 mg.hr/l; CI = 5.58, 4.14, 3.96 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),h,10.00,144812,DB00650,Leucovorin
,10073326,AUC,"The mean parameters obtained for the early, mid-, and late collection periods were the following: trimetrexate: t1/2 = 8.29, 9.15, 10.00 hr; AUC = 16.85, 22.38, 24.49 mg.hr/l; CI = 5.58, 4.14, 3.96 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),[h·mg] / [l],16.85,144813,DB00650,Leucovorin
,10073326,AUC,"The mean parameters obtained for the early, mid-, and late collection periods were the following: trimetrexate: t1/2 = 8.29, 9.15, 10.00 hr; AUC = 16.85, 22.38, 24.49 mg.hr/l; CI = 5.58, 4.14, 3.96 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),[h·mg] / [l],22.38,144814,DB00650,Leucovorin
,10073326,AUC,"The mean parameters obtained for the early, mid-, and late collection periods were the following: trimetrexate: t1/2 = 8.29, 9.15, 10.00 hr; AUC = 16.85, 22.38, 24.49 mg.hr/l; CI = 5.58, 4.14, 3.96 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),[h·mg] / [l],24.49,144815,DB00650,Leucovorin
,10073326,AUC,"The mean parameters obtained for the early, mid-, and late collection periods were the following: trimetrexate: t1/2 = 8.29, 9.15, 10.00 hr; AUC = 16.85, 22.38, 24.49 mg.hr/l; CI = 5.58, 4.14, 3.96 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),[l] / [h],3.96,144816,DB00650,Leucovorin
,10073326,t1/2,"DDS: t1/2 = 14.99, 16.59, 15.13 hr; AUC = 30.60, 35.29, 36.08 mg.hr/l; CI = 3.82, 3.49, 3.01 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),h,14.99,144817,DB00650,Leucovorin
,10073326,t1/2,"DDS: t1/2 = 14.99, 16.59, 15.13 hr; AUC = 30.60, 35.29, 36.08 mg.hr/l; CI = 3.82, 3.49, 3.01 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),h,16.59,144818,DB00650,Leucovorin
,10073326,t1/2,"DDS: t1/2 = 14.99, 16.59, 15.13 hr; AUC = 30.60, 35.29, 36.08 mg.hr/l; CI = 3.82, 3.49, 3.01 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),h,15.13,144819,DB00650,Leucovorin
,10073326,AUC,"DDS: t1/2 = 14.99, 16.59, 15.13 hr; AUC = 30.60, 35.29, 36.08 mg.hr/l; CI = 3.82, 3.49, 3.01 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),[h·mg] / [l],30.60,144820,DB00650,Leucovorin
,10073326,AUC,"DDS: t1/2 = 14.99, 16.59, 15.13 hr; AUC = 30.60, 35.29, 36.08 mg.hr/l; CI = 3.82, 3.49, 3.01 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),[h·mg] / [l],35.29,144821,DB00650,Leucovorin
,10073326,AUC,"DDS: t1/2 = 14.99, 16.59, 15.13 hr; AUC = 30.60, 35.29, 36.08 mg.hr/l; CI = 3.82, 3.49, 3.01 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),[h·mg] / [l],36.08,144822,DB00650,Leucovorin
,10073326,AUC,"DDS: t1/2 = 14.99, 16.59, 15.13 hr; AUC = 30.60, 35.29, 36.08 mg.hr/l; CI = 3.82, 3.49, 3.01 l/hr, respectively.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),[l] / [h],3.01,144823,DB00650,Leucovorin
,10073326,t1/2,"Monoacetyldapsone: t1/2 = 20.25, 18.66, 16.32 hr; AUC = 24.05, 24.06, 23.86 mg.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),h,20.25,144824,DB00650,Leucovorin
,10073326,t1/2,"Monoacetyldapsone: t1/2 = 20.25, 18.66, 16.32 hr; AUC = 24.05, 24.06, 23.86 mg.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),h,18.66,144825,DB00650,Leucovorin
,10073326,t1/2,"Monoacetyldapsone: t1/2 = 20.25, 18.66, 16.32 hr; AUC = 24.05, 24.06, 23.86 mg.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),h,16.32,144826,DB00650,Leucovorin
,10073326,AUC,"Monoacetyldapsone: t1/2 = 20.25, 18.66, 16.32 hr; AUC = 24.05, 24.06, 23.86 mg.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),mg,24.05,144827,DB00650,Leucovorin
,10073326,AUC,"Monoacetyldapsone: t1/2 = 20.25, 18.66, 16.32 hr; AUC = 24.05, 24.06, 23.86 mg.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),mg,24.06,144828,DB00650,Leucovorin
,10073326,AUC,"Monoacetyldapsone: t1/2 = 20.25, 18.66, 16.32 hr; AUC = 24.05, 24.06, 23.86 mg.",Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073326/),mg,23.86,144829,DB00650,Leucovorin
≥,25342291,(MTX),Delayed plasma excretion was defined as (MTX) ≥1 μM at 42 hours (h).,Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342291/),μM,1,144930,DB00650,Leucovorin
<,25342291,MTX),Leucovorin was administered at 42 h and then every 6 h until (MTX) <0.1 μM.,Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342291/),μM,0.1,144931,DB00650,Leucovorin
,25342291,clearance,Population average (inter-individual variation) MTX clearance was 96.0 ml/min/m² (41.1 CV %) and increased with age.,Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342291/),[ml] / [min·m²],96.0,144932,DB00650,Leucovorin
,16187114,MTD,The MTD of 5-FU was 100 mg/kg/week whereas the MTD of 5-FU + PN401 was 200 mg/kg/week.,5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187114/),[mg] / [kg·week],200,148340,DB00650,Leucovorin
,10632324,duration of response,Median duration of response in colorectal cancer patients was 12 months.,Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632324/),month,12,149163,DB00650,Leucovorin
,12546525,objective response rates,"The objective response rates were 23%, 39% and 28%, respectively (p = 0.02).",Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12546525/),%,23,151150,DB00650,Leucovorin
,12546525,objective response rates,"The objective response rates were 23%, 39% and 28%, respectively (p = 0.02).",Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12546525/),%,39,151151,DB00650,Leucovorin
,12546525,objective response rates,"The objective response rates were 23%, 39% and 28%, respectively (p = 0.02).",Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12546525/),%,28,151152,DB00650,Leucovorin
,3260621,peak plasma concentration,"Following the two-hour infusion of dl-CF, mean peak plasma concentration and elimination half-life of I-5-formyltetrahydrofolic acid (I-CF) were 24 +/- 6 mumol/L and 0.8 +/- 0.1 hour, respectively.",Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),[μM] / [l],24,151438,DB00650,Leucovorin
,3260621,elimination half-life,"Following the two-hour infusion of dl-CF, mean peak plasma concentration and elimination half-life of I-5-formyltetrahydrofolic acid (I-CF) were 24 +/- 6 mumol/L and 0.8 +/- 0.1 hour, respectively.",Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),h,0.8,151439,DB00650,Leucovorin
,3260621,steady-state plasma level,CI of dl-CF over five days yielded a mean steady-state plasma level of I-CF of only 1.2 +/- 0.5 mumol/L.,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),[μM] / [l],1.2,151440,DB00650,Leucovorin
,3260621,Peak,Peak and steady-state plasma concentrations of the metabolite 5-methyl tetrahydrofolic acid were comparable in the two schedules (17 +/- 8 mumol/L for the two-hour infusion and 12 +/- 5 mumol/L for the CI).,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),[μM] / [l],17,151441,DB00650,Leucovorin
,3260621,steady-state plasma concentrations,Peak and steady-state plasma concentrations of the metabolite 5-methyl tetrahydrofolic acid were comparable in the two schedules (17 +/- 8 mumol/L for the two-hour infusion and 12 +/- 5 mumol/L for the CI).,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),[μM] / [l],12,151442,DB00650,Leucovorin
,3260621,Areas under the concentration v time curve (AUC),Areas under the concentration v time curve (AUC) of total reduced folates were significantly greater under conditions of CI: 89.0 v 16.7 mmol/L/min for the two-hour infusion.,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),,89,151443,DB00650,Leucovorin
,3260621,Areas under the concentration v time curve (AUC),Areas under the concentration v time curve (AUC) of total reduced folates were significantly greater under conditions of CI: 89.0 v 16.7 mmol/L/min for the two-hour infusion.,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),,16.7,151444,DB00650,Leucovorin
,21265469,clearance (CL),"At the steady-state, the clearance (CL) of MTX (6.28 +/- 2.79 l h(-1)) was correlated with its CL(R) (r(s) = 0.79, p < 0.0001) which accounted for 61% (SD 26%) of the former.",High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21265469/),[l] / [h],6.28,151559,DB00650,Leucovorin
,10520733,CL,"The following population parameters were obtained using a two-compartment model: CL = 3.51 L/h (inter-individual variability: 66%), Vd = 8.67 L (58%), k12 = 0.0044 h(-1)(105%), k21 = 0.039 h(-1)(25%).",Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520733/),[l] / [h],3.51,151916,DB00650,Leucovorin
,10520733,Vd,"The following population parameters were obtained using a two-compartment model: CL = 3.51 L/h (inter-individual variability: 66%), Vd = 8.67 L (58%), k12 = 0.0044 h(-1)(105%), k21 = 0.039 h(-1)(25%).",Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520733/),l,8.67,151917,DB00650,Leucovorin
,10520733,k12,"The following population parameters were obtained using a two-compartment model: CL = 3.51 L/h (inter-individual variability: 66%), Vd = 8.67 L (58%), k12 = 0.0044 h(-1)(105%), k21 = 0.039 h(-1)(25%).",Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520733/),1/[h],0.0044,151918,DB00650,Leucovorin
,10520733,k21,"The following population parameters were obtained using a two-compartment model: CL = 3.51 L/h (inter-individual variability: 66%), Vd = 8.67 L (58%), k12 = 0.0044 h(-1)(105%), k21 = 0.039 h(-1)(25%).",Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520733/),1/[h],0.039,151919,DB00650,Leucovorin
>,28278081,progression free survival,"Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the CSN-38 1.5 h > 50.24 ng/ml subset was remarkably longer than that of the CSN-38 1.5 h ≤ 50.24 ng/ml subset.",Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28278081/),[ng] / [ml],50.24,152655,DB00650,Leucovorin
,28278081,progression free survival,"Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the CSN-38 1.5 h > 50.24 ng/ml subset was remarkably longer than that of the CSN-38 1.5 h ≤ 50.24 ng/ml subset.",Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28278081/),,1,152656,DB00650,Leucovorin
≤,28278081,progression free survival,"Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the CSN-38 1.5 h > 50.24 ng/ml subset was remarkably longer than that of the CSN-38 1.5 h ≤ 50.24 ng/ml subset.",Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28278081/),[ng] / [ml],50.24,152657,DB00650,Leucovorin
,8729951,steady-state total plasma reduced folate concentrations,"Based on pharmacokinetics at higher doses, steady-state total plasma reduced folate concentrations of 1 microM would be expected from the administration of leucovorin 50 mg/m2 by 24 h infusion.",A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729951/),μM,1,153821,DB00650,Leucovorin
,8729951,total response rate,"Among the 32 evaluable patients, there were 14 partial remissions for a total response rate of 44% (95% confidence interval 27-61%).",A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729951/),%,44,153822,DB00650,Leucovorin
,7857100,inhibition rate,"2) TS inhibition rate in the tumor tissue was 66.8% in UFTL group and 53.2% in UFT group, and there was a significant difference between these two groups.",[Pharmacokinetic study in biochemical modulation therapy of UFT with leucovorin tablet]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7857100/),%,66.8,153862,DB00650,Leucovorin
,7857100,inhibition rate,"2) TS inhibition rate in the tumor tissue was 66.8% in UFTL group and 53.2% in UFT group, and there was a significant difference between these two groups.",[Pharmacokinetic study in biochemical modulation therapy of UFT with leucovorin tablet]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7857100/),%,53.2,153863,DB00650,Leucovorin
,9816135,maximum tolerated dose,"The maximum tolerated dose was 3750 mg/m2, with grade 3 or 4 leukopenia (one patient), stomatitis (one patient), and leukoencephalopathy (one patient).",High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816135/),[mg] / [m],3750,154929,DB00650,Leucovorin
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,2.7,155899,DB00650,Leucovorin
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,6.5,155900,DB00650,Leucovorin
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,4.2,155901,DB00650,Leucovorin
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,9.9,155902,DB00650,Leucovorin
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,43,155903,DB00650,Leucovorin
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,58,155904,DB00650,Leucovorin
,10561369,objective response rate,"Antitumor activity was observed at almost all dose levels, with an objective response rate of 22%.","Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561369/),%,22,156071,DB00650,Leucovorin
,10561369,time to progression,Median time to progression was 6.3 months and overall survival was 15 months.,"Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561369/),month,6.3,156072,DB00650,Leucovorin
,10561369,overall survival,Median time to progression was 6.3 months and overall survival was 15 months.,"Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561369/),month,15,156073,DB00650,Leucovorin
,20085906,area under the curve,"The free platinum area under the curve was 15.7-18.9 microg h/ml when 40 mg/m(2) of oxaliplatin was administered, which was comparable to the area under the curve at 85 mg/m(2) in patient with normal renal function.",Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20085906/),[h·μg] / [ml],15.7-18.9,156299,DB00650,Leucovorin
,29159476,area-under-the-concentration-time-curve (AUC),"No significant differences in first cycle 5FU area-under-the-concentration-time-curve (AUC) were found between sarcopenic and non-sarcopenic patients (17.3 vs. 19.3 AUC, p = 0.43).",The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159476/),auc,17.3,156991,DB00650,Leucovorin
,29159476,area-under-the-concentration-time-curve (AUC),"No significant differences in first cycle 5FU area-under-the-concentration-time-curve (AUC) were found between sarcopenic and non-sarcopenic patients (17.3 vs. 19.3 AUC, p = 0.43).",The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159476/),auc,19.3,156992,DB00650,Leucovorin
,16303861,time to progression,"Median time to progression was 9.9 months [lower 95% confidence limit (CL) 7.9, upper 95% CL not reached].",Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303861/),month,9.9,157278,DB00650,Leucovorin
,11432616,terminal half-life,"The mean PK parameters were: terminal half-life of ultrafiltrable platin, 17.75 +/- 9.29 hours; renal elimination, 48.7% +/- 14.1% of the applied dose; renal clearance 135.55 +/- 45.32 ml/min.",Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),h,17.75,157854,DB00650,Leucovorin
,11432616,renal elimination,"The mean PK parameters were: terminal half-life of ultrafiltrable platin, 17.75 +/- 9.29 hours; renal elimination, 48.7% +/- 14.1% of the applied dose; renal clearance 135.55 +/- 45.32 ml/min.",Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),%,48.7,157855,DB00650,Leucovorin
,11432616,renal clearance,"The mean PK parameters were: terminal half-life of ultrafiltrable platin, 17.75 +/- 9.29 hours; renal elimination, 48.7% +/- 14.1% of the applied dose; renal clearance 135.55 +/- 45.32 ml/min.",Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),[ml] / [min],135.55,157856,DB00650,Leucovorin
,11432616,area under the plasma-concentration curve (AUC),The mean area under the plasma-concentration curve (AUC) increased linearly from 3.22 +/- 0.61 microg x h/ml to 18.45 +/- 8.90 microg x h/ml through the first five dose levels (P = 0.0004).,Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),[h·μg] / [ml],3.22,157857,DB00650,Leucovorin
,11432616,area under the plasma-concentration curve (AUC),The mean area under the plasma-concentration curve (AUC) increased linearly from 3.22 +/- 0.61 microg x h/ml to 18.45 +/- 8.90 microg x h/ml through the first five dose levels (P = 0.0004).,Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),[h·μg] / [ml],18.45,157858,DB00650,Leucovorin
,27807652,area under the concentration-time curve,"The median initial area under the concentration-time curve for FU was 23 mg h/L. Twenty-nine patients (60%) achieved the target concentration at the first cycle, and all 48 achieved it within the fourth cycle.",Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807652/),[h·mg] / [l],23,161866,DB00650,Leucovorin
,27807652,overall response rate,The overall response rate was 48% (95% confidence intervals = 34-62%).,Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807652/),%,48,161867,DB00650,Leucovorin
,27807652,progression-free,"The median progression-free and overall survival rates were 11.3 and 24.1 months, respectively.",Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807652/),month,11.3,161868,DB00650,Leucovorin
,27807652,overall survival rates,"The median progression-free and overall survival rates were 11.3 and 24.1 months, respectively.",Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807652/),month,24.1,161869,DB00650,Leucovorin
,17656482,overall response rate,"The overall response rate was 9% (5/57, 95% CI: 4-19%).",Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656482/),%,9,163216,DB00650,Leucovorin
,17656482,time to progression,"The median time to progression was 2.7 months, and the median survival time was 11.1 months.",Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656482/),month,2.7,163217,DB00650,Leucovorin
,17656482,survival time,"The median time to progression was 2.7 months, and the median survival time was 11.1 months.",Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656482/),month,11.1,163218,DB00650,Leucovorin
,17289892,Maximum tolerated dose,Maximum tolerated dose of irinotecan in FOLFIRI schedule with celecoxib is 200 mg/m2.,"Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17289892/),mg,200,166306,DB00650,Leucovorin
,3501547,Peak TRF concentrations,"Peak TRF concentrations at the 200-, 400-, 800-, and 1600-mg doses were 3.42 +/- 0.65, 4.05 +/- 1.04, 4.81 +/- 0.14, and 5.11 +/- 1.81 microM, respectively.",Bioavailability of high-dose oral leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501547/),μM,3.42,166989,DB00650,Leucovorin
,3501547,Peak TRF concentrations,"Peak TRF concentrations at the 200-, 400-, 800-, and 1600-mg doses were 3.42 +/- 0.65, 4.05 +/- 1.04, 4.81 +/- 0.14, and 5.11 +/- 1.81 microM, respectively.",Bioavailability of high-dose oral leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501547/),μM,4.05,166990,DB00650,Leucovorin
,3501547,Peak TRF concentrations,"Peak TRF concentrations at the 200-, 400-, 800-, and 1600-mg doses were 3.42 +/- 0.65, 4.05 +/- 1.04, 4.81 +/- 0.14, and 5.11 +/- 1.81 microM, respectively.",Bioavailability of high-dose oral leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501547/),μM,4.81,166991,DB00650,Leucovorin
,3501547,Peak TRF concentrations,"Peak TRF concentrations at the 200-, 400-, 800-, and 1600-mg doses were 3.42 +/- 0.65, 4.05 +/- 1.04, 4.81 +/- 0.14, and 5.11 +/- 1.81 microM, respectively.",Bioavailability of high-dose oral leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501547/),μM,5.11,166992,DB00650,Leucovorin
,3501547,Peak L-CF levels,"Peak L-CF levels at 200, 400, 800, and 1600 were 0.15 +/- 0.11, 0.21 +/- 0.14, 0.23 +/- 0.11, and 0.34 +/- 0.16 microM.",Bioavailability of high-dose oral leucovorin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501547/),μM,0.15,166993,DB00650,Leucovorin
,3501547,Peak L-CF levels,"Peak L-CF levels at 200, 400, 800, and 1600 were 0.15 +/- 0.11, 0.21 +/- 0.14, 0.23 +/- 0.11, and 0.34 +/- 0.16 microM.",Bioavailability of high-dose oral leucovorin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501547/),μM,0.21,166994,DB00650,Leucovorin
,3501547,Peak L-CF levels,"Peak L-CF levels at 200, 400, 800, and 1600 were 0.15 +/- 0.11, 0.21 +/- 0.14, 0.23 +/- 0.11, and 0.34 +/- 0.16 microM.",Bioavailability of high-dose oral leucovorin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501547/),μM,0.23,166995,DB00650,Leucovorin
,3501547,Peak L-CF levels,"Peak L-CF levels at 200, 400, 800, and 1600 were 0.15 +/- 0.11, 0.21 +/- 0.14, 0.23 +/- 0.11, and 0.34 +/- 0.16 microM.",Bioavailability of high-dose oral leucovorin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501547/),μM,0.34,166996,DB00650,Leucovorin
,1643698,steady-state FUra concentrations,Limited pharmacokinetic sampling at levels 3 and 4 revealed mean steady-state FUra concentrations of around 1.0 microM with infusions of FUra/LV+DP.,"A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643698/),μM,1.0,167173,DB00650,Leucovorin
,8306417,concentration,The mean concentration observed at the end of the infusion was 1016 +/- 143 mumol/l.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),mum,101,170722,DB00650,Leucovorin
,8306417,clearance,The clearance was 49.1 +/- 11.7 ml min-1 m-2.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),[ml] / [(m)^2·min],49.1,170723,DB00650,Leucovorin
,8306417,t1/2 alpha,The decay of the plasma concentration of MTX after completion of the infusion followed a two-compartment model with a t1/2 alpha of 2.66 +/- 0.82 h and a t1/2 beta of 15.69 +/- 8.63 h.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),h,2.66,170724,DB00650,Leucovorin
,8306417,t1/2 beta,The decay of the plasma concentration of MTX after completion of the infusion followed a two-compartment model with a t1/2 alpha of 2.66 +/- 0.82 h and a t1/2 beta of 15.69 +/- 8.63 h.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),h,15.69,170725,DB00650,Leucovorin
,8306417,volume of distribution,The volume of distribution was 0.32 +/- 0.08 l/kg.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),[l] / [kg],0.32,170726,DB00650,Leucovorin
,22565063,Material,"Material recoveries from the liquid-liquid extraction technique were 97-110% and 86-91% for tegafur and 5-FU, respectively.",Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22565063/),%,97-110,173148,DB00650,Leucovorin
,22565063,recoveries,"Material recoveries from the liquid-liquid extraction technique were 97-110% and 86-91% for tegafur and 5-FU, respectively.",Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22565063/),%,97-110,173149,DB00650,Leucovorin
,22565063,recoveries,"Material recoveries from the liquid-liquid extraction technique were 97-110% and 86-91% for tegafur and 5-FU, respectively.",Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22565063/),%,86-91,173150,DB00650,Leucovorin
,2231760,alpha half-life,"A dose-related increase in peak plasma levels of AZT was observed, and the alpha half-life of AZT in plasma (75 min) was unaffected by these high doses.","Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231760/),min,75,175020,DB00650,Leucovorin
,21656756,area under the concentration-time curve,"Treatment was comprised of 12 cycles of chemotherapy administered over 35 weeks: 3 cycles of carboplatin (dose targeted to area under the concentration-time curve of 8 mg/mL × min on Day 1) and ifosfamide (at a dose of 2.65 g/m(2) daily ×3 days) and 1 cycle of doxorubicin (at a dose of 25 mg/m(2) daily ×3 days) before surgical resection, followed by 2 additional cycles of the combination of carboplatin and ifosfamide and 3 cycles each of doxorubicin (25 mg/m(2) daily ×2 days) combined with ifosfamide or carboplatin.",Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656756/),[mg] / [min·ml],8,176531,DB00650,Leucovorin
,21656756,event-free survival rate,The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98).,Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656756/),%,66.7,176532,DB00650,Leucovorin
,21656756,event-free survival rate,The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98).,Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656756/),%,66.0,176533,DB00650,Leucovorin
≥,32965540,Ctrough,An empirical target of bemarituzumab Ctrough of ≥ 60 µg/mL was projected to achieve > 95% receptor occupancy based on in vitro data.,Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32965540/),[μg] / [ml],60,176909,DB00650,Leucovorin
,12877360,Cmax,"Comparing day 1 with day 4, Cmax of platinum in PUF was significantly increased (84 +/- 13 ng/ml vs. 131 +/- 22 ng/ml, P = 0.012) as well as AUC0-24h of platinum in PUF (0.97 +/- 0.29 microg x h/ml vs. 1.90 +/- 0.44 microg x h/ml, P = 0.018).",Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877360/),[ng] / [ml],84,177425,DB00650,Leucovorin
,12877360,Cmax,"Comparing day 1 with day 4, Cmax of platinum in PUF was significantly increased (84 +/- 13 ng/ml vs. 131 +/- 22 ng/ml, P = 0.012) as well as AUC0-24h of platinum in PUF (0.97 +/- 0.29 microg x h/ml vs. 1.90 +/- 0.44 microg x h/ml, P = 0.018).",Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877360/),[ng] / [ml],131,177426,DB00650,Leucovorin
,12877360,AUC0-24h,"Comparing day 1 with day 4, Cmax of platinum in PUF was significantly increased (84 +/- 13 ng/ml vs. 131 +/- 22 ng/ml, P = 0.012) as well as AUC0-24h of platinum in PUF (0.97 +/- 0.29 microg x h/ml vs. 1.90 +/- 0.44 microg x h/ml, P = 0.018).",Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877360/),[h·μg] / [ml],0.97,177427,DB00650,Leucovorin
,12877360,AUC0-24h,"Comparing day 1 with day 4, Cmax of platinum in PUF was significantly increased (84 +/- 13 ng/ml vs. 131 +/- 22 ng/ml, P = 0.012) as well as AUC0-24h of platinum in PUF (0.97 +/- 0.29 microg x h/ml vs. 1.90 +/- 0.44 microg x h/ml, P = 0.018).",Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877360/),[h·μg] / [ml],1.90,177428,DB00650,Leucovorin
,20567127,serum ultrafiltrate concentrations,"The serum ultrafiltrate concentrations of platinum were 800, 1, 000, 300, <200, and <200 ng/mLat 1, 2, 3 hr, 1 week, and 2 weeks after the start of infusion, respectively, which were closely comparable with the population pharmacokinetic data in Japanese patients with normal renal function.",[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20567127/),[ng] / [ml],800,177568,DB00650,Leucovorin
,20567127,serum ultrafiltrate concentrations,"The serum ultrafiltrate concentrations of platinum were 800, 1, 000, 300, <200, and <200 ng/mLat 1, 2, 3 hr, 1 week, and 2 weeks after the start of infusion, respectively, which were closely comparable with the population pharmacokinetic data in Japanese patients with normal renal function.",[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20567127/),[ng] / [ml],"1, 000",177569,DB00650,Leucovorin
,20567127,serum ultrafiltrate concentrations,"The serum ultrafiltrate concentrations of platinum were 800, 1, 000, 300, <200, and <200 ng/mLat 1, 2, 3 hr, 1 week, and 2 weeks after the start of infusion, respectively, which were closely comparable with the population pharmacokinetic data in Japanese patients with normal renal function.",[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20567127/),[ng] / [ml],300,177570,DB00650,Leucovorin
<,20567127,serum ultrafiltrate concentrations,"The serum ultrafiltrate concentrations of platinum were 800, 1, 000, 300, <200, and <200 ng/mLat 1, 2, 3 hr, 1 week, and 2 weeks after the start of infusion, respectively, which were closely comparable with the population pharmacokinetic data in Japanese patients with normal renal function.",[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20567127/),[ng] / [ml],200,177571,DB00650,Leucovorin
,31657864,clearance,"The population clearance and volume were 90 mL/min/m2 and 14.4 L/m2 , respectively.",Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31657864/),[ml] / [m2·min],90,178274,DB00650,Leucovorin
,31657864,volume,"The population clearance and volume were 90 mL/min/m2 and 14.4 L/m2 , respectively.",Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31657864/),[l] / [m2],14.4,178275,DB00650,Leucovorin
,11840401,extraction ratios,"In contrast, the final 5-FU catabolite alpha-fluoro-beta-alanine (FBAL) accumulated to a concentration of 276 micromol/L on day 5 (approximately twofold higher than expected from the literature) despite good removal by hemodialysis with extraction ratios of 0.6 to 0.85 over the filter membrane.",Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11840401/),,0.6 to 0.85,182968,DB00650,Leucovorin
,2311173,rapid,"With a mean of 56.5 min, 1-CHO-THF exhibits a rapid body clearance of 222 ml/min, about 60% of which is caused by metabolism to CH3-THF and 40%, by renal excretion.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],222,183012,DB00650,Leucovorin
,2311173,body clearance,"With a mean of 56.5 min, 1-CHO-THF exhibits a rapid body clearance of 222 ml/min, about 60% of which is caused by metabolism to CH3-THF and 40%, by renal excretion.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],222,183013,DB00650,Leucovorin
,2311173,terminal half-life,"CH3-THF has a terminal half-life of 208 min and a total body clearance of 88.9 ml/min, which is essentially the same as the renal clearance.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),min,208,183014,DB00650,Leucovorin
,2311173,total body clearance,"CH3-THF has a terminal half-life of 208 min and a total body clearance of 88.9 ml/min, which is essentially the same as the renal clearance.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],88.9,183015,DB00650,Leucovorin
,2311173,AUC,"Due to the lower clearance of CH3-THF, its AUC (2,132 microM x min) exceeds that of 1-CHO-THF (1445 microM x min) by approximately 50%.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),min·μM,"2,132",183016,DB00650,Leucovorin
,2311173,AUC,"Due to the lower clearance of CH3-THF, its AUC (2,132 microM x min) exceeds that of 1-CHO-THF (1445 microM x min) by approximately 50%.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),min·μM,1445,183017,DB00650,Leucovorin
,2311173,total body,"In contrast to that of the reduced 1-folates, the total body and renal clearance of d-CHO-THF is very low, with values of 13.2 and 12.9 ml/min, respectively.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],13.2,183018,DB00650,Leucovorin
,2311173,renal clearance,"In contrast to that of the reduced 1-folates, the total body and renal clearance of d-CHO-THF is very low, with values of 13.2 and 12.9 ml/min, respectively.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],12.9,183019,DB00650,Leucovorin
,2311173,AUC,"This results in a very high AUC of 24, 269 microM x min, which is higher by factors of 17 and 11 than those of 1-CHO-THF and CH3-THF, respectively.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),min·μM,"24, 269",183020,DB00650,Leucovorin
,1646754,peak concentration,"After an intramuscular dose of 50 mg, plasma MTX levels rose rapidly, reached a peak concentration of 5.8 x 10(-6) M/liter at 1 hour and persisted above 10(-6) M/liter normally considered inhibitory for DNA synthesis, for approximately 7 1/2 hours.",Correlation of plasma methotrexate concentration with human chorionic gonadotropin and therapeutic response to low-dose methotrexate-citrovorum factor in low-medium-risk gestational trophoblastic tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646754/),[M] / [l],5.8 x 10(-6),183905,DB00650,Leucovorin
,17218488,MTD,The MTD was 1250 mg daily with dizziness being the most frequent dose-limiting toxicity (DLT).,"A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17218488/),,125,184670,DB00650,Leucovorin
,17218488,progression-free survival,Median progression-free survival was 11.4 months.,"A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17218488/),month,11.4,184671,DB00650,Leucovorin
,17218488,MTD,The MTD of PTK/ZK in combination with FOLFOX4 in this patient population is 1250 mg daily.,"A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17218488/),mg,1250,184672,DB00650,Leucovorin
,2388292,peak plasma concentrations,"Following intravenous administration, peak plasma concentrations of (6R) LV, (6S) LV, and 5-CH3 THF were 148 +/- 32, 59.1 +/- 22, and 17.8 +/- 17 microM, respectively.",Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388292/),μM,148,185215,DB00650,Leucovorin
,2388292,peak plasma concentrations,"Following intravenous administration, peak plasma concentrations of (6R) LV, (6S) LV, and 5-CH3 THF were 148 +/- 32, 59.1 +/- 22, and 17.8 +/- 17 microM, respectively.",Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388292/),μM,59.1,185216,DB00650,Leucovorin
,2388292,peak plasma concentrations,"Following intravenous administration, peak plasma concentrations of (6R) LV, (6S) LV, and 5-CH3 THF were 148 +/- 32, 59.1 +/- 22, and 17.8 +/- 17 microM, respectively.",Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388292/),μM,17.8,185217,DB00650,Leucovorin
,2388292,Steady-state plasma concentrations,"Steady-state plasma concentrations of (6R) LV and 5-CH3 THF were approximately 1.5 +/- 0.23 and 2.8 +/- 0.41 microM, respectively.",Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388292/),μM,1.5,185218,DB00650,Leucovorin
,2388292,Steady-state plasma concentrations,"Steady-state plasma concentrations of (6R) LV and 5-CH3 THF were approximately 1.5 +/- 0.23 and 2.8 +/- 0.41 microM, respectively.",Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388292/),μM,2.8,185219,DB00650,Leucovorin
,2388292,half-life,"After administration of high doses of LV intravenously, conversion of (6S) LV to 5-CH3 THF was saturable, as indicated by the prolonged (6S) LV half-life of 58 minutes and the slow (6S) LV clearance of 119.2 +/- 38 mL/min, compared with previously reported data for administration of low doses.",Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388292/),min,58,185220,DB00650,Leucovorin
,2388292,clearance,"After administration of high doses of LV intravenously, conversion of (6S) LV to 5-CH3 THF was saturable, as indicated by the prolonged (6S) LV half-life of 58 minutes and the slow (6S) LV clearance of 119.2 +/- 38 mL/min, compared with previously reported data for administration of low doses.",Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388292/),[ml] / [min],119.2,185221,DB00650,Leucovorin
,25342290,C(max) ratio,"The Modufolin® to Isovorin® C(max) ratio for methyleneTHF was 113 at 200 mg/m² and 52 at 60 mg/m²; the AUC(last) ratios were 17 and 9, respectively.",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,113,185291,DB00650,Leucovorin
,25342290,C(max) ratio,"The Modufolin® to Isovorin® C(max) ratio for methyleneTHF was 113 at 200 mg/m² and 52 at 60 mg/m²; the AUC(last) ratios were 17 and 9, respectively.",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,52,185292,DB00650,Leucovorin
,25342290,AUC(last) ratios,"The Modufolin® to Isovorin® C(max) ratio for methyleneTHF was 113 at 200 mg/m² and 52 at 60 mg/m²; the AUC(last) ratios were 17 and 9, respectively.",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,17,185293,DB00650,Leucovorin
,25342290,AUC(last) ratios,"The Modufolin® to Isovorin® C(max) ratio for methyleneTHF was 113 at 200 mg/m² and 52 at 60 mg/m²; the AUC(last) ratios were 17 and 9, respectively.",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,9,185294,DB00650,Leucovorin
,25342290,C(max) ratio,"The THF plasma concentrations were also higher after Modufolin® administration (C(max) ratio 23, AUC(last) ratio 13 at 200 mg/m²; C(max) ratio 15, AUC(last) ratio 11 at 60 mg/m²).",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,23,185295,DB00650,Leucovorin
,25342290,AUC(last) ratio,"The THF plasma concentrations were also higher after Modufolin® administration (C(max) ratio 23, AUC(last) ratio 13 at 200 mg/m²; C(max) ratio 15, AUC(last) ratio 11 at 60 mg/m²).",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,13,185296,DB00650,Leucovorin
,25342290,C(max) ratio,"The THF plasma concentrations were also higher after Modufolin® administration (C(max) ratio 23, AUC(last) ratio 13 at 200 mg/m²; C(max) ratio 15, AUC(last) ratio 11 at 60 mg/m²).",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,15,185297,DB00650,Leucovorin
,25342290,AUC(last) ratio,"The THF plasma concentrations were also higher after Modufolin® administration (C(max) ratio 23, AUC(last) ratio 13 at 200 mg/m²; C(max) ratio 15, AUC(last) ratio 11 at 60 mg/m²).",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,11,185298,DB00650,Leucovorin
,16299240,area under the curve,"Complete bioavailability of aminopterin was confirmed, with a mean area under the curve of 0.52 +/- 0.03 micromol hour/L after oral dosing.",Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299240/),[h·μM] / [l],0.52,185420,DB00650,Leucovorin
,8523062,Css,"A Css of 2.2 +/- 0.8 mumol/L for 5-FU was achieved on the recommended schedule, which compares favorably with conventional IV 5-FU regimens.",Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523062/),[μM] / [l],2.2,186105,DB00650,Leucovorin
,10448274,half-life of the rapid phase,"The half-life of the rapid phase averaged 8.0 min, and was of the same order of magnitude as the 5-FU elimination half-life determined from plasma data.",Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10448274/),min,8.0,186797,DB00650,Leucovorin
,10448274,half-life of the terminal part of the,"The half-life of the terminal part of the curve averaged 8 h; such decrease in salivary concentrations could be due to changes in salivary gland function caused by 5-FU, which results in reduced salivary flow rate.",Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10448274/),h,8,186798,DB00650,Leucovorin
,26489552,in,"Since the levels of tumor markers increased, the 5-FU dose was increased from 2,700 to 3,000 mg/m2 using a Jackson-type pump and an extended infusion time of 53 hours.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),,53,191430,DB00650,Leucovorin
,26489552,areas under the concentration vs. time curve (AUC mg,"The areas under the concentration vs. time curve (AUC mg・h/L)were 21 and 44 mg・h/L for the Jackson- and bottle-type pumps, respectively.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),[mg・h] / [l],21,191431,DB00650,Leucovorin
,26489552,areas under the concentration vs. time curve (AUC mg,"The areas under the concentration vs. time curve (AUC mg・h/L)were 21 and 44 mg・h/L for the Jackson- and bottle-type pumps, respectively.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),[mg・h] / [l],44,191432,DB00650,Leucovorin
,26489552,AUC,"The AUC decreased to 27 mg・h/L, but the liver metastases were reduced and the adverse effects subsided to Grade 1.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),[mg・h] / [l],27,191433,DB00650,Leucovorin
,9815764,Cmax,"The platinum concentration curves were quite similar from one course to another, with a high peak value 2 h after administration (day 1, Cmax = 3201 +/- 609 microgram/liter) and a rapid decrease (day 8, 443 +/- 99 microgram/liter).","Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),[μg] / [l],3201,192024,DB00650,Leucovorin
,9815764,Cmax,"The platinum concentration curves were quite similar from one course to another, with a high peak value 2 h after administration (day 1, Cmax = 3201 +/- 609 microgram/liter) and a rapid decrease (day 8, 443 +/- 99 microgram/liter).","Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),[μg] / [l],443,192025,DB00650,Leucovorin
,9815764,total platinum half-life,The mean total platinum half-life in plasma was 9 days.,"Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),d,9,192026,DB00650,Leucovorin
,9815764,UC:total platinum ratio,"The mean UC:total platinum ratio was 15% at day 1 and 5% at days 8, 15, and 22 in the 3-week treatment course.","Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),%,15,192027,DB00650,Leucovorin
,9815764,UC:total platinum ratio,"The mean UC:total platinum ratio was 15% at day 1 and 5% at days 8, 15, and 22 in the 3-week treatment course.","Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),%,5,192028,DB00650,Leucovorin
,18408443,AUC,AUC was 5.67-10.21 mg/L x h.,[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18408443/),[mg] / [h·l],5.67-10.21,192374,DB00650,Leucovorin
,18408443,dial,The dialysis removal rate was 84.0%.,[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18408443/),%,84.0,192375,DB00650,Leucovorin
,18408443,removal rate,The dialysis removal rate was 84.0%.,[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18408443/),%,84.0,192376,DB00650,Leucovorin
,9661893,MTD,The MTD of single-agent IdUrd administered on this schedule was 4125 mg/m2/day for 4 days; and that of the IdUrd in combination was 3438 mg/m2/day.,Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661893/),[mg] / [d·m2],4125,192784,DB00650,Leucovorin
,9661893,MTD,The MTD of single-agent IdUrd administered on this schedule was 4125 mg/m2/day for 4 days; and that of the IdUrd in combination was 3438 mg/m2/day.,Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661893/),[mg] / [d·m2],3438,192785,DB00650,Leucovorin
,9661893,AUCperitoneal/ AUCplasma,The geometric mean pharmacological advantage (AUCperitoneal/ AUCplasma) was 181 at 625 mg/m2/day and 90 at 4538 mg/m2/day.,Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661893/),,181,192786,DB00650,Leucovorin
,9661893,AUCperitoneal/ AUCplasma,The geometric mean pharmacological advantage (AUCperitoneal/ AUCplasma) was 181 at 625 mg/m2/day and 90 at 4538 mg/m2/day.,Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661893/),,90,192787,DB00650,Leucovorin
,8422689,Peak plasma concentrations,Peak plasma concentrations (300-500 microM) of 5FU were comparable in human and murine plasma.,Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),μM,300-500,192924,DB00650,Leucovorin
,8422689,half-life of plasma elimination,"The half-life of plasma elimination (during the period from 15 to 120 min) in both mouse and man ranged from 10 to 20 min, whereas at between 2 and 8 h, plasma concentrations varied from 0.1 to 1 microM, the half-life being about 100 min.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),min,10 to 20,192925,DB00650,Leucovorin
,8422689,half-life,"The half-life of plasma elimination (during the period from 15 to 120 min) in both mouse and man ranged from 10 to 20 min, whereas at between 2 and 8 h, plasma concentrations varied from 0.1 to 1 microM, the half-life being about 100 min.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),min,100,192926,DB00650,Leucovorin
,8422689,tumor concentrations,"5FU tumor concentrations varied between 0.78-21.6, 0.44-6.1, and 0.17-10.8 mumol/kg wet wt., respectively.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),[μM] / [kg·wet·wt],0.78-21.6,192927,DB00650,Leucovorin
,8422689,tumor concentrations,"5FU tumor concentrations varied between 0.78-21.6, 0.44-6.1, and 0.17-10.8 mumol/kg wet wt., respectively.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),[μM] / [kg·wet·wt],0.44-6.1,192928,DB00650,Leucovorin
,8422689,tumor concentrations,"5FU tumor concentrations varied between 0.78-21.6, 0.44-6.1, and 0.17-10.8 mumol/kg wet wt., respectively.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),[μM] / [kg·wet·wt],0.17-10.8,192929,DB00650,Leucovorin
,8422689,tissue concentration/plasma concentration ratio,"At between 4 and 48 h, the tissue concentration/plasma concentration ratio was at least 10.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),,10,192930,DB00650,Leucovorin
,1747791,response rate,Phase II studies in metastatic colorectal cancer in 345 patients have demonstrated an average response rate of 36% (range 15-59%) and a prospective randomized study performed by the Mid-Atlantic Oncology Program (MAOP) has confirmed a higher response rate with 5FU infusion compared with a bolus schedule.,5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747791/),%,36,194732,DB00650,Leucovorin
,9193347,MTD,"The MTD of FU given in this fashion with PN401 rescue was 1,000 mg/m2, at which level two of six patients had neutropenic fever.","Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193347/),[mg] / [m2],"1,000",194919,DB00650,Leucovorin
,9193347,MTD,"The MTD of FU with PN401 rescue is 1,000 mg/m2 and the recommended dose for phase II trials is 800 mg/m2 given weekly for 6 weeks with dose escalation.","Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193347/),[mg] / [m2],"1,000",194920,DB00650,Leucovorin
,3431588,half-life (t1/2),"After iv administration of [14C]PTX to rats, the elimination profile of intact drug from plasma was first order with a half-life (t1/2) of 38 minutes.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),min,38,195566,DB00650,Leucovorin
,3431588,plasma t1/2,"Pharmacokinetic studies in the dog indicated a mean plasma t1/2 (after iv dose) of 2.15 hours, total body clearance of 0.625 liters/hr/kg and steady-state volume of distribution of 1.82 liters/kg; the absolute bioavailability was 0.64.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),h,2.15,195567,DB00650,Leucovorin
,3431588,total body clearance,"Pharmacokinetic studies in the dog indicated a mean plasma t1/2 (after iv dose) of 2.15 hours, total body clearance of 0.625 liters/hr/kg and steady-state volume of distribution of 1.82 liters/kg; the absolute bioavailability was 0.64.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),[l] / [h·kg],0.625,195568,DB00650,Leucovorin
,3431588,steady-state volume of distribution,"Pharmacokinetic studies in the dog indicated a mean plasma t1/2 (after iv dose) of 2.15 hours, total body clearance of 0.625 liters/hr/kg and steady-state volume of distribution of 1.82 liters/kg; the absolute bioavailability was 0.64.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),[l] / [kg],1.82,195569,DB00650,Leucovorin
,3431588,absolute bioavailability,"Pharmacokinetic studies in the dog indicated a mean plasma t1/2 (after iv dose) of 2.15 hours, total body clearance of 0.625 liters/hr/kg and steady-state volume of distribution of 1.82 liters/kg; the absolute bioavailability was 0.64.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),,0.64,195570,DB00650,Leucovorin
>,12171874,peak FUra concentrations,Serial plasma samples revealed peak FUra concentrations of >100 micro M; at 100 micro g/m2 IFN-gamma plasma concentrations >5 units/ml persisted for 6.5 h and >1 unit/ml for 28.5 h.,"Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12171874/),μM,100,195641,DB00650,Leucovorin
,11697844,clearance (CL),"5-FU clearance (CL) was lower (range 14.12-25.17 l/h/m2), and the area under the curve (AUC) was higher (range 14.70-26.20 h x microg/ml) than those observed in 84 patients with mild toxicities (CL, 56.30 +/- 3.60 l/h/M2; AUC, 7.91 +/- 0.44 h x microg/ml).","Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697844/),[l] / [h·m2],14.12-25.17,198817,DB00650,Leucovorin
,11697844,area under the curve (AUC),"5-FU clearance (CL) was lower (range 14.12-25.17 l/h/m2), and the area under the curve (AUC) was higher (range 14.70-26.20 h x microg/ml) than those observed in 84 patients with mild toxicities (CL, 56.30 +/- 3.60 l/h/M2; AUC, 7.91 +/- 0.44 h x microg/ml).","Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697844/),[h·μg] / [ml],14.70-26.20,198818,DB00650,Leucovorin
,11697844,CL,"5-FU clearance (CL) was lower (range 14.12-25.17 l/h/m2), and the area under the curve (AUC) was higher (range 14.70-26.20 h x microg/ml) than those observed in 84 patients with mild toxicities (CL, 56.30 +/- 3.60 l/h/M2; AUC, 7.91 +/- 0.44 h x microg/ml).","Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697844/),[l] / [M2·h],56.30,198819,DB00650,Leucovorin
,11697844,AUC,"5-FU clearance (CL) was lower (range 14.12-25.17 l/h/m2), and the area under the curve (AUC) was higher (range 14.70-26.20 h x microg/ml) than those observed in 84 patients with mild toxicities (CL, 56.30 +/- 3.60 l/h/M2; AUC, 7.91 +/- 0.44 h x microg/ml).","Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697844/),[h·μg] / [ml],7.91,198820,DB00650,Leucovorin
,18445839,area under the curve,FU doses were adjusted weekly in arm B based on a single-point measurement of FU plasma concentrations at steady state until the therapeutic range (targeted area under the curve 20-25 mg x h x L(-1)) previously established in other studies was reached.,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),[h·mg] / [l],20-25,199994,DB00650,Leucovorin
,18445839,objective response rate,An intent-to-treat analysis of the 208 patients showed the objective response rate was 18.3% in arm A and 33.7% in arm B (P = .004).,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),%,18.3,199995,DB00650,Leucovorin
,18445839,objective response rate,An intent-to-treat analysis of the 208 patients showed the objective response rate was 18.3% in arm A and 33.7% in arm B (P = .004).,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),%,33.7,199996,DB00650,Leucovorin
,18445839,overall survival,Median overall survival was 16 months in arm A and 22 months in arm B (P = .08).,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),month,16,199997,DB00650,Leucovorin
,18445839,overall survival,Median overall survival was 16 months in arm A and 22 months in arm B (P = .08).,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),month,22,199998,DB00650,Leucovorin
,9252705,steady-state plasma concentration,"The steady-state plasma concentration averaged 0.31 +/- 0.11 microgram/ml (i.e., 2.4 microM).",Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252705/),[μg] / [ml],0.31,200847,DB00650,Leucovorin
,9252705,steady-state plasma concentration,"The steady-state plasma concentration averaged 0.31 +/- 0.11 microgram/ml (i.e., 2.4 microM).",Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252705/),μ,2.4,200848,DB00650,Leucovorin
,9252705,apparent elimination half-life,5-FUra plasma levels declined rapidly after the end of infusion with an apparent elimination half-life of 7.08 +/- 3.21 minutes.,Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252705/),min,7.08,200849,DB00650,Leucovorin
,9252705,Clearance,Clearance ranged from 776 to 3023 ml/min/m2.,Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252705/),[ml] / [m2·min],776 to 3023,200850,DB00650,Leucovorin
,1557647,steady-state serum levels,"Mean steady-state serum levels of 5-FU at 500 mg/m2 given as a 4-hour infusion were 16.55 +/- 9.34 mumol/L and 18.23 +/- 12.77 mumol/L with and without IFN, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l],16.55,202136,DB00650,Leucovorin
,1557647,steady-state serum levels,"Mean steady-state serum levels of 5-FU at 500 mg/m2 given as a 4-hour infusion were 16.55 +/- 9.34 mumol/L and 18.23 +/- 12.77 mumol/L with and without IFN, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l],18.23,202137,DB00650,Leucovorin
,1557647,area under the curve,"Mean area under the curve (mumol/L x min) was 4,008 +/- 2,133 and 5,114 +/- 2,567 with and without interferon, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l·min],"4,008",202138,DB00650,Leucovorin
,1557647,area under the curve,"Mean area under the curve (mumol/L x min) was 4,008 +/- 2,133 and 5,114 +/- 2,567 with and without interferon, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l·min],"5,114",202139,DB00650,Leucovorin
,16770096,survival time,The median survival time of the 13 patients was 17 months.,[Second-line chemotherapy with pharmacokinetic modulating chemotherapy for unresectable colorectal carcinoma recurrences resistant to 5-FU-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770096/),month,17,203732,DB00650,Leucovorin
,21208844,progression-free survival,"The Response Evaluation Criteria in Solid Tumors response rate was 11 of 14 (78%), median progression-free survival was 9.5 months, and median overall survival was 30 months.","Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21208844/),month,9.5,204548,DB00650,Leucovorin
,21208844,overall survival,"The Response Evaluation Criteria in Solid Tumors response rate was 11 of 14 (78%), median progression-free survival was 9.5 months, and median overall survival was 30 months.","Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21208844/),month,30,204549,DB00650,Leucovorin
,21208844,MTD,The MTD of erlotinib with FOLFOX4 with or without bevacizumab is 100 mg daily.,"Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21208844/),mg,100,204550,DB00650,Leucovorin
,1733436,area under the plasma concentration--time curve,"The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05).",A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733436/),[μg] / [h·ml],163,205844,DB00650,Leucovorin
,1733436,peak plasma concentration,"The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05).",A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733436/),[μg] / [ml],18.5,205845,DB00650,Leucovorin
,1733436,steady state volume of distribution,"The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05).",A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733436/),1/[(m)^2],7.41,205846,DB00650,Leucovorin
,1733436,steady state volume of distribution,"The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05).",A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733436/),1/[(m)^2],11.21,205847,DB00650,Leucovorin
,27542957,time to MTX clearance,"Hypoalbuminemia was associated with a significantly longer time to MTX clearance (median 96 vs. 72 h, p = 0.004).",Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27542957/),h,96,206005,DB00650,Leucovorin
,27542957,time to MTX clearance,"Hypoalbuminemia was associated with a significantly longer time to MTX clearance (median 96 vs. 72 h, p = 0.004).",Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27542957/),h,72,206006,DB00650,Leucovorin
,1568210,steady-state plasma concentrations,"The mean steady-state plasma concentrations of (6S)-folinic acid and its principal metabolite (6S)-5-methyltetrahydrofolate at the 250 mg/m2/day dose were 2.7 and 5.1 microM, respectively.",Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568210/),μM,2.7,207014,DB00650,Leucovorin
,1568210,steady-state plasma concentrations,"The mean steady-state plasma concentrations of (6S)-folinic acid and its principal metabolite (6S)-5-methyltetrahydrofolate at the 250 mg/m2/day dose were 2.7 and 5.1 microM, respectively.",Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568210/),μM,5.1,207015,DB00650,Leucovorin
,19151579,peak concentration,"Serum 5-FU levels were higher at night, and the peak concentration of 5-FU was / 398 ng/mL.",[Pharmacokinetic monitoring of 5-fluorouracil may improve the clinical benefit with an individualized regimen-a case report]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151579/),[ng] / [ml],/ 398,207321,DB00650,Leucovorin
,7738622,objective response rate,An objective response rate of 15% (one complete response [CR] and 13 partial responses [PRs]) for 5-FU/FA and 13% (two CRs and nine PRs) for 5-FU/FA/DP was observed.,Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),%,15,207980,DB00650,Leucovorin
,7738622,objective response rate,An objective response rate of 15% (one complete response [CR] and 13 partial responses [PRs]) for 5-FU/FA and 13% (two CRs and nine PRs) for 5-FU/FA/DP was observed.,Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),%,13,207981,DB00650,Leucovorin
,7738622,time to progression,"The median time to progression (P = .8) and the median survival time (11.6 months for 5-FU/FA v 9.3 months for 5-FU/FA/DP; P = .14, log-rank test) were not different between treatment arms.",Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),month,11.6,207982,DB00650,Leucovorin
,7738622,survival time,"The median time to progression (P = .8) and the median survival time (11.6 months for 5-FU/FA v 9.3 months for 5-FU/FA/DP; P = .14, log-rank test) were not different between treatment arms.",Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),month,9.3,207983,DB00650,Leucovorin
,8004761,t1/2 beta,Plasma decay was biphasic with a t1/2 beta of approximately 2 h.,Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004761/),h,2,208339,DB00650,Leucovorin
>,8004761,Plasma clearance,Plasma clearance was high (> 200 1 h-1).,Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004761/),[1] / [h],200,208340,DB00650,Leucovorin
,9552066,Peak methotrexate concentrations,"Peak methotrexate concentrations ranged from 3.7 to 55 micromol/L (mean, 17.1 micromol/L) in CSF and 178 to 1,700 micromol/L (mean, 779 micromol/L) in serum.",High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),[μM] / [l],17.1,208573,DB00650,Leucovorin
,9552066,Peak methotrexate concentrations,"Peak methotrexate concentrations ranged from 3.7 to 55 micromol/L (mean, 17.1 micromol/L) in CSF and 178 to 1,700 micromol/L (mean, 779 micromol/L) in serum.",High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),[μM] / [l],"178 to 1,700",208574,DB00650,Leucovorin
,9552066,Peak methotrexate concentrations,"Peak methotrexate concentrations ranged from 3.7 to 55 micromol/L (mean, 17.1 micromol/L) in CSF and 178 to 1,700 micromol/L (mean, 779 micromol/L) in serum.",High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),[μM] / [l],779,208575,DB00650,Leucovorin
,9552066,survival,Median survival in the HD i.v. MTX group was 13.8 months versus 2.3 months in the i.t. MTX group (P = .003).,High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),month,13.8,208576,DB00650,Leucovorin
,9552066,survival,Median survival in the HD i.v. MTX group was 13.8 months versus 2.3 months in the i.t. MTX group (P = .003).,High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),month,2.3,208577,DB00650,Leucovorin
,7917928,Michaelis constant (KM),"With the Michaelis constant (KM) set at 15 microM, values were derived for the volume of distribution (Vd), the maximum rate of non-linear elimination (Vmax) and the first-order elimination rate constant (K1.e).",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),μM,15,208699,DB00650,Leucovorin
,7917928,Vd,"Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[l] / [(m)^2],10.4,208700,DB00650,Leucovorin
,7917928,Vmax,"Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[μM] / [h·l],182,208701,DB00650,Leucovorin
,7917928,k1.e,"Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),1/[h],4.35,208702,DB00650,Leucovorin
,7917928,Vd,"No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[l] / [(m)^2],10.0,208703,DB00650,Leucovorin
,7917928,Vmax,"No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[μM] / [h·l],141,208704,DB00650,Leucovorin
,7917928,k1.e,"No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),1/[h],3.96,208705,DB00650,Leucovorin
,7917928,AUC0-22 h,"Mean trapezoidal AUC0-22 h was similar in the two groups (control patients 116 microM h, IFN-alpha patients 125 microM h).",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),h·μM,116,208706,DB00650,Leucovorin
,7917928,AUC0-22 h,"Mean trapezoidal AUC0-22 h was similar in the two groups (control patients 116 microM h, IFN-alpha patients 125 microM h).",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),h·μM,125,208707,DB00650,Leucovorin
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],18.6,209363,DB00650,Leucovorin
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],21,209364,DB00650,Leucovorin
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],1.06,209365,DB00650,Leucovorin
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],1.47,209366,DB00650,Leucovorin
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],1.55,209367,DB00650,Leucovorin
,22528576,overall survival,Four (40 %) patients were successfully downstaged to resection and/or ablation with a median overall survival of 15.2 months.,Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),month,15.2,209368,DB00650,Leucovorin
,6609768,plasma half-life (beta),"The plasma half-life (beta) of the unnatural (d) isomer was 451 +/- 24 (S.E.) min compared to 31.6 +/- 1.1 min for the natural (l) isomer, and 227 +/- 20 min for its active metabolite, 5-CH3-THF.",Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6609768/),min,451,209405,DB00650,Leucovorin
,6609768,plasma half-life (beta),"The plasma half-life (beta) of the unnatural (d) isomer was 451 +/- 24 (S.E.) min compared to 31.6 +/- 1.1 min for the natural (l) isomer, and 227 +/- 20 min for its active metabolite, 5-CH3-THF.",Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6609768/),min,31.6,209406,DB00650,Leucovorin
,6609768,plasma half-life (beta),"The plasma half-life (beta) of the unnatural (d) isomer was 451 +/- 24 (S.E.) min compared to 31.6 +/- 1.1 min for the natural (l) isomer, and 227 +/- 20 min for its active metabolite, 5-CH3-THF.",Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6609768/),min,227,209407,DB00650,Leucovorin
,11014408,maximum rate of elimination,"On day 1 the mean values (with interindividual variability as expressed by the coefficient of variation) were 1390 mg x h(-1) (20%), and 5.57 mg x L(-1) (22%) for the maximum rate of elimination, and the half-saturating plasma concentration.",Dose and time dependencies of 5-fluorouracil pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014408/),[mg] / [h],1390,210381,DB00650,Leucovorin
,11014408,half-saturating plasma concentration,"On day 1 the mean values (with interindividual variability as expressed by the coefficient of variation) were 1390 mg x h(-1) (20%), and 5.57 mg x L(-1) (22%) for the maximum rate of elimination, and the half-saturating plasma concentration.",Dose and time dependencies of 5-fluorouracil pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014408/),[mg] / [h],1390,210382,DB00650,Leucovorin
,11014408,maximum rate of elimination,"On day 1 the mean values (with interindividual variability as expressed by the coefficient of variation) were 1390 mg x h(-1) (20%), and 5.57 mg x L(-1) (22%) for the maximum rate of elimination, and the half-saturating plasma concentration.",Dose and time dependencies of 5-fluorouracil pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014408/),[mg] / [l],5.57,210383,DB00650,Leucovorin
,11014408,half-saturating plasma concentration,"On day 1 the mean values (with interindividual variability as expressed by the coefficient of variation) were 1390 mg x h(-1) (20%), and 5.57 mg x L(-1) (22%) for the maximum rate of elimination, and the half-saturating plasma concentration.",Dose and time dependencies of 5-fluorouracil pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014408/),[mg] / [l],5.57,210384,DB00650,Leucovorin
,3257913,bioavailable,"Oral leucovorin was 92% bioavailable compared with intravenous administration and produced a predictably different pattern of circulating folates, 5-methyltetrahydrofolate being the predominant form.","Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257913/),%,92,212204,DB00650,Leucovorin
,27871319,MTD,The MTD of PEP02 was determined as 80 mg/m2.,A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27871319/),[mg] / [m2],80,212352,DB00650,Leucovorin
,27871319,MTD,"The MTD of PEP02 on day 1 in combination with 24-h infusion of 5-FU and LV on days 1 and 8, every 3 weeks was 80 mg/m2, which will be the recommended dose for future studies.",A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27871319/),mg,80,212353,DB00650,Leucovorin
,10668856,distribution half-life,The distribution half-life of ultrafiltrated plasma platinum ranges from 10 to 25 minutes and its terminal elimination half-life is 26 hours (determined with FAAS) or 270 hours (ICP-MS).,Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),min,10 to 25,213128,DB00650,Leucovorin
,10668856,terminal elimination half-life,The distribution half-life of ultrafiltrated plasma platinum ranges from 10 to 25 minutes and its terminal elimination half-life is 26 hours (determined with FAAS) or 270 hours (ICP-MS).,Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),h,26,213129,DB00650,Leucovorin
,10668856,terminal elimination half-life,The distribution half-life of ultrafiltrated plasma platinum ranges from 10 to 25 minutes and its terminal elimination half-life is 26 hours (determined with FAAS) or 270 hours (ICP-MS).,Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),h,270,213130,DB00650,Leucovorin
,10668856,elimination half-life,"The elimination half-life of erythrocytic platinum is 12 to 50 days, close to that of erythrocytes.",Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),d,12 to 50,213131,DB00650,Leucovorin
,3496173,flow rate,Separation of these compounds was achieved on a Waters Spherical C18 column at a flow rate of 0.8 ml.min-1.,Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),[ml] / [min],0.8,216015,DB00650,Leucovorin
,3496173,apparent half-life,"Mean apparent half-life values for folinic acid and its metabolite were 7.02 +/- 1.81 h and 3.90 +/- 0.86 respectively in the first protocol, 4.80 +/- 1.48 h and 4.74 +/- 1.47 h in the second protocol.",Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),h,7.02,216016,DB00650,Leucovorin
,3496173,apparent half-life,"Mean apparent half-life values for folinic acid and its metabolite were 7.02 +/- 1.81 h and 3.90 +/- 0.86 respectively in the first protocol, 4.80 +/- 1.48 h and 4.74 +/- 1.47 h in the second protocol.",Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),,3.90,216017,DB00650,Leucovorin
,3496173,apparent half-life,"Mean apparent half-life values for folinic acid and its metabolite were 7.02 +/- 1.81 h and 3.90 +/- 0.86 respectively in the first protocol, 4.80 +/- 1.48 h and 4.74 +/- 1.47 h in the second protocol.",Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),h,4.80,216018,DB00650,Leucovorin
,3496173,apparent half-life,"Mean apparent half-life values for folinic acid and its metabolite were 7.02 +/- 1.81 h and 3.90 +/- 0.86 respectively in the first protocol, 4.80 +/- 1.48 h and 4.74 +/- 1.47 h in the second protocol.",Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),h,4.74,216019,DB00650,Leucovorin
,11286326,time to reach peak concentration (tmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,2,217445,DB00650,Leucovorin
,11286326,peak plasma drug concentration (Cmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],3 to 4,217446,DB00650,Leucovorin
,11286326,elimination half-life (t(1/2)),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,0.55 to 0.89,217447,DB00650,Leucovorin
,11286326,Recovery,Recovery of drug-related material in urine and faeces is nearly 100%.,Clinical pharmacokinetics of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),%,100,217448,DB00650,Leucovorin
,11286326,Cmax,Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],0.22 to 0.31,217449,DB00650,Leucovorin
,11286326,area under the concentration-time curve (AUC),Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[h·mg] / [l],0.461 to 0.698,217450,DB00650,Leucovorin
,7018678,alpha-phase half-life,"The alpha-phase half-life of LV was about 15 mins, but LV was readily detectable by the assay for 3-4 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),min,15,218709,DB00650,Leucovorin
,7018678,apparent half-life,"The level of mTHFA increased for at least 60 mins, being equimolar with LV by 30 mins, and then decreased slowly with an apparent half-life of 2-3 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),h,2-3,218710,DB00650,Leucovorin
,11818199,area under the plasma concentration curve (AUC),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),min·μM,113,219549,DB00650,Leucovorin
,11818199,area under the plasma concentration curve (AUC),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),,114,219550,DB00650,Leucovorin
,11818199,area under the plasma concentration curve (AUC),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),,98,219551,DB00650,Leucovorin
,11818199,peak levels (Cmax),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,1.2,219552,DB00650,Leucovorin
,11818199,peak levels (Cmax),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,1.3,219553,DB00650,Leucovorin
,11818199,peak levels (Cmax),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,1.0,219554,DB00650,Leucovorin
,11818199,AUC,The AUC for the 5-FU/LV courses was 3083 microM x min for day 1 and 3809 for day 5 (P=0.002).,Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),min·μM,3083,219555,DB00650,Leucovorin
,11818199,AUC,The AUC for the 5-FU/LV courses was 3083 microM x min for day 1 and 3809 for day 5 (P=0.002).,Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),,3809,219556,DB00650,Leucovorin
,11818199,Cmax,"The Cmax was 170.1 and 196.2 microM (P=0.06) and the clearance 2.6 and 1.9 l/min, respectively (P=0.002).",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,170.1,219557,DB00650,Leucovorin
,11818199,Cmax,"The Cmax was 170.1 and 196.2 microM (P=0.06) and the clearance 2.6 and 1.9 l/min, respectively (P=0.002).",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,196.2,219558,DB00650,Leucovorin
,11818199,clearance,"The Cmax was 170.1 and 196.2 microM (P=0.06) and the clearance 2.6 and 1.9 l/min, respectively (P=0.002).",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),[l] / [min],2.6,219559,DB00650,Leucovorin
,11818199,clearance,"The Cmax was 170.1 and 196.2 microM (P=0.06) and the clearance 2.6 and 1.9 l/min, respectively (P=0.002).",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),[l] / [min],1.9,219560,DB00650,Leucovorin
,2230874,half-life (T1/2),"The half-life (T1/2) of this tumor pool of ""trapped"" 5FU was 0.33 to 1.3 hours (20 to 78 minutes), much longer than the T1/2 of 5FU in blood (5 to 15 minutes).",Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230874/),h,0.33 to 1.3,224542,DB00650,Leucovorin
,2230874,half-life (T1/2),"The half-life (T1/2) of this tumor pool of ""trapped"" 5FU was 0.33 to 1.3 hours (20 to 78 minutes), much longer than the T1/2 of 5FU in blood (5 to 15 minutes).",Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230874/),min,20 to 78,224543,DB00650,Leucovorin
,2230874,T1/2,"The half-life (T1/2) of this tumor pool of ""trapped"" 5FU was 0.33 to 1.3 hours (20 to 78 minutes), much longer than the T1/2 of 5FU in blood (5 to 15 minutes).",Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230874/),min,5 to 15,224544,DB00650,Leucovorin
,1893377,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of TBAF was 821 +/- 97 (SE) nM, occurring at a median of 8 h; the Cmax of (6S)-leucovorin was 77 +/- 11 nM, occurring at 4 h.",Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1893377/),nM,821,225312,DB00650,Leucovorin
,1893377,Cmax,"The maximum plasma concentration (Cmax) of TBAF was 821 +/- 97 (SE) nM, occurring at a median of 8 h; the Cmax of (6S)-leucovorin was 77 +/- 11 nM, occurring at 4 h.",Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1893377/),nM,77,225313,DB00650,Leucovorin
,1893377,TBAF,The TBAF concentration fell to 146 +/- 42 nM by 24 h.,Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1893377/),nM,146,225314,DB00650,Leucovorin
,1893377,concentration,The TBAF concentration fell to 146 +/- 42 nM by 24 h.,Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1893377/),nM,146,225315,DB00650,Leucovorin
,1000510,t1/2,"Within 24 hr after dosages of greater than 24 mg/kg, the rate of tumor cell loss increased to a point characterized by a single exponential (t1/2=8.5 hr).","Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1000510/),h,8.5,225954,DB00650,Leucovorin
,27913881,PFS,"The median PFS, TTF, and OS were 4.13, 3.70, and 11.40 months.",Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27913881/),month,4.13,226375,DB00650,Leucovorin
,27913881,TTF,"The median PFS, TTF, and OS were 4.13, 3.70, and 11.40 months.",Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27913881/),month,3.70,226376,DB00650,Leucovorin
,27913881,TTF,"The median PFS, TTF, and OS were 4.13, 3.70, and 11.40 months.",Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27913881/),month,11.40,226377,DB00650,Leucovorin
,27913881,OS,"The median PFS, TTF, and OS were 4.13, 3.70, and 11.40 months.",Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27913881/),month,11.40,226378,DB00650,Leucovorin
,304376,half-lives,"Thus, the plasma clearance over the 50-200-mg/kg range may be represented by a single dose-scalable biexponential model with half-lives of 1.8 +/- 0.1 and 8.4 +/- 0.5 hours.",Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/304376/),h,1.8,226929,DB00650,Leucovorin
,304376,half-lives,"Thus, the plasma clearance over the 50-200-mg/kg range may be represented by a single dose-scalable biexponential model with half-lives of 1.8 +/- 0.1 and 8.4 +/- 0.5 hours.",Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/304376/),h,8.4,226930,DB00650,Leucovorin
,304376,Urinary clearance,Urinary clearance has been determined at 104 +/- 8 ml/minute over the dose range of 50-300 mg/kg and only 60% of the MTX was excreted in the urine by 72 hours.,Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/304376/),[ml] / [min],104,226931,DB00650,Leucovorin
,10223231,response rate,"Two complete responses and 15 partial responses were observed (response rate of 47.2%; 95% confidence interval, 30.1-64.4%).",A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223231/),%,47.2,228049,DB00650,Leucovorin
,10223231,response duration,The median response duration was 9.6 months.,A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223231/),month,9.6,228050,DB00650,Leucovorin
,10223231,survival,"The median survival and time to progression were 11.9 months and 7.1 months, respectively.",A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223231/),month,11.9,228051,DB00650,Leucovorin
,10223231,time to progression,"The median survival and time to progression were 11.9 months and 7.1 months, respectively.",A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223231/),month,7.1,228052,DB00650,Leucovorin
,9877235,elimination half-life,The elimination half-life of 5-FU following UFT administration is approximately 7 h compared with 0.2 h with i.v. 5-FU.,UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877235/),h,7,228378,DB00650,Leucovorin
,9877235,elimination half-life,The elimination half-life of 5-FU following UFT administration is approximately 7 h compared with 0.2 h with i.v. 5-FU.,UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877235/),h,0.2,228379,DB00650,Leucovorin
,9877235,response rates,"In phase II studies of UFT plus oral leucovorin for the treatment of advanced colorectal cancer, response rates ranged from 25 to 42%.",UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877235/),%,25 to 42,228380,DB00650,Leucovorin
,22382460,AUC,"Because individual factors other than dose change may also affect the change in AUC, longitudinal PK monitoring in all cycles and dose adjustment to ensure AUC in the desired range of 20-30 mg · h/L are recommended.",Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382460/),[h·mg] / [l],20-30,228886,DB00650,Leucovorin
,2958611,plasma concentrations,"Median MTX plasma concentrations, measured 42 hours after infusion, were significantly higher in patients with Down syndrome versus control patients (average 0.47 vs 0.24 mumol/L, respectively, P = 0.03).",Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958611/),[μM] / [l],0.47,230580,DB00650,Leucovorin
,2958611,plasma concentrations,"Median MTX plasma concentrations, measured 42 hours after infusion, were significantly higher in patients with Down syndrome versus control patients (average 0.47 vs 0.24 mumol/L, respectively, P = 0.03).",Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958611/),[μM] / [l],0.24,230581,DB00650,Leucovorin
,2958611,clearance,The average MTX clearance was 64.1 mL/min/m2 in Down syndrome vs an average control value of 80.6 mL/min/m2 (P = 0.13).,Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958611/),[ml] / [m2·min],64.1,230582,DB00650,Leucovorin
,2958611,clearance,The average MTX clearance was 64.1 mL/min/m2 in Down syndrome vs an average control value of 80.6 mL/min/m2 (P = 0.13).,Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958611/),[ml] / [m2·min],80.6,230583,DB00650,Leucovorin
,9932161,MTD,The median MTD was 475 mg/m2/day (95% CI: 450-500) in the FU bolus arm with stomatitis +/- diarrhea being the most common DLT.,5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),[mg] / [d·m2],475,231829,DB00650,Leucovorin
,9932161,MTD,"Gastrointestinal side effects were also dose-limiting in the two-hour infusion arm; however, the median MTD was 600 mg/m2/day (95% CI: 568-632).",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),mg,600,231830,DB00650,Leucovorin
,9932161,overall response rates,The overall response rates were 27.5% (95% CI: 15-44%; 1 CR and 10 PR) for patients treated in the bolus arm and 14.5% (95% CI: 5-28%; 1 CR and 5 PR) for those treated in the two-hour infusion arm.,5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),%,27.5,231831,DB00650,Leucovorin
,9932161,overall response rates,The overall response rates were 27.5% (95% CI: 15-44%; 1 CR and 10 PR) for patients treated in the bolus arm and 14.5% (95% CI: 5-28%; 1 CR and 5 PR) for those treated in the two-hour infusion arm.,5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),%,14.5,231832,DB00650,Leucovorin
,9932161,time to progression,"Analogous to recorded response, median time to progression (8.5 vs. 6.25) and overall survival time (14.0 vs. 11.0) tended to be superior in the FU bolus arm.",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),,8.5,231833,DB00650,Leucovorin
,9932161,time to progression,"Analogous to recorded response, median time to progression (8.5 vs. 6.25) and overall survival time (14.0 vs. 11.0) tended to be superior in the FU bolus arm.",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),,6.25,231834,DB00650,Leucovorin
,9932161,overall survival time,"Analogous to recorded response, median time to progression (8.5 vs. 6.25) and overall survival time (14.0 vs. 11.0) tended to be superior in the FU bolus arm.",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),,14.0,231835,DB00650,Leucovorin
,9932161,overall survival time,"Analogous to recorded response, median time to progression (8.5 vs. 6.25) and overall survival time (14.0 vs. 11.0) tended to be superior in the FU bolus arm.",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),,11.0,231836,DB00650,Leucovorin
,23179335,response rate,"The response rate and progression-free survival at 4.0 mg/kg was 8.3 % and 7.59 months, respectively.",A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179335/),%,8.3,232228,DB00650,Leucovorin
,23179335,progression-free survival,"The response rate and progression-free survival at 4.0 mg/kg was 8.3 % and 7.59 months, respectively.",A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179335/),month,7.59,232229,DB00650,Leucovorin
,23179335,RPTD,The RPTD of aflibercept in combination with FOLFIRI for Japanese patients with mCRC was determined to be 4.0 mg/kg every 2 weeks.,A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179335/),[mg] / [kg],4.0,232230,DB00650,Leucovorin
,8032956,time of distribution (t1/2 alpha,"When leucovorin was administered, the time of distribution (t1/2 alpha for 5-FU increased from 8.9 +/- 2.4 to 12.8 +/- 2.5 min (p < 0.0005) and the volume of distribution (Vd) increased from 0.129 +/- 0.039 to 0.237 +/- 0.033 L/kg (p < 0.03).",5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032956/),min,8.9,233379,DB00650,Leucovorin
,8032956,time of distribution (t1/2 alpha,"When leucovorin was administered, the time of distribution (t1/2 alpha for 5-FU increased from 8.9 +/- 2.4 to 12.8 +/- 2.5 min (p < 0.0005) and the volume of distribution (Vd) increased from 0.129 +/- 0.039 to 0.237 +/- 0.033 L/kg (p < 0.03).",5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032956/),min,12.8,233380,DB00650,Leucovorin
,8032956,volume of distribution (Vd),"When leucovorin was administered, the time of distribution (t1/2 alpha for 5-FU increased from 8.9 +/- 2.4 to 12.8 +/- 2.5 min (p < 0.0005) and the volume of distribution (Vd) increased from 0.129 +/- 0.039 to 0.237 +/- 0.033 L/kg (p < 0.03).",5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032956/),[l] / [kg],0.129,233381,DB00650,Leucovorin
,8032956,volume of distribution (Vd),"When leucovorin was administered, the time of distribution (t1/2 alpha for 5-FU increased from 8.9 +/- 2.4 to 12.8 +/- 2.5 min (p < 0.0005) and the volume of distribution (Vd) increased from 0.129 +/- 0.039 to 0.237 +/- 0.033 L/kg (p < 0.03).",5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032956/),[l] / [kg],0.237,233382,DB00650,Leucovorin
,1634927,steady-state MTX plasma concentration,"During infusion, the steady-state MTX plasma concentration was 11.3 +/- 4.8 mumol/L.",Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),[μM] / [l],11.3,233852,DB00650,Leucovorin
,1634927,initial half-life (t1/2 alpha),The initial half-life (t1/2 alpha) of MTX decreased from 5.8 +/- 2.1 minutes to 0.7 +/- 0.02 minutes after enzyme administration.,Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),min,5.8,233853,DB00650,Leucovorin
,1634927,initial half-life (t1/2 alpha),The initial half-life (t1/2 alpha) of MTX decreased from 5.8 +/- 2.1 minutes to 0.7 +/- 0.02 minutes after enzyme administration.,Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),min,0.7,233854,DB00650,Leucovorin
,1634927,area under the plasma concentration time curve,The postinfusion area under the plasma concentration time curve of MTX was 301 +/- 171 mumol/L/min without CPDG2 compared with 19.6 +/- 6.1 mumol/L/min with CPDG2.,Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),[μM] / [l·min],301,233855,DB00650,Leucovorin
,1634927,area under the plasma concentration time curve,The postinfusion area under the plasma concentration time curve of MTX was 301 +/- 171 mumol/L/min without CPDG2 compared with 19.6 +/- 6.1 mumol/L/min with CPDG2.,Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),[μM] / [l·min],19.6,233856,DB00650,Leucovorin
,26988222,steady-state MTX concentration,The median steady-state MTX concentration at the end of 6-hr infusion was 486 µM/L (range 227-790).,Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988222/),[μM] / [l],486,238828,DB00650,Leucovorin
,26988222,systemic MTX clearance,The median systemic MTX clearance was 4.14 L/h/m(2) (range 1.98-9.35).,Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988222/),[h·l] / [m(2],4.14,238829,DB00650,Leucovorin
,26988222,concentration,The median MTX concentration after 24 h from the beginning of infusion was 3.29 µM/L (range 1.14-100.44).,Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988222/),[μM] / [l],3.29,238830,DB00650,Leucovorin
minor,26988222,clearance,"Moreover, a systemic MTX clearance at the end of infusion minor than 3 L/h/m(2) can predict a delayed elimination (p: 0.0179).",Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988222/),[h·l] / [m(2],3,238831,DB00650,Leucovorin
,27933371,response rate,S-1 has shown a response rate of 35% in chemonaïve patients with metastatic colorectal cancer (mCRC).,Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933371/),%,35,239202,DB00650,Leucovorin
,27933371,overall response rate,"The overall response rate was 67% (95% confidence interval, 38-88%).",Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933371/),%,67,239203,DB00650,Leucovorin
,22683364,objective response rate,"The objective response rate was 69.7% in the PK-adjusted arm, and median overall survival and median progression-free survival were 28 and 16 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,69.7,239461,DB00650,Leucovorin
,22683364,overall survival,"The objective response rate was 69.7% in the PK-adjusted arm, and median overall survival and median progression-free survival were 28 and 16 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,28,239462,DB00650,Leucovorin
,22683364,progression-free survival,"The objective response rate was 69.7% in the PK-adjusted arm, and median overall survival and median progression-free survival were 28 and 16 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,16,239463,DB00650,Leucovorin
,22683364,objective response rate,"In the traditional patients who received BSA dosage, objective response rate was 46%, and overall survival and progression-free survival were 22 and 10 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,46,239464,DB00650,Leucovorin
,22683364,overall survival,"In the traditional patients who received BSA dosage, objective response rate was 46%, and overall survival and progression-free survival were 22 and 10 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,22,239465,DB00650,Leucovorin
,22683364,overall survival,"In the traditional patients who received BSA dosage, objective response rate was 46%, and overall survival and progression-free survival were 22 and 10 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,10,239466,DB00650,Leucovorin
,22683364,progression-free survival,"In the traditional patients who received BSA dosage, objective response rate was 46%, and overall survival and progression-free survival were 22 and 10 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,10,239467,DB00650,Leucovorin
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,1.7,239468,DB00650,Leucovorin
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,0.8,239469,DB00650,Leucovorin
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,12,239470,DB00650,Leucovorin
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,15,239471,DB00650,Leucovorin
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,25,239472,DB00650,Leucovorin
,14981990,AUC,Pharmacokinetic analysis revealed an AUC value of 85.3 micrograms x min/ml after HAI.,"Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14981990/),[min·μg] / [ml],85.3,239494,DB00650,Leucovorin
,14981990,AUC,Recalculating these values with the previously reported AUC value for systemic administration (161 micrograms x min/ml) revealed a liver extraction ratio of 0.47 for Oxa.,"Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14981990/),[min·μg] / [ml],161,239495,DB00650,Leucovorin
,14981990,liver extraction ratio,Recalculating these values with the previously reported AUC value for systemic administration (161 micrograms x min/ml) revealed a liver extraction ratio of 0.47 for Oxa.,"Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14981990/),,0.47,239496,DB00650,Leucovorin
,21150775,maximum tolerated dose,The maximum tolerated dose of 5-FU was 3750 mg/m²/48 h/week with this tri-monthly schedule.,"Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21150775/),[mg] / [48·h·m²·week],375,242234,DB00650,Leucovorin
,21150775,progression-free survival,"Median progression-free survival and overall survival were 4.1 months (range: 1.8-12.5) and 10.5 months (range: 2.7-32.1), respectively.","Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21150775/),month,4.1,242235,DB00650,Leucovorin
,21150775,overall survival,"Median progression-free survival and overall survival were 4.1 months (range: 1.8-12.5) and 10.5 months (range: 2.7-32.1), respectively.","Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21150775/),month,10.5,242236,DB00650,Leucovorin
,1714790,volume of distribution at steady-state,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [kg],0.398,242987,DB00650,Leucovorin
,1714790,systemic clearance,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [h·kg],0.0956,242988,DB00650,Leucovorin
,1714790,terminal elimination half-life,"The terminal elimination half-life (9.29 hours) of methotrexate was similar to other reported values in adult patients, thus indicating that increases in methotrexate volume of distribution and clearance may offset each other in obesity.",Disposition of high-dose methotrexate in an obese cancer patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),h,9.29,242989,DB00650,Leucovorin
,8862717,maximum tolerated dose,The maximum tolerated dose of IFN was 18 MU/m2.,"A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8862717/),[Mu] / [m2],18,246204,DB00650,Leucovorin
,14648016,apparent IFN-gamma clearance,The median (range) apparent IFN-gamma clearance was 46 l/m(2) per hour (2.6-92 l/m(2) per hour).,Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648016/),[l] / [h·m(2)],46,246402,DB00650,Leucovorin
above,14648016,AUC(0--> infinity ),"IFN-gamma AUC(0--> infinity ) and time above 33.3 pg/ml significantly correlated with Fas upregulation in several PBMC compartments, but dosage was significantly correlated with this pharmacodynamic marker only in CD4(+) and CD56(+) cells.",Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648016/),[pg] / [ml],33.3,246403,DB00650,Leucovorin
above,14648016,time,"IFN-gamma AUC(0--> infinity ) and time above 33.3 pg/ml significantly correlated with Fas upregulation in several PBMC compartments, but dosage was significantly correlated with this pharmacodynamic marker only in CD4(+) and CD56(+) cells.",Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648016/),[pg] / [ml],33.3,246404,DB00650,Leucovorin
,8173194,ratio AUC peritoneum,The pharmacokinetic advantage of 5-FU-ip was confirmed in our study (ratio AUC peritoneum/plasma between 160 and 328).,[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173194/),,160 and 328,248004,DB00650,Leucovorin
,8173194,plasmatic AUC,The systemic exposure to 5-FU (plasmatic AUC ranging from 73.4 to 173.21 microM) and to AF were found in efficacious ranges.,[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173194/),μM,73.4 to 173.21,248005,DB00650,Leucovorin
,8617578,overall response rate,The overall response rate was 40% (C.I. 23-60%).,A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8617578/),%,40,249848,DB00650,Leucovorin
,8983929,percentage AUC-ratios,"The extent of biotransformation of CHO-THFA into CH3-THFA, which takes place in the blood, is not influenced by IFN because percentage AUC-ratios CHO-THFA:CH3-THFA were 89.5:10.5% for the control group and 88.8:11.2% for the IFN group.",Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983929/),%,89.5,250515,DB00650,Leucovorin
,8983929,percentage AUC-ratios,"The extent of biotransformation of CHO-THFA into CH3-THFA, which takes place in the blood, is not influenced by IFN because percentage AUC-ratios CHO-THFA:CH3-THFA were 89.5:10.5% for the control group and 88.8:11.2% for the IFN group.",Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983929/),%,10.5,250516,DB00650,Leucovorin
,8983929,percentage AUC-ratios,"The extent of biotransformation of CHO-THFA into CH3-THFA, which takes place in the blood, is not influenced by IFN because percentage AUC-ratios CHO-THFA:CH3-THFA were 89.5:10.5% for the control group and 88.8:11.2% for the IFN group.",Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983929/),%,88.8,250517,DB00650,Leucovorin
,11157039,area under the curve,"rhuMAbVEGF, 3 mg/kg IV, was administered weekly for 8 weeks with (1) doxorubicin 50 mg/m(2) every 4 weeks; (2) carboplatin at area under the curve of 6 plus paclitaxel 175 mg/m(2) every 4 weeks; and (3) fluorouracil (5-FU) 500 mg/m(2) with leucovorin 20 mg/m(2) weekly, weeks 1 to 6 every 8 weeks.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),,6,250656,DB00650,Leucovorin
,11157039,peak serum level,"The mean (+/- SD) peak serum level of rhuMAbVEGF was 167 +/- 46 microg/mL, and the mean terminal half-life was 13 days.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),[μg] / [ml],167,250657,DB00650,Leucovorin
,11157039,terminal half-life,"The mean (+/- SD) peak serum level of rhuMAbVEGF was 167 +/- 46 microg/mL, and the mean terminal half-life was 13 days.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),d,13,250658,DB00650,Leucovorin
,12351598,objective response rate,"In five patients (11.9%) a complete and in 25 (59.5%) a partial response was demonstrated, for an objective response rate of 71.4% (95% confidence interval, 47% to 83%).","Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12351598/),%,71.4,253135,DB00650,Leucovorin
,12351598,progression-free,"Median progression-free and overall survival times were 10.4 and 26.5 months, respectively.","Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12351598/),month,10.4,253136,DB00650,Leucovorin
,12351598,overall survival times,"Median progression-free and overall survival times were 10.4 and 26.5 months, respectively.","Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12351598/),month,26.5,253137,DB00650,Leucovorin
,15277535,response rate,"The response rate for the Japanese patients and the patients in the United States was 36.4% (95% CI, 22.4% to 52.2%) and 34.1% (95% CI, 20.5% to 49.9%), respectively.","Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277535/),%,36.4,255007,DB00650,Leucovorin
,15277535,response rate,"The response rate for the Japanese patients and the patients in the United States was 36.4% (95% CI, 22.4% to 52.2%) and 34.1% (95% CI, 20.5% to 49.9%), respectively.","Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277535/),%,34.1,255008,DB00650,Leucovorin
,3501546,Relative bioavailabilities,"Relative bioavailabilities were 78%, 62%, 49%, and 42% for the 40-, 60-, 80-, and 100-mg doses, respectively.",Absorption kinetics of orally administered leucovorin calcium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501546/),%,78,255535,DB00650,Leucovorin
,3501546,Relative bioavailabilities,"Relative bioavailabilities were 78%, 62%, 49%, and 42% for the 40-, 60-, 80-, and 100-mg doses, respectively.",Absorption kinetics of orally administered leucovorin calcium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501546/),%,62,255536,DB00650,Leucovorin
,3501546,Relative bioavailabilities,"Relative bioavailabilities were 78%, 62%, 49%, and 42% for the 40-, 60-, 80-, and 100-mg doses, respectively.",Absorption kinetics of orally administered leucovorin calcium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501546/),%,49,255537,DB00650,Leucovorin
,3501546,Relative bioavailabilities,"Relative bioavailabilities were 78%, 62%, 49%, and 42% for the 40-, 60-, 80-, and 100-mg doses, respectively.",Absorption kinetics of orally administered leucovorin calcium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501546/),%,42,255538,DB00650,Leucovorin
,3501546,Absolute bioavailability,"Absolute bioavailability of the 200-mg oral dose of leucovorin based on AUC was 31% compared with that of the iv dose (6,848 vs. 22,298 ng.hr/ml, respectively).",Absorption kinetics of orally administered leucovorin calcium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501546/),[h·ng] / [ml],31,255539,DB00650,Leucovorin
,3501546,Absolute bioavailability,"Absolute bioavailability of the 200-mg oral dose of leucovorin based on AUC was 31% compared with that of the iv dose (6,848 vs. 22,298 ng.hr/ml, respectively).",Absorption kinetics of orally administered leucovorin calcium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501546/),[h·ng] / [ml],"6,848",255540,DB00650,Leucovorin
,3501546,Absolute bioavailability,"Absolute bioavailability of the 200-mg oral dose of leucovorin based on AUC was 31% compared with that of the iv dose (6,848 vs. 22,298 ng.hr/ml, respectively).",Absorption kinetics of orally administered leucovorin calcium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3501546/),[h·ng] / [ml],"22,298",255541,DB00650,Leucovorin
,10388099,objective response rate,"In a phase II trial in advanced colorectal cancer, UFT plus oral leucovorin produced an objective response rate of 42%, with survival similar to weekly i.v. 5-FU plus leucovorin.",UFT Plus Oral Leucovorin: A New Oral Treatment for Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388099/),%,42,256413,DB00650,Leucovorin
,17922560,AUC(24) ratio,"The bid : tid AUC(24) ratio (90% CI) was 1.8 (1.55, 2.10) with fluorouracil, 2.0 (1.59, 2.57) with uracil and 1.2 (1.02, 1.36) with tegafur, indicating that the bid and tid schedules were not bioequivalent.",A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922560/),,1,257071,DB00650,Leucovorin
,17922560,AUC(24) ratio,"The bid : tid AUC(24) ratio (90% CI) was 1.8 (1.55, 2.10) with fluorouracil, 2.0 (1.59, 2.57) with uracil and 1.2 (1.02, 1.36) with tegafur, indicating that the bid and tid schedules were not bioequivalent.",A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922560/),,2,257072,DB00650,Leucovorin
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,20,257868,DB00650,Leucovorin
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,27,257869,DB00650,Leucovorin
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,24,257870,DB00650,Leucovorin
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),,27,257871,DB00650,Leucovorin
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,14,257872,DB00650,Leucovorin
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),,0,257873,DB00650,Leucovorin
,10938396,objective response rate,"The objective response rate was 87%, with 50% complete response (CR) and 37% partial response.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),%,87,259576,DB00650,Leucovorin
,10938396,Failure rate,Failure rate was 13% (stable disease).,"Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),%,13,259577,DB00650,Leucovorin
,10938396,peak plasma levels,"The average peak plasma levels for the 6 courses of CDDP, 5-FU, dl-FA and mTHF were 4.9+/-0.76 microM, 4.1+/-0.54 microM, 29.1+/-2.4 microM and 4.8+/-0.31 microM respectively.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),μM,4.9,259578,DB00650,Leucovorin
,10938396,peak plasma levels,"The average peak plasma levels for the 6 courses of CDDP, 5-FU, dl-FA and mTHF were 4.9+/-0.76 microM, 4.1+/-0.54 microM, 29.1+/-2.4 microM and 4.8+/-0.31 microM respectively.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),μM,4.1,259579,DB00650,Leucovorin
,10938396,peak plasma levels,"The average peak plasma levels for the 6 courses of CDDP, 5-FU, dl-FA and mTHF were 4.9+/-0.76 microM, 4.1+/-0.54 microM, 29.1+/-2.4 microM and 4.8+/-0.31 microM respectively.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),μM,29.1,259580,DB00650,Leucovorin
,10938396,peak plasma levels,"The average peak plasma levels for the 6 courses of CDDP, 5-FU, dl-FA and mTHF were 4.9+/-0.76 microM, 4.1+/-0.54 microM, 29.1+/-2.4 microM and 4.8+/-0.31 microM respectively.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),μM,4.8,259581,DB00650,Leucovorin
over,2783879,survival,The median survival for CR patients was over 26.7 months and 16.5 months for the PR patients.,Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783879/),month,26.7,264310,DB00650,Leucovorin
,2783879,survival,The median survival for CR patients was over 26.7 months and 16.5 months for the PR patients.,Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783879/),month,16.5,264311,DB00650,Leucovorin
,2783879,survival,The median survival for stable patients was 9.5 months and 5.5 months for patients with progressive disease.,Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783879/),month,9.5,264312,DB00650,Leucovorin
,2783879,survival,The median survival for stable patients was 9.5 months and 5.5 months for patients with progressive disease.,Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783879/),month,5.5,264313,DB00650,Leucovorin
,8823500,elimination half-life,The elimination half-life ranged from 22 to 42 h when he was off dialysis but fell to a median of 5.5 h during dialysis.,Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823500/),h,22 to 42,266747,DB00650,Leucovorin
,8823500,elimination half-life,The elimination half-life ranged from 22 to 42 h when he was off dialysis but fell to a median of 5.5 h during dialysis.,Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823500/),h,5.5,266748,DB00650,Leucovorin
,16047145,complete response,One complete response (54.1+ months) and 2 partial responses were observed.,Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,54,269519,DB00650,Leucovorin
,16047145,Time to progression,"Time to progression was 4.4 months (0.8-54.1+), and median survival was 8.0 months (0.8-54.1+).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,4.4,269520,DB00650,Leucovorin
,16047145,survival,"Time to progression was 4.4 months (0.8-54.1+), and median survival was 8.0 months (0.8-54.1+).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,8.0,269521,DB00650,Leucovorin
,16047145,Cmax,"There was a significant reduction of 5-FU Cmax in plasma the second day of treatment if vasopressin was used (3.4+/-2.5 and 6.1+/-5.4 mumol/l, respectively, p<0.05).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),[μM] / [l],3.4,269522,DB00650,Leucovorin
,16047145,Cmax,"There was a significant reduction of 5-FU Cmax in plasma the second day of treatment if vasopressin was used (3.4+/-2.5 and 6.1+/-5.4 mumol/l, respectively, p<0.05).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),[μM] / [l],6.1,269523,DB00650,Leucovorin
,16047145,Tumour response,Tumour response was 4.4% and median survival time 8.0 months.,Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),%,4.4,269524,DB00650,Leucovorin
,16047145,survival time,Tumour response was 4.4% and median survival time 8.0 months.,Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,8.0,269525,DB00650,Leucovorin
,1919632,overall response rate,"In 22 patients without prior 5-FU therapy, three complete (13.6%) and seven partial (31.8%) responses were seen, for an overall response rate of 45.4% (95% confidence interval, 24.4% to 67.8%).",A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919632/),%,45.4,269680,DB00650,Leucovorin
,12081632,Cl,"Ten kinetic profiles obtained after 10 courses of MTX (1.5 g/m2) in seven patients with inflammatory breast cancer were used to establish the population pharmacokinetic parameters (Cl, 8.16 L/h; t1/2, 12.7 h).",Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081632/),[l] / [h],8.16,271476,DB00650,Leucovorin
,12081632,t1/2,"Ten kinetic profiles obtained after 10 courses of MTX (1.5 g/m2) in seven patients with inflammatory breast cancer were used to establish the population pharmacokinetic parameters (Cl, 8.16 L/h; t1/2, 12.7 h).",Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081632/),h,12.7,271477,DB00650,Leucovorin
,25173761,C max,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[μg] / [ml],5.18,273362,DB00650,Leucovorin
,25173761,C max,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[μg] / [ml],47.80,273363,DB00650,Leucovorin
,25173761,C max,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[μg] / [ml],69.93,273364,DB00650,Leucovorin
,25173761,AUC0-t,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[h·μg] / [ml],25.85,273365,DB00650,Leucovorin
,25173761,AUC0-t,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[h·μg] / [ml],194.53,273366,DB00650,Leucovorin
,25173761,AUC0-t,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[h·μg] / [ml],355.26,273367,DB00650,Leucovorin
,25173761,AUC0-∞,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[h·μg] / [ml],30.24,273368,DB00650,Leucovorin
,25173761,AUC0-∞,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[h·μg] / [ml],215.43,273369,DB00650,Leucovorin
,25173761,AUC0-∞,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[h·μg] / [ml],417.88,273370,DB00650,Leucovorin
,25173761,t 1/2,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),h,8.77,273371,DB00650,Leucovorin
,25173761,t 1/2,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),h,7.64,273372,DB00650,Leucovorin
,25173761,t 1/2,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),h,9.08,273373,DB00650,Leucovorin
,25173761,CL,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[l] / [h],1.12,273374,DB00650,Leucovorin
,25173761,CL,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[l] / [h],1.55,273375,DB00650,Leucovorin
,25173761,CL,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),[l] / [h],0.78,273376,DB00650,Leucovorin
,25173761,V d,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),,13.75,273377,DB00650,Leucovorin
,25173761,V d,"Following a single intravenous administration of disodium folinate 20, 200, and 300 mg/m(2), the mean (standard deviation) pharmacokinetic parameters were as follows: C max = 5.18 (0.58), 47.80 (10.10), and 69.93 (9.72) µg/mL; AUC0-t = 25.85 (3.36), 194.53 (30.18), and 355.26 (35.31) µg h/mL; AUC0-∞ = 30.24 (6.19), 215.43 (27.34), and 417.88 (54.81) µg h/mL; t 1/2 = 8.77 (2.57), 7.64 (1.81), and 9.08 (1.64) h; CL = 1.12 (0.18), 1.55(0.25), and 0.78 (0.09) L/h; V d = 13.75 (2.61), 17.38 (6.44), and 10.05 (1.49) L, respectively.","Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173761/),,17.38,273378,DB00650,Leucovorin
